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ABSTRACT 
Theresa Marie Coles: Sleep Disturbance in Individuals Diagnosed with Colorectal Cancer: Factors 
Associated with Sleep Disturbance and Changes in Sleep Disturbance 
(Under the direction of Bryce Reeve) 
This dissertation evaluates sleep disturbance in individuals with colorectal cancer (CRC), with the 
objectives of providing insight on the patient, disease and treatment characteristics associated with sleep 
disturbance (and change in sleep disturbance), investigating whether there is variation in these factors 
across levels of sleep disturbance severity (and change in sleep disturbance severity), and finally 
assessing the relationship between sleep disturbance (and change in sleep disturbance) and exercise 
(and change in exercise). We also investigated possible heterogeneity in the relationship between sleep 
disturbance and these factors. Data were obtained from the MY-Health study, a community-based 
observational study of adults diagnosed with cancer collected through four Surveillance, Epidemiology 
and End Results (SEER) cancer registries. Patient-Reported Outcomes Measurement Information 
System (PROMIS) measures were administered to patients to measure sleep, anxiety, depression, 
fatigue, pain interference, and social and physical functioning. Participants (n = 734) self-reported 
demographic information, comorbidities, treatment type, and dates of treatment. Data were collected at 
two time points after diagnosis: approximately 10 and 17 months after diagnosis. Regression mixture 
models (RMM) (to evaluate heterogeneity) and multiple regression models were used to evaluate the 
relationship between sleep disturbance and patient, disease, and treatment factors, as well as exercise. 
Overall, results of the RMM analyses provided evidence that the relationship between sleep disturbance 
and patient, disease, treatment characteristics, and exercise levels was consistent at every severity level 
of sleep disturbance. Factors yielding statistically significant relationships with sleep disturbance at 
approximately 10 months after CRC were 2 or more comorbid conditions, non-retirees, anxiety, pain 
interference, and fatigue. Change in anxiety and fatigue yielded statistically significant relationships with 
change in sleep disturbance. Coefficients were small; CRC patients should be screened for sleep 
disturbance throughout the cancer continuum. We found no relationship between exercise approximately 
iv 
at or above American College of Sports Medicine guidelines and sleep disturbance at approximately 10 
and 17 months after CRC diagnosis (or change increase in exercise and change in sleep disturbance). 
Exercise has clear health benefits and although this study does not provide evidence that exercise is 
associated with better sleep quality, CRC patients should continue to be encouraged to exercise.  
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CHAPTER 1. INTRODUCTION 
This dissertation highlights sleep as an important but often overlooked aspect of health-related 
quality of life (HRQOL) in individuals diagnosed with colorectal cancer (CRC). The prevalence of insomnia 
in cancer patients undergoing chemotherapy is 43%,
1
 between 30% and 87% of cancer patients are 
estimated to experience sleep disturbance.
2
 The prevalence of sleep disturbance in CRC patients is 
unknown but a secondary data analysis from a randomized control trial estimated that at least half of 
individuals diagnosed with CRC experience decrements in sleep.
3
 Although CRC is the third most 
common adult cancer diagnosed in the United States
4
 with more than 1.1 million individuals currently 
living with the disease,
5
 few studies examined sleep quality in the CRC population. HRQOL differs by 
cancer site
6
 and individuals diagnosed with CRC manage unique consequences of CRC treatment such 
as bowel control and stomas along with more general aspects of cancer and cancer treatment such as 
fatigue, anxiety, pain, and nausea,
7,8
 all of which have implications for sleep quality.  
Consequences of sleep disturbance include decreased cognitive functioning
9
 and fatigue,
10,11
 and 
cancer patients attribute impaired daytime functioning, trouble keeping up at work and social activities, 
and mood disturbance to sleep disturbance.
12
 Sleep disturbance is also a risk factor for infectious and 
cardiovascular diseases and depression
13
 and is associated with loss in work productivity and work 
quality as well as an increased number of visits to health professionals.
14
 With a 90% five-year survival 
rate for localized disease and 70% five-year survival rate for regional stages,
15
 patients diagnosed with 
CRC can expect to live relatively healthy lives for some time. With much of life still ahead for many CRC 
survivors, sleep quality should be assessed because the consequences of poor sleep negatively impact 
HRQOL, reduce work productivity, and increase risk of developing other comorbidities. Yet sleep has 
rarely been included as an outcome in CRC research.  
Individuals diagnosed with CRC may experience a range of sleep quality stretching from no sleep 
disturbance to severe insomnia (or another diagnosed sleep disorder). The etiology and severity of sleep 
disturbance may vary from patient to patient. For example, sleep disturbance may be caused by anxiety 
2 
related to cancer diagnosis for one person,
16-19
 but another person may attribute sleep disturbance to 
physical symptoms such as pain or nausea,
20,21
 and these factors may vary by severity of sleep 
disturbance. Chemotherapy, in particular, has been shown to negatively impact circadian rhythms
19,22
 and 
is associated with sleep disturbance in other cancers; the relationship between sleep disturbance and 
chemotherapy may be time dependent, with patients experiencing worse sleep disturbance during or 
immediately following chemotherapy. The relationship between sleep disturbance and CRC treatment is 
unknown. By understanding patient-level factors associated with poorer or better quality sleep, 
researchers could provide new insight to clinicians on the patient, disease, and treatment characteristics 
associated with worse sleep disturbance or worsening sleep disturbance. Identifying patient-level factors 
associated with sleep disturbance may also provide insight in the design of future randomized studies to 
identify patients who would benefit most from an intervention for severe sleep disturbance.  
Once sleep disturbance has been identified in individuals diagnosed with CRC, patients who 
would benefit from interventions to improve sleep quality are faced with a number of treatment options 
aimed mostly at treating clinically significant levels of insomnia or other diagnosed sleep disorders. 
Exercise improves sleep quality in healthy individuals
23
 and is recommended by the American College of 
Sports Medicine in cancer patients because it improves physical function, HRQOL, and cancer-related 
fatigue.
24
 Little research has explored the relationship between exercise and sleep in the CRC population, 
and assessing the relationship between exercise and sleep disturbance in CRC patients is important 
because exercise may provide a simple, safe, practical, low-cost option for managing sleep disturbance 
that can be tailored to each patient. Further, exercise may mitigate sleep disturbance that is meaningful to 
a patient but does not meet specifications to be diagnosed as a clinical sleep disorder. 
This dissertation evaluates sleep disturbance in individuals with CRC, with the objectives of 
providing insight on the patient, disease, and treatment characteristics associated with sleep disturbance, 
investigating whether there is variation in these factors across levels of sleep disturbance severity and 
finally assessing the relationship between sleep disturbance and exercise.  
To address these objectives, we conducted a secondary data analysis using a community-based 
dataset including adults diagnosed with stage I-III CRC. Data were collected at two time points: 
approximately 10 months after CRC diagnosis and again around 17 months after diagnosis, key time 
3 
points in the cancer continuum when most stage I-III CRC patients are transitioning (or have transitioned) 
off treatment. This dissertation includes two overarching research aims: 
Aim 1: Evaluate the relationship between sleep disturbance and patient, disease, and 
treatment characteristics: 
 Aim 1a: evaluate relationship between sleep disturbance and patient, disease, and treatment 
characteristics approximately 10 months after diagnosis; 
 Aim 1b: evaluate relationship between change in sleep disturbance and patient, disease, and 
treatment characteristics from approximately 10 to approximately 17 months after diagnosis.  
Primary hypothesis: Time since last chemotherapy treatment will be among the strongest factors 
associated with sleep disturbance outcomes.  
Aim 2: Evaluate the relationship between sleep disturbance and exercise. 
Primary hypotheses: Patients who were classified as moderately or highly active exercisers will 
report less sleep disturbance than patients who did not exercise. Patients who increased exercise activity 
groups from 10 to 17 months after diagnosis would experience a decline in sleep disturbance. 
This dissertation is organized into seven chapters. Chapter 2 is a literature review, describing 
CRC treatment and known HRQOL challenges for individuals diagnosed with CRC, the conceptual model 
for this research, known factors associated with sleep disturbance and exercise, and previous research 
on sleep disturbance. Chapter 3 provides a description of the overall methods used in this dissertation, 
outlining the overall study design, variables of interest, analytic models, and power analyses. Chapters 4 
through 6 describe the three studies driving this dissertation. Chapter 4 (manuscript 1) addresses Aim 1 
in its entirety: identifying patient, disease, and treatment characteristics associated with of sleep 
disturbance (and change in sleep disturbance) in individuals diagnosed with stage I, II, or III CRC and 
whether there was variation in patient, disease, and treatment characteristics across levels of sleep 
disturbance severity (or magnitude of change in sleep disturbance). Chapter 5 (manuscript 2) focuses on 
the relationship between the amount of exercise and severity of sleep disturbance cross-sectionally at 
approximately 10 and about 17 months after CRC diagnosis. Chapter 6 (manuscript 3) further addresses 
Aim 2 by evaluating the relationship between change in sleep disturbance and change in exercise from 
4 
approximately 10 to 17 months after diagnosis. Chapter 7 summarizes dissertation results and discusses 
clinical and policy relevance and future research.  
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CHAPTER 2. LITERATURE REVIEW 
2.1 Overview 
Sleep disturbance was considered a core cancer symptom by the National Cancer Institute 
Steering Committee
25
 and a Delphi consensus,
26
 but research on sleep in cancer patients is minimal 
compared to other aspects of health-related quality of life (HRQOL), particularly in the colorectal cancer 
(CRC) population. Within the cancer population, sleep studies are most prominent in breast cancer. Sleep 
literature from the general population and other cancers are integrated in this literature review to 
supplement not-yet-developed information in the literature about the CRC population. This chapter 
presents background information on key topics related to CRC (e.g., risk factors, treatment, prognosis) 
and sleep in CRC patients (e.g., factors associated with sleep disturbance, relationship between sleep 
and exercise). Chapter 2 also presents the conceptual model that ties these research topics together. 
2.2 Colorectal Cancer Summary 
CRC is cancer that starts in the colon or rectum.
27
 CRC is the third most common adult cancer in 
the United States
4
 and more than 1.1 million people live with CRC,
5
 approximately the population of 
Rhode Island.
28
 About 135,430 new cases are expected to be diagnosed in 2017.
29
 
2.2.1 Risk Factors 
Risk factors for CRC include certain health conditions, lifestyle factors, and specific racial/ethnic 
backgrounds. Health conditions associated with higher risk of CRC include inflammatory bowel disease, 
family history of CRC or polyps, genetic syndromes such as familial adenomatous polyposis or Lynch 
syndrome, and type 2 diabetes.
30,31
 Lifestyle factors associated with increased risk of CRC include lack of 
physical activity, diet low in fruits and vegetables, obesity, and alcohol and tobacco use.
30
 Some racial 
and ethnic backgrounds put patients at greater risk for developing CRC. For example, for unknown 
reasons, African Americans have the highest CRC incidence and mortality rates in the United States.
31
 
Ashkenazi Jews have the highest CRC risk in the entire world, a status attributed to a specific gene.
31
 
Another possible risk factor for CRC is night shift work.
32
  
 6 
2.2.2 Symptoms that Signal CRC Prior to Diagnosis 
CRC usually develops from adenomatous polyps in the colon or rectum.
33
 Symptoms of CRC are 
usually due to these polyps, such as blood in stool, abdominal pain, aches or cramps that do not go 
away, and unexplained weight loss.
34
 Some patients do not experience any symptoms,
34
 highlighting the 
importance of CRC screening.  
2.2.3 Screening 
Treatment works best when CRC is found early, therefore regular screenings for adults between 
the ages of 50 and 75 are recommended by the United States Preventive Services Task Force 
(USPSTF).
35
 Screening may include high-sensitivity fecal occult blood testing (FOBT), sigmoidoscopy, 
and colonoscopy.
36
 High-sensitivity FOBTs are noninvasive and are recommended once a year.
37
 
Individuals collect a small amount of stool for lab testing where the samples are tested for blood.
37
 A 
sigmoidoscopy is recommended every five years.
38
 During a sigmoidoscopy, a physician inserts a thin, 
flexible tube into the rectum to detect polyps or cancer inside the rectum and lower one-third of the 
colon.
37
 Colonoscopy is recommended every ten years and is similar to sigmoidoscopy except that the 
physician is able to check for polyps and cancer inside the rectum and entire colon.
37
 During this test, 
clinicians may remove any polyps and some cancers.
37
  
The median age of CRC diagnosis is 68 years, and most CRC patients are diagnosed between 
ages 65 and 75.
5
 CRC is more often diagnosed at later stages with only 40% of patients diagnosed with 
localized-stage disease.
39
 Incident cases are almost evenly split between males (47%) and females 
(36%).
5
 Incidence rates are highest in blacks and lowest in Asians/Pacific Islanders.
40
  
2.2.4 Stages and Grades 
CRC stages and grades guide clinicians on how to treat the cancer. CRC staging is based on the 
results of various tests such as physical exams, biopsies and imaging tests, and surgery.
41
 The American 
Joint Committee on Cancer (AJCC) Tumor Node and Metastases (TNM) system is most often used to 
stage CRC.
41
 Clinicians take these three factors into account when naming the stage. Specifically, they 
will look at how far the tumor has grown into the wall of the intestine or nearby organs, if the cancer has 
spread to nearby lymph nodes, and if the cancer has metastasized (spread) to other organs of the body.
41
 
If CRC spreads, it usually spreads to the liver or lungs.
41
 The cancer is given an overall numeric stage, 
 7 
which is then subdivided into stage groupings determined by the status of the tumor, lymph nodes, and 
metastases (e.g., T, N, and M). Patients with stage 0 cancer are at the earliest stage in which the cancer 
has not grown beyond the inner layer of the colon or rectum.
41
 Stage I cancer is defined as cancer that 
has grown through the inner layers of the colon or rectum (e.g., mucosa) but has not spread to nearby 
lymph nodes or distant sites.
41
 Stage II cancer includes cancer that has grown into the outermost layers 
of the colon or rectum and may have reached nearby tissues but has not reached lymph nodes or distant 
sites.
41
 Stage III is defined as cancer that has spread to nearby lymph nodes and may have grown to 
other nearby tissues or organs.
41
 Stage IV CRC includes cancer that has grown through the walls of the 
colon or rectum and may or may not have spread to nearby lymph nodes but has spread to at least one 
distant organ or distant lymph nodes.
41
 CRC grades also guide clinicians in treatment and prognosis 
decisions. CRC grade is decided based on a visual assessment of the cancer under a microscope
41
 and 
grades are assigned between 1 and 4. Grade 1 indicates that the cancer resembles normal colorectal 
tissue and grade 4 indicates that the cancer looks very abnormal.
41
 Lower-grade cancers are expected to 
grow and spread more slowly than higher-grade cancers.
41
 
2.2.5 Treatment 
Treatment for CRC varies by stage and grade. Stage I CRC includes surgery (which may take 
place during a colonoscopy) to remove the polyp. If the grade is high or if cancer cells were located at the 
edges of the polyp, follow-up surgery may be indicated. If the cancer was not part of a polyp, patients 
undergo a partial colectomy to remove a section of the colon and nearby lymph nodes. Other than 
surgery, no additional treatment is indicated for stage 0 and I CRC.
42,43
  
Treatment for stage II CRC includes surgery to remove the section of the colon or rectum afflicted 
by cancer and nearby lymph nodes.
42,43
 If the colon cancer is deemed higher risk, oncologists may 
recommend chemotherapy as an adjuvant treatment (after surgery).
42
 Chemotherapy options include 5-
FU, leucovorin and capecitabine.
42,43
 If there is uncertainty about the surgery removing all of the cancer, 
providers may recommend radiation therapy to destroy any remaining cancer cells.
42,43
 Stage II rectal 
cancer is more aggressive and treatment includes chemotherapy, radiation, and surgery.
43
 To begin, 
patients with stage II rectal cancer may undergo both chemotherapy and/or radiation therapy.
43
 The 
second phase is typically surgery, followed by the third phase, chemo.
43
  
 8 
Stage III colon cancer includes surgery to remove the section of colon with cancer as well as 
nearby lymph nodes
42
 and surgery is almost always followed up with adjuvant chemotherapy using the 
FOLFOX (5-FU, leucovorin and oxaliplatin) or CapeOx (capecitabine and oxalipatin) regimens (other 
regimens may apply depending on personal characteristics).
42
 As with Stage II colon cancer, radiation 
therapy may be advised if it were suspected that cancer cells were left behind during surgery.
42
 The 
treatment for stage III rectal cancer usually includes chemotherapy, radiation, and surgery
43
. First, 
patients are administered chemotherapy and radiation (called chemoradiation) to shrink the cancer before 
surgery.
43
 The surgery removes the rectal tumor and nearby lymph nodes (and sometimes includes pelvic 
exenteration if the cancer has reached nearby organs).
43
 After surgery, patients undergo chemotherapy 
for approximately six months.
43
 
Patients with stage IV CRC have cancer in distant organs and tissues, therefore surgery is 
indicated when cancer has spread to only a few areas.
42
 The purpose of the surgery is to remove the 
affected colon, nearby lymph nodes, and other tissues where the cancer may have spread. The cancer is 
either pre-treated with chemotherapy before surgery (called neoadjuvant chemotherapy) or chemotherapy 
may be given after surgery (adjuvant therapy) (or both).
42
 If metastases are too large to be removed via 
surgery, chemotherapy is the primary treatment. In this case, surgery may be needed for other reasons, 
such as unblocking the colon.
42
 Chemotherapy regimens for stage IV colon and rectal cancer are 
extremely varied but may include FOLFOX, CapeOX, FOLFIRI (leucovorin, 5-FU, and irinotecan), and 
combinations that include a compound to target the growth of blood vessels (vascular endothelial growth 
factor (VEGF)) in tumors such as bevacizumab.
42,43
 Patients with rectal cancer may undergo additional 
treatments before and after surgery that include radiation.
43
 For example, patients with stage IV rectal 
cancer may undergo chemo and/or radiation before surgery, then undergo chemotherapy and/or radiation 
after surgery.
43
 
To aid in healing after surgery, patients may have a colostomy to connect the colon to the outside 
of the abdomen. This procedure allows stool to pass through the opening in the abdomen and collect into 
an external pouch. Colostomies may be temporary or permanent, but most are temporary. 
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2.2.6 Prognosis 
Patients diagnosed with localized disease have an overall 5-year survival rate of 90% and 
patients diagnosed with regional disease have a 70% survival rate.
15
 Table 2.1 displays the five-year 
survival rate for colon and rectal cancers by stage as reported by the American Cancer Society.
44
 These 
statistics are based on stage of diagnosis (not current stage). Survival rates are derived from CRC 
statistics between 2004 and 2010 when current treatments may not have been available.
44
  
 
Table 2.1. Five-Year Survival Rate for Colon and Rectal Cancers 
 Colon Rectal 
Stage I 92% 87% 
Stage II 63-87% 49-80% 
Stage III 53-89% 58-84% 
Stage IV 11% 12% 
 
 
Death rates in blacks (29.4 per 100,000 population) are more than double Asians/Pacific 
Islanders (13.1 per 100,000 population) and approximately 50% higher than non-Hispanic whites (19.2 
per 100,000 population).
40
  
2.3 Importance of Studying Sleep Disturbance in Individuals Diagnosed with CRC 
The survival rate for a majority of CRC survivors is relatively high (see Table 2.1); patients will live 
for quite some time with the HRQOL impacts of the disease, diagnosis, and treatment. CRC patients 
experience worse health-related quality of life (HRQOL) than that of the healthy population.
6,45,46
 CRC not 
only has HRQOL implications for patients but also for caregivers.
47,48
 Thus, the impact of CRC on HRQOL 
in the United States is substantial. 
The prevalence of sleep disturbance or insomnia in the cancer population is approximately three 
times higher than the general population,
49
 and the prevalence of sleep disorders in CRC is not well-
studied, 
50
 but one study showed that half of the study participants diagnosed with CRC likely experience 
decrements in sleep.
3
  
Most cancer-related sleep research is focused on breast cancer patients. The experiences of 
CRC patients are different from breast cancer (notably, night sweats attributed to hormonal therapies in 
breast cancer are associated with sleep disturbance,
51
 and ostomies
52
 are associated with sleepiness); 
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CRC is diagnosed in men and women, and the type and location of surgery and treatment regimens are 
different. Therefore, the information derived from breast cancer studies can only inform CRC research, 
not supplement CRC research. The severity of impact on HRQOL and the type of HRQOL domains 
impacted by cancer differ by cancer type;
6
 CRC patients should be studied independently to better 
understand their unique HRQOL experiences.  
2.4 HRQOL in Individuals Diagnosed with Colorectal Cancer 
Individuals diagnosed with CRC may experience a number of symptoms and HRQOL impacts 
due to cancer or cancer treatment, all of which may change over time given changes in treatment and 
health status. This dissertation investigates sleep disturbance as patients transition out of treatment and 
into the survivorship stage, 10 to 17 months post-diagnosis. The following section will summarize relevant 
published research. Generally, HRQOL improved over time but CRC survivors may experience persistent 
HRQOL decrements for five or more years after diagnosis. 
2.4.1 General Impact of CRC on HRQOL 
A population-based observational study compared the HRQOL of older Americans (>= 65 years) 
after CRC diagnosis with the HRQOL of the general U.S. population.
45
 CRC patients who had been 
diagnosed within the previous six months reported the most dramatic declines in physical functioning, 
general health, mental health, social functioning and vitality compared to the general population.
45
 These 
declines exceeded minimally important difference thresholds relevant for each scale. Vitality and general 
health continued to decline until 12 and 18 months post-diagnosis for CRC patients respectively, also 
exceeding the minimal important difference thresholds.
45
 
In a German study it was found that one year after CRC diagnosis, insomnia and fatigue were the 
most prominent symptoms compared to nausea, pain, appetite loss, constipation and diarrhea, with over 
half reporting symptoms related to insomnia (e.g., trouble sleeping) and almost 80% reporting symptoms 
of fatigue (e.g., feeling tired, weak).
20
 CRC patients reported worse emotional and social functioning 
compared to the general German population.
20
  
A qualitative study including individuals with CRC within 18 months of diagnosis identified 
common HRQOL themes described by patients
.8
 Half of the participants reported no psychological 
changes since before CRC diagnosis. Of the patients that reported psychological changes, patients were 
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primarily concerned about cancer recurrence and reported changes in depression and anxiety. 
Approximately half of the patients described worsened physical function caused by loss of strength and 
fatigue. Social functioning was a concern for some patients due to access to bathroom facilities. Patients 
reported fewer social interactions attributed to tiredness and friends treating them differently. CRC 
patients reported that the cancer affected sexual relationships. These findings were also echoed in 
another qualitative study assessing open-ended responses written by CRC patients at various 
survivorship stages (mostly under 3 years post-treatment).
53
 Bowel/ostomy trouble, sexual function, 
fatigue, and nerve toxicity were among the most impacted areas of life for CRC patients. Neuropathy, 
fatigue, and trouble with bowel/ostomy decreased in difficulty over time. 
Five or more years post-diagnosis, individuals diagnosed with CRC generally reported similar 
HRQOL compared with population norms.
54
 However, CRC survivors reported slightly worse physical 
functioning, depression, and anxiety than the general population.  
2.4.2 Impact of Surgery on HRQOL 
A recent study of CRC patients who underwent surgery described trajectories of recovery within 
the first 2 years after surgery.
55
 Patients were administered a number of HRQOL outcome measures 
(e.g., Quality of Life in Adult Cancer Survivors (QLACS), EQ-5D, Personal Wellbeing Index) at 3, 9, 15, 
and 24 months after surgery. Results show a general improvement in HRQOL over 24 months after 
surgery. 
Age may play an important role in functioning within a month after surgery with older patients (> 
70 years) having worse HRQOL outcomes (e.g., physical, emotional, and social functioning) than younger 
patients.
56
 
2.4.3 Impact of Colostomy on HRQOL 
After surgery, some patients have colostomies to aid in recovery. A study comparing HRQOL 
between patients who had ostomies due to cancer versus non-cancer patients who had ostomies for 
other reasons found that cancer patients reported better HRQOL than non-cancer ostomy patients.
52
 
Overall, patients reported that ostomies influenced their lives by causing fatigue, sleeplessness, 
leakages, pain, decrements in physical functioning, and special travel, clothing, and diet considerations.
52
 
A German study compared HRQOL outcomes for CRC patients with and without stomas, and patients 
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with stomas reported worse social functioning, fatigue, nausea/vomiting, pain, insomnia, and appetite 
loss.
20
 
2.4.4 Impact of Chemotherapy on HRQOL 
Oxaliplatin is approved for first-line adjuvant chemotherapy treatment of stage III CRC and 
advanced CRC.
57
 Despite its efficacy, it is associated with peripheral neuropathy,
57
 which presents as 
weakness, numbness, or pain in the hands and feet and is attributed to nerve damage. In an 
observational study, 89% of individuals diagnosed with stage III or IV CRC undergoing oxaliplatin 
chemotherapy experienced at least one symptom of peripheral neuropathy.
58
 Notably, patients who 
experienced worse peripheral neuropathy also experienced worse sleep disturbance.  
Another study compared HRQOL for patients who underwent a curative resection (surgery) and 
adjuvant chemotherapy treatment of oral uracil/ftorafur (UFT) plus leucovorin (LV) versus curative 
resection alone for individuals diagnosed with stage II and III colon cancer.
59
 Clinically significant 
differences were found between treatment groups with worse HRQOL in the adjuvant chemotherapy arm 
on role function, fatigue, dyspnea, and financial difficulties.
59
  
An RCT followed CRC patients’ HRQOL through adjuvant chemotherapy and up to 5 years after 
as measured by the EORTC QLQ-C30.
60
 Patients were randomized to protracted venous infusion (PVI) 5-
FU for 12 weeks or 5-FU and leucovorin (LV) for 6 months.
60
 HRQOL trajectories were similar with 
patients in the 12-week PVI 5-FU arm recovering more quickly than the 6-month 5-FU + LV arm.
60
 
HRQOL worsened within two weeks of starting chemotherapy, but patients recovered to pre-
chemotherapy HRQOL as they transitioned off of the chemotherapy regimen (week 12 and 24 depending 
on the study arm).
60
 HRQOL continued to improve after chemotherapy ended and reached a plateau 
between 1 and 5 years post-chemotherapy.
60
  
A recent study examined patients’ symptoms and HRQOL up to 16 months after chemotherapy.
61
 
The study included individuals diagnosed with CRC, lung cancer, or lymphoma who underwent 
chemotherapy. The study found that symptom severity generally persisted 16 months after 
chemotherapy.
61
 Descriptive statistics show that sleep, fatigue, and pain outcomes fluctuated after 
chemotherapy, but fatigue and pain generally improved while sleep outcomes worsened.
61
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2.4.5 Impact of Radiotherapy on HRQOL 
Patients who underwent adjuvant radiotherapy for rectal cancer were assessed prior to radiation 
and 4-6 weeks after radiation. Fatigue and appetite loss significantly worsened by the end of radiotherapy 
compared to before, but patient functioning did not change significantly. HRQOL in general returned to 
pre-treatment levels 4-6 weeks after radiotherapy. 
2.5 Conceptual Model 
Figure 2.1 illustrates a conceptual framework proposed by Evans and Stoddart to model 
determinants of health.
62
 This model, called the Health Field Model, was developed by the Program in 
Population Health of the Canadian Institute for Advanced Research (CIAR).
63
 The CIAR consisted of an 
interdisciplinary group of researchers, communicators, and policymakers in Canada who wanted to 
understand implications for resource allocations in population health and who were concerned about 
health inequities.
63,64
 Evans and Stoddart were among the first researchers to call for a more holistic 
perspective on determinants of health, including the social environment.
65
 Although the Health Field 
Model was developed by individuals interested in Canadian health policy, the seminal paper titled 
“Producing Health, Consuming Health Care” is widely read. The model is relevant in the United 
States,
66,67
 many diseases,
64
 nursing,
68
 and even the design of outdoor spaces to increase public activity 
levels
69
 and environmental policy.
70
 
The Health Field Model emphasizes three aspects of health, including disease status (e.g., CRC), 
health and functional capacity (e.g., sleep), and well-being (e.g., HRQOL), each of which could be 
considered an outcome in research studies. The differentiation of these aspects of health is an important 
feature of the Health Field Model because it illustrates that each of the three health outcomes are a result 
of dynamic relationships among the individual factors. The model will be applied to this dissertation to 
provide a framework for identifying factors associated sleep disturbance (“Health and Function” box), and 
to evaluate exercise as a possible behavior associated with less sleep disturbance (“Individual Response” 
box). CRC status is affected by health care (e.g., chemotherapy, surgery), social environment, physical 
environmental, genetic and individual behaviors/biology, and indirectly by well-being and 
prosperity/financial status. Factors influencing health and function such as sleep disturbance include the 
disease itself and individual behaviors/biology, as well as health care/treatment indirectly. All of these 
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aspects play a role in well-being. Health behaviors (e.g., exercise) are seen as intermediate factors that 
are influenced by social, physical, genetic, and financial factors and even general well-being. The health 
behavior of interest in this dissertation is exercise. Sleep disturbance fits within the “Health and Function” 
box, thus this dissertation focuses on this aspect of health as the outcome. The model depicts “Health 
and Function” affecting well-being, which includes HRQOL. 
 
Figure 2.1. Health field model. 
 
 
Figure redrawn from: Evans RG, Stoddart GL: Producing health, consuming health care. Soc Sci Med 31:1347-63, 
1990
62 
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2.6 Sleep 
2.6.1 Sleep Physiology 
The Bureau of Labor Statistics reports that Americans spend approximately one-third of time 
asleep.
71
 Sleep physiology is complex and sleep patterns change over individuals’ life span. This section 
provides a brief introduction to sleep physiology and adult sleep patterns.  
There are two types of sleep: (1) non-rapid eye movement (NREM) and rapid eye-movement 
(REM). NREM includes four sleep stages, with each stage representing deeper sleep and NREM sleep 
makes up between 75% and 80% of total sleep time.
72
 NREM and REM alternate cyclically during sleep 
episodes.
72
 As individuals sleep, their REM time increases and dreaming most often occurs during REM 
sleep.
72
  
Many physiological changes occur during NREM and REM sleep.
72
 For example, brain activity 
decreases during NREM but increases in REM. Heart rate and blood pressure slow from wakefulness 
during NREM but then increase compared to NREM during REM. Sympathetic nerve activity increases 
during REM. Airway resistance increases during NREM and REM, and respiratory flow becomes 
increasingly faster and more erratic during REM. The cough reflex is suppressed during REM and NREM 
sleep. During REM, body temperature is not regulated (e.g., no shivering or sweating). Renal function 
changes cause more concentrated and reduced urine flow. Clearly, many body systems are affected 
during sleep, with many implications for individuals with sleep disorders. 
As adults age, there are changes in how sleep is initiated and maintained, as well as the 
percentage of time spent in each stage of sleep. Generally, sleep efficiency, the ability to initiate and 
maintain sleep, decreases with age.
73
 As adults age, they typically adopt earlier wake times and 
experience reduced sleep consolidation. Arousal during sleep increases with age. Specifically, night 
awakenings to go to the bathroom (nocturia) is a common experience among elderly and is associated 
with poorer sleep. Sleep complaints differ by gender with women expressing worse sleep problems than 
men.
73
 There is some evidence of racial differences in sleep quality.
73
 
2.6.2 Sleep Disorders 
The International Classification of Sleep Disorders lists 59 sleep disorders
74
 categorized into 
seven groups: 
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1. Insomnia (e.g., chronic short-term) 
2. Sleep-related breathing disorders (e.g., obstructive sleep apnea, sleep-related 
hypoventilation disorders) 
3. Central disorders of hypersomnolence (e.g., narcolepsy) 
4. Circadian rhythm sleep-wake disorders (e.g., delayed sleep phase disorder, irregular sleep-
wake rhythm disorder) 
5. Parasomnias (e.g., sleep walking, sleep terrors) 
6. Sleep-related movement disorders (e.g., restless legs syndrome, periodic limb movement 
disorder) 
7. Other sleep disorders 
Insomnia is defined as “persistent sleep difficulty despite adequate opportunity and 
circumstances for sleep, which is accompanied by daytime consequences that are attributable to the 
sleep disturbance.”
75
 Insomnia is often considered the primary sleep disorder associated with cancer.
11,76
 
The second category, sleep-related breathing disorders, is characterized by respiration problems during 
sleep due to obstruction or reduced/absent respiratory effort. Individuals who have sleep-related 
breathing disorders experience breathing cessation, reduced breathing and/or arousal from sleep due to 
airway resistance.
75
 Sleep-related hypoventilation can be caused by obesity and medications that cause 
respiratory depression such as opioids, which are often administered to cancer patients for pain control.
75
 
The third category, central disorders of hypersomnolence, includes a range of sleep disorders that cannot 
be attributed to any other sleep disorder but cause daytime sleepiness.
75
 Examples of these disorders 
include insufficient sleep syndrome and “Long sleeper” which are characterized by abnormally short or 
long episodes of sleep compared to age-defined norms. Hypersomnia (excessive sleepiness) can be 
caused by medical or neurologic disorders, drugs or substances, or psychiatric diagnoses.
75
 Circadian 
rhythm sleep-wake disorders are caused by misalignments of individuals’ circadian clocks. Irregular 
sleep-wake circadian rhythm sleep-wake disorder is caused by a lack of social schedule, physical activity, 
and daytime light synchronization and is often experienced by chronically ill individuals (including cancer 
patients).
75
 Parasomnias include undesirable behaviors while sleeping such as nightmares, sleep terrors, 
or sleepwalking, none of which are necessarily associated with medications or other diseases.
75
 Sleep-
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related movement disorders include restless leg syndrome and bruxism (e.g., clenching/grinding of teeth 
during sleep). 
2.6.3 Sleep Disturbance Defined 
Cancer patients experience difficulty falling asleep, difficulty staying asleep, and nighttime 
awakenings.
76
 Based on qualitative development with input from patients, clinicians, and stakeholders 
and subsequent quantitative evaluations of relevant sleep disturbance concepts, the Patient-Reported 
Outcomes Measurement Information System (PROMIS) Sleep Disturbance item bank and definition of 
sleep disturbance measured by these items was published.
77,78
 The PROMIS Sleep Disturbance scale is 
the outcome variable in all aims of this dissertation, therefore the PROMIS definition of sleep disturbance 
applies to all aims of this dissertation: 
“The PROMIS Sleep Disturbance item bank assesses perceptions of sleep quality, sleep 
depth, and restoration associated with sleep; perceived difficulties and concerns with 
getting to sleep or staying asleep; and perceptions of the adequacy of and satisfaction 
with sleep. The PROMIS Sleep Disturbance Scale does not include symptoms of specific 
sleep disorders, nor does it provide subjective estimates of sleep quantities (e.g., the total 
amount of sleep, time to fall asleep, or amount of wakefulness during sleep).”
55 
 
2.7 Factors Associated with Sleep Quality 
2.7.1 Factors in the General Population 
In the general population, psychiatric conditions play an important role in sleep quality; 
depressive symptoms are associated with difficulties falling asleep but not with lower sleep efficiency or 
total sleep time and anxiety is associated with worse sleep quality.
73,79,80,81
 Other health conditions impact 
the quality of sleep such as conditions associated with pain (e.g., chronic pain, arthritis, hip fracture, 
fibromyalgia, back pain), cardiovascular diseases (e.g., stroke, heart attack, angina), respiratory 
conditions (e.g., asthma, bronchitis), diabetes, and gastroesphageal reflux.
73
 Retirement from work is 
associated with better sleep quality.
73
 Physical functioning, such as mobility limitations, visual impairment, 
lack of exercise, alcohol use, and smoking
82
 contribute to declines in sleep quality in adults.
73
 Men 
experience more awakenings but women typically have more trouble falling asleep.
72
 Being a parent is 
associated with worse sleep quality.
83,84
 Employment status may play a role in sleep quality.
84
 For 
example, patients who are employed may sleep less because of work anxiety. A sense of financial 
security also plays a role in sleep quality for individuals diagnosed with cancer.
85
 Other demographic and 
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personal characteristics have been shown to be important predictors of insomnia in the general 
population, including lower education/socioeconomic status.
86
 
Physiology. Patients’ age and gender play important physiological roles in sleep quality.
72
 Sleep 
efficiency declines with age
72
 but the relationship between age and sleep is complicated.
73
 For example, it 
is unclear if the physiological phenomenon of decreased sleep efficiency with age should be considered 
insomnia or merely accepted as part of normal aging by patients who are growing older.
73
 Predictors of 
sleep disturbance may vary by age. Three key studies highlighted predictors of sleep disturbance in 
younger (age 17–24) and older (age 50 or older) populations. First, a study of sleep in older-
adolescent/college students (age 17–24) found that poor sleep quality was associated with negative 
moods (e.g., anger, confusion, depression, fatigue, tension, stress) and illness.
87
 Students reporting 
worse sleep consumed more alcohol per day than better sleepers and were more likely to use alcohol to 
induce sleep.
87
 Tension and stress were the most salient predictors of sleep quality, and approximately 
20% of students reported that stress interfered with sleep at least once a week.
87
 Gender, alcohol, 
caffeine, exercise, and television/videogame exposure were not statistically significant predictors of sleep 
quality.
87
 Second, in a recent review of risk factors for sleep disturbance in older adults, female gender, 
depressed mood, and physical illness were the most consistent risk factors for future sleep disturbance.
88
 
In this population, chronological age was not a consistent predictor of future sleep disturbance,
88
 but this 
may be because the physiological changes due to age may have already taken place by age 50 or soon 
thereafter. Third, a population-based study examined the relationship between insomnia, psychological 
variables, and HRQOL variables in adults age 50 or older.
89
 Researchers found that insomnia diagnoses 
and symptoms were predicted by previous insomnia episodes, depressive symptoms, and lower scores 
on the vitality and role physical (limitations in accomplishments/work due to physical health) subscales on 
the Short Form Health Survey (SF-12).
89
  
2.7.2 Factors in Individuals Diagnosed with Cancer 
Most studies that identify factors associated with sleep disturbance in cancer patients actually 
identify patient characteristics associated with insomnia or poor sleep using a cut point on the Pittsburgh 
Sleep Quality Index (PSQI) scale
90-92
 instead of a continuous measure of sleep disturbance. In addition, 
although HRQOL differs by cancer site,
6
 very few (if any) studies investigate factors related to sleep in the 
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CRC population specifically. Most studies assessing sleep disturbance have been in mixed-site advanced 
cancer and breast cancer populations. Of the relevant mixed-site cancer studies reviewed as part of this 
literature review, patients with CRC accounted for less than 22% of each sample.
91,93-95
 
In the oncology literature, the independent variables entered into models to find factors 
associated with sleep disturbance vary from study to study, but depression,
90,92,93,95
 anxiety,
94,95
 and 
pain
94,95
 were often statistically significant predictors of sleep disturbance or insomnia. Other factors 
include hopelessness,
93
 post-traumatic stress disorder (due to cancer diagnosis),
93
 physical health and 
functioning,
90,92,93
 health behaviors (sleep behaviors),
90,91
 patient characteristics (e.g., gender, age),
90-92
 
sedative use,
94
 fatigue,
94
 consuming more cigarettes,
92
 and having undergone surgery.
91
  
Although depression, anxiety, and pain are important factors associated with sleep disturbance in 
many studies, they are not always statistically significant in the models. Models varied widely from study 
to study depending on the cancer sites, stages, and window of time covered by the studies, as well as 
covariates entered in the models. For example, in a study that predicted sleep quality among head and 
neck cancer patients with any stage disease (stage 0-4) one year after diagnosis, depression, smoking, 
xerostomia
a
 (dryness in mouth) and pain were predictors of sleep quality. Pain was highlighted as a 
strong predictor of worsened sleep, but pain is more prevalent among individuals diagnosed with head 
and neck cancer versus other cancers.
96
 Another study including patients diagnosed with advanced lung, 
breast, gastrointestinal, urogenital (and other) cancers aimed to identify correlates of sleep quality.
93
 All 
patients in the study were in palliative care, and statistically significant predictors of sleep quality (using 
multivariate methods) were the SF-12 mental and physical component scales and post-traumatic stress 
disorder (due to cancer diagnosis).
93
  
In contradiction to the general population, in which older age is often associated with worse sleep, 
younger age is sometimes associated with higher risk for cancer-related insomnia.
2,21,97
 The reason for 
this is unclear, but it is possible that the expectations for better health among younger patients might be a 
factor.
2
 Also, younger patients often undergo more aggressive treatment regimens leading to worse 
HRQOL overall.
2
 
                                                     
a
 Xerostomia, a side effect of radiation, may negatively impact individuals’ sleep because patients may be 
more apt to wake up during the night due to discomfort, thereby drinking liquids during the night, and 
consequently causing more awakenings to use the bathroom. 
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Treatment-related factors may impact patients emotionally and physically (either directly or 
because of side effects). For example, medications commonly administered to patients diagnosed with 
cancer such as opioids, antiemetic medications, and corticosteroids are associated with sleep 
disruption.
98
 Symptoms associated with cancer treatment such as dyspnea, gastrointestinal symptoms 
(e.g., chemotherapy-induced nausea), and pain are associated with sleep impairment.
21
 Studies that 
reviewed the effect of cancer treatment on sleep disturbance found that chemotherapy was particularly 
detrimental to sleep.
21,99
 Most studies that assessed the relationship between treatment trajectories and 
sleep or HRQOL were in breast cancer; other studies assessed a mixture of patients diagnosed with 
different types of cancer. One study including patients diagnosed with a variety of cancers, pointed to a 
decline in HRQOL severity within one year after diagnosis.
100
 Two other studies assessing the 
longitudinal relationship between sleep and fatigue in breast cancer patients undergoing chemotherapy 
found that sleep quality was poor prior to chemotherapy but there was little change in sleep quality during 
chemotherapy.
16,17
 Another study in breast cancer found persistent sleep problems before and after 
surgery for breast cancer.
101
 HRQOL (including sleep) was assessed as part of a randomized trial of 
chemotherapy in ovarian cancer patients.
18
 The study authors found an immediate deterioration in sleep 
and other aspects of HRQOL around the first cycle of chemotherapy and then a statistically significant 
improvement in sleep and other aspects of HRQOL throughout chemotherapy.
18
 The trajectory of sleep 
disturbance throughout and after treatment for patients with CRC is unknown. 
2.8 Sleep and Symptom Clusters 
Cancer patients experience a number of symptoms attributed to the disease or treatment. Until 
the early 2000s, most cancer symptom research focused on individual symptoms.
102
 Although this 
research was important in understanding the precursors and effects of singular symptoms, cancer 
patients rarely report only one symptom
103
 and symptoms may affect each other. Consequently, treating 
one symptom may have effects on other symptoms and functions. The term “symptom cluster” was 
introduced by Dodd and colleagues in 2001 to describe multiple co-occurring symptoms that may or may 
not have a common cause.
104
 Ferrans posited that the relationship between symptoms and functional 
outcomes is not unidirectional.
105
 Although sleep has been identified as a core cancer symptom 
25
 
26
 that 
has complicated relationships with other symptoms and functional outcomes,
9
 many studies do not 
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include sleep in symptom cluster research. Few (if any) studies investigate symptom clusters specifically 
in CRC. Nonetheless, there is some evidence that sleep, depression, anxiety, and fatigue are related and 
comprise a symptom cluster in other cancers. For example, a prospective longitudinal evaluation of the 
symptom cluster of sleep, fatigue, depression, anxiety, and cognitive impairment in women with breast 
cancer undergoing chemotherapy found that the composition of the symptom cluster was supported with 
similar patterns of severity and changes over time.
106
 Another study in breast cancer supported a similar 
cluster of depression, fatigue, and sleep disturbance.
107
 A descriptive study of patients diagnosed with 
lung cancer who had undergone surgery within the previous week found that almost 77% of patients 
reported co-occurrence of pain, fatigue, sleep disturbance, and distress.
108
 A small (n = 120) descriptive 
study with elderly patients diagnosed with colorectal, lung, head/neck, breast, gynecological, prostate, or 
esophageal cancer at any disease stage found that pain, fatigue, insomnia, and mood disturbance were 
very prevalent in elderly patients who were receiving chemotherapy or radiotherapy.
81
 
2.9 Consequences of Disturbed Sleep 
The importance of sleep is well-documented in the literature; sleep disturbance is associated with 
worse health, increased mortality, decreased cognitive functioning,
9
 fatigue,
10,11
 reduced immune 
response, and reduced HRQOL.
9,109,110
 Sleep disturbance is also a risk factor for progression of CRC,
3
 
infectious diseases, cardiovascular diseases, and depression.
13
 Further, cancer patients described 
impaired daytime functioning, trouble keeping up at work and with social activities, and mood disturbance 
as a result of sleep disturbance.
12
 Thus, sleep disturbance has serious implications for overall HRQOL. 
Sleep disturbance is also associated with increased healthcare resource use (e.g., visits to health 
professionals) and decreased work productivity and work quality in chronically ill patients.
14
 The economic 
impact of fatigue in the workplace due to insomnia or insufficient sleep syndrome was estimated to be 
$13.2 million annually in a study published in 2010 based on the general U.S. population of working 
adults.
111
 
2.10 Treatments for Sleep Disturbance 
Cancer patients and clinicians are faced with two options for treating sleep disturbance: 
pharmacotherapies and cognitive behavioral therapy. Pharmacologic treatment options (e.g., 
benzodiazepine-receptor agonists, antidepressants, melatonin agonists) are associated with adverse 
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daytime side effects such as sedation or dizziness. Despite recommendations that pharmacotherapies 
should only be administered for 4 to 6 weeks,
21
 cancer patients may be treated for sleep disturbance with 
these medications long beyond this period.  
Cognitive behavioral therapy (CBT) is recommended by the American Academy of Sleep 
Medicine as a first-line therapy for patients with insomnia. CBT includes relaxation therapy, sleep 
hygiene, and cognitive therapy. Unfortunately, a lack of providers with CBT expertise and patient 
adherence issues are considerable barriers to sleep treatment efficacy.
9
 
Of these treatment options, neither are directly associated with additional health benefits, but 
another potential treatment with accumulating evidence of its effectiveness is exercise. Exercise improves 
aerobic fitness
112
 and other aspects of quality of life such as anxiety, pain, and fatigue, all of which are 
associated sleep disturbance.
113-115
 Exercise has been evaluated as a treatment for sleep disturbance in 
the healthy U.S. population
23,116
 and a number of RCTs and observational studies have investigated 
exercise as a possible treatment for sleep disturbance in cancer patients.
113,117-121
 Exercise is generally 
accessible and a low-cost alternative treatment for sleep disturbance. 
2.11 Exercise 
2.11.1 Measuring Exercise  
Exercise intensity is measured in various ways, including subjective and objective measurements.  
Objective measures of activity. 
Wearable devices such as accelerometers, pedometers, heart-rate monitors, and armbands are 
objective measures of physical activity.
122
 Devices are more expensive than subjective measures of 
activity and require specialized software and hardware, but they are associated with many benefits.
122
 
Devices are generally easy to use and they can capture large amounts of data on duration of physical 
activity and time spent participating in different intensities of exercise.
122
 Depending on the type of activity 
researchers are interested in measuring, some devices are better than others. For example, some 
accelerometers cannot differentiate body position (e.g., standing, sitting, lying down),
123
 pedometers are 
accurate measures of running or walking but cannot measure other activities such as swimming.
122
  
Exercise training is associated with improvements in cardiorespiratory fitness.
124
 The gold 
standard measurement of cardiorespiratory fitness is the maximal or peak oxygen consumption 
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(VO2peak).
125,126
 VO2peak has also been used to categorize training intensity in cancer patients.
124
 To 
measure VO2peak, cardiopulmonary exercise testing involves measuring patient metabolic data via 
expiratory gas analysis. After a brief warmup, patients’ workload is increased incrementally throughout 
the test until patients feel overly fatigued (volitional fatigue), achieve a set respiratory exchange ratio 
(RPE) (e.g., 1.10
126
) or patients become limited by symptoms. For example, if patients experience chest 
pain, dizziness, or nausea, the test would stop. Heart rate, RPE and VO2 are measured regularly 
throughout the test. VO2peak is calculated using an average of the highest values during the last minute of 
the test.
126
 Clearly, VO2peak measurements require significant resources and measuring cardiorespiratory 
fitness to track exercise intensity is not feasible in many studies. 
Subjective measures of activity. 
Self-reported physical activity questionnaires are patient-reported and based on individuals’ 
perceived exercise intensity, recall of activity duration, and frequency of exercise. Self-reported 
questionnaires are the most common mode of exercise assessment because they are easy and efficient 
to use and they are a low-cost alternative to objective measures.
122
 Disadvantages of self-reported 
exercise include recall and social desirability bias.
122
 Examples of self-reported questionnaires on 
physical activity commonly used in research to include the past-week Modifiable Activity Questionnaire 
(MAQ
127
), Recent Physical Activity Questionnaire (RPAQ
128
), and the 7-day Physical Activity Recall 
(PAR
129
).  
Self-report activity diaries/logs are a specific type of self-reported questionnaire in which study 
participants record their physical activity in real time.
122
 Diaries are more burdensome for patients but are 
associated with less recall bias. Bouchard’s Physical Activity Record (BAR) is an example of a physical 
activity diary in which study participants record their physical activity every 15 minutes for three days.
130
 
The BAR is a highly reliable (intraclass correlation = 0.96) measure of energy expenditure over the three-
day administration period.
130
 
Another type of physical activity measurement is direct observation. Observers monitor and 
record study participants’ activity.
122
 This type of physical activity measurement is applicable when 
participants can be monitored in contained spaces (e.g., hospital room) or when participants have 
difficulty recalling their activities (e.g., young children, adults with cognitive deficits).
122
 Direct observation 
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may only be cost-prohibitive when working with study participants who are unable to complete self-report 
questionnaires. 
Exercise recommendations for cancer patients. 
In 1995, the Centers for Disease Control and Prevention and the American College of Sports 
Medicine recommended that every U.S. adult should accumulate 30 minutes or more of moderate-
intensity physical activity on most, preferably all, days of the week.
57
 Other entities have provided cancer-
specific recommendations. For example, the American College of Sports Medicine (ACSM) recommends 
150 minutes of moderate-intensity exercise per week or 75 minutes of vigorous exercise per week.
15
 
Researchers from the American Cancer Society went further to say “some activity is better than none and 
exceeding the guidelines is likely to provide additional health benefits.”
58
 
The ACSM advises that cancer patients should be assessed for peripheral neuropathies, 
musculoskeletal morbidities, and cardiovascular disease.
24
 Cardiac toxicity due to cancer treatments may 
go undetected.
24
 Specific to CRC, the ACSM recommends that patients should establish consistent and 
proactive infection prevention for ostomies if they plan to participate in exercise more vigorous than 
walking.
24
 Infection risk is higher for patients undergoing chemotherapy or radiation due to compromised 
immune function.
24
 CRC patients with ostomies should also seek physician permission prior to 
participating in contact sports or weight training due to risk of hernia.
24
  
Exercise defined. 
The terms physical activity and exercise are often used interchangeably but there is an important 
difference in definitions. Physical activity is “any bodily movement produced by skeletal muscles that 
requires energy expenditure.”
131
 Exercise is physical activity that is “planned, structured and repetitive to 
improve physical fitness.”
131
 
Exercise measurement in this dissertation. 
The MY-Health study included three patient-reported items intended to measure the number of 
times patients engaged in different intensities of exercise per week: 
1. Now think about vigorous activities you did in your free time that take hard physical effort, 
such as aerobics, running, soccer, fast bicycling, or fast swimming. Do not include walking. In 
the past 7 days, how many times did you do vigorous activities? 
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2. Now think about the activities that take moderate physical effort that you did in your free time 
during the last 7 days. Moderate physical activities make you breathe somewhat harder than 
normal, such as bicycling, dancing, swimming and gardening. Do not include walking. In the 
past 7 days, how many times did you do moderate activities? 
3. Now think about walking that you did in your free time during the last 7 days, such as walking 
for fun, relaxation, exercise or walking the dog. Please do not include walking for 
transportation. In the past 7 days, how many times did you walk during your free time? 
Response choices for the three exercise items were: 
 None 
 Once 
 2 to 4 times 
 5 to 7 times 
 8 to 10 times 
 11 times or more 
Four exercise groups were derived to characterize patients’ level of activity (see Chapter 3 
Methods for additional details on derivation).  
The exercise questions administered in the MY-Health study are not part of a psychometrically 
evaluated scale, however the questions are very similar to those found in other psychometrically 
evaluated scales such as the Godin Leisure-Time Physical Activity Questionnaire
132
 (relevant items 
pictured in Figure 2). The Godin Leisure-Time Physical Activity Questionnaire is often used in oncologic 
settings,
133,134
 and validity studies support its use in ranking healthy adults into exercise categories of 
“active” and “insufficiently active.”
135
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Figure 2.2. Portion of the Godin Leisure-Time Physical Activity questionnaire.  
 
 
 
 
2.11.2 Relationship Between Exercise and Sleep 
Within the cancer population, exercise has been associated with many benefits including 
improved fitness,
112,136,137
 quality of life,
136
 physical function,
136
 and reduced fatigue,
115
 anxiety,
121,138
 and 
depression.
138
 Given the strong associations between sleep and HRQOL, it is plausible that exercise may 
also improve sleep, but not many exercise studies assess sleep as an outcome in the cancer literature. 
For example, a study of patients with stage II-III CRC found a statistically significant association between 
fitness and HRQOL and depression.
139
 Had this study included sleep disturbance as an outcome, 
exercise may have also been a significant driver for improved sleep.  
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Two studies that looked at change in sleep over time showed no significant effect of exercise on 
change in sleep disturbance, but both studies were in breast cancer.
140,141
 A meta-analysis conducted as 
part of a Cochrane review found a significant effect of exercise on sleep outcomes 3 months after the 
exercise interventions began compared to control arms. There was no statistically significant difference at 
time points longer than 3 months. Of the studies investigating sleep in the Cochrane review, none 
focused specifically on patients diagnosed with CRC.
121
 Another recent RCT in breast cancer found that 
physical activity may prevent worsening of sleep disturbance.
142
 
Three studies investigated the association between sleep and exercise with a focus on CRC 
patients, including two observational studies
120,119
 and one RCT.
117
 Of these studies, the RCT showed the 
most promising results indicating that exercise may improve sleep but all patients were diagnosed with 
stage IV disease. Cheville and colleagues enrolled 66 patients diagnosed with stage IV colorectal or lung 
cancer and followed patients over the course of 8 weeks. They assessed a home-based exercise 
intervention in which patients exercised four or more days a week. The intervention resulted in a 
statistically significant improvement in sleep for the patients who participated in the exercise intervention 
versus those who were randomized to the usual care arm.
117
 The two observational studies did not find a 
relationship between sleep and exercise, but both were small—119 adult participants
119
 and 45 adult 
participants
120
—and neither were powered to detect differences in sleep outcomes. The larger 
observational study conducted by Cho and colleagues incorporated a self-reported questionnaire to 
measure exercise.
119
 The exercise questions were not part of a validated scale but were developed 
specifically for the study. Items measured frequency, intensity, and duration of exercise. The smaller 
observational study conducted by Lin and colleagues employed an opt-in exercise protocol such that 
participants were placed in a supervised exercise group or a usual care group based on their 
preference.
120
 The supervised exercise group participated in moderate-intensity aerobic and resistance 
exercise for 12 weeks. Exercise intensity, duration, and frequency was not measured for the usual care 
group.  
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CHAPTER 3. METHODS 
3.1 Methods Overview 
The analyses conducted as part of this dissertation used data from a large community-based 
observational study that included over 5000 individuals diagnosed with cancer. These data were subset 
to colorectal (CRC) patients only to address research questions specific to this dissertation. The timing of 
data collection was of particular importance in developing research objectives and hypotheses. Thus, the 
parent study is described first (Section 3.2), then Section 3.3 outlines research objectives and 
hypotheses. Section 3.4 picks up with detailed information on the analysis dataset used in this 
dissertation. Analytic methods and power analyses are described in Section 3.5.  
3.2 MY-Health Study 
Data for this dissertation were obtained from a community-based study of over 5000 individuals 
diagnosed with cancer. Designed to evaluate the psychometric properties of Patient-Reported Outcomes 
Measurement Information System (PROMIS) measures in a diverse population of cancer patients, 
Georgetown University’s Measuring Your Health study (MY-Health) recruited adults diagnosed with one 
of seven cancers (e.g., breast, prostate, colorectal, non-small cell lung, non-Hodgkin lymphoma, uterine, 
or cervical cancer) through four Surveillance, Epidemiology and End Results (SEER) cancer registries in 
the United States (California (two registries), Louisiana, and New Jersey) between 2011 and 2013.
143
 
Individuals aged 21 years and older and diagnosed within the previous 6–13 months were invited to 
participate in the MY-Health study via mail. Participants completed questionnaires using mail-in hard copy 
questionnaires at two time points:  
(1) Approximately 10 months after diagnosis (mean = 9.73, range = 6-30 months)  
(2) Approximately 17 months after diagnosis (mean = 17.42, range = 11-36 months) 
For brevity, the first data collection will be referred to as the Month 10 data collection and the 
second data collection will be referred to as the Month 17 data collection. 
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Race/ethnic minorities and younger patients were oversampled. Questionnaires were available in 
English, Spanish, and Mandarin. Most data were collected via self-reported questionnaires, but some 
medical information (e.g., cancer site, age at diagnosis, cancer stage) were collected via SEER. 
Additional details on the study design, procedures, and measures administered in the study were 
previously published.
143
  
3.3 Research Objectives and Hypotheses 
As noted in Chapter 1 (Introduction), this dissertation included two aims with the purpose of 
splitting the largest aim, Aim 2, into two manuscripts. Because the dissertation includes three 
manuscripts, for clarity, research objectives and hypotheses will be referred to by manuscript number 
instead of by aim. 
Research objectives and hypotheses: 
3.3.1 MANUSCRIPT 1 
Research objective 1a: Investigate whether there was variation in patient, disease, and 
treatment characteristics across levels of sleep disturbance severity at Month 10. 
 Hypothesis 1a: Associations between factors (e.g., patient, disease, and treatment 
characteristics) and sleep disturbance differ by severity of sleep disturbance.  
Research objective 1b: Evaluate the relationship between sleep disturbance and patient, 
disease, and treatment characteristics with the goal of identifying correlates of sleep disturbance at Month 
10. 
 Hypothesis 1b: Patients who were currently undergoing chemotherapy during the time of data 
collection or those who had more recently undergone chemotherapy would report worse sleep 
disturbance than patients who never had chemotherapy.  
Research objective 1c: Investigate whether there was variation in patient, disease, and 
treatment characteristics across the magnitude of change in sleep disturbance severity from Month 10 to 
Month 17. 
 Hypothesis 1c: Associations between sleep disturbance and patient-level factors (e.g., patient, 
disease, and treatment characteristics) vary by magnitude of change in sleep disturbance.  
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Exploratory research objective 1d: Evaluate the relationship between change in sleep 
disturbance (Month 10 to Month 17) and patient, disease, and treatment characteristics with the goal of 
identifying correlates of change in sleep disturbance. 
3.3.2 MANUSCRIPT 2 
Research objective 2a: Investigate whether the relationship between exercise and sleep 
disturbance differed by severity of sleep disturbance at Month 10 and at Month 17. 
 Hypothesis 2a: The relationship between exercise and sleep disturbance differs by severity of 
sleep disturbance.  
Research objective 2b: Evaluate the relationship between exercise and sleep disturbance at 
Month 10.  
 Hypothesis 2b: Patients who were categorized as moderately or highly active at Month 10 would 
experience less sleep disturbance than patients who did not exercise. 
Research objective 2c: Evaluate the relationship between exercise and sleep disturbance at 
Month 17.  
 Hypothesis 2c: Patients who were categorized as moderately or highly active at Month 17 would 
experience less sleep disturbance than patients who did not exercise. 
 
3.3.3 MANUSCRIPT 3 
Research objective 3a: Investigate whether the relationship between change in sleep 
disturbance and change exercise differed by magnitude of change in sleep disturbance from Month 10 to 
Month 17. 
 Hypothesis 3a: The relationship between change in sleep disturbance and change in exercise 
activity differs by magnitude of change in sleep disturbance. 
Research objective 3b: Evaluate the relationship between change in sleep and change in 
exercise from Month 10 to Month 17. 
 Hypothesis 3b: Patients who increase exercise activity from 10 months to 17 months after 
diagnosis would experience a decline in sleep disturbance. 
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3.4 Analysis Dataset 
Of the MY-Health sample, 734 individuals had been diagnosed with stage I, II, or III CRC and 
participated in the Month 10 data collection. Approximately 54% of these patients participated in the 
follow-up assessment at Month 17 (n = 400).  
Figure 3.1 illustrates the MY-Health data collection time points and how they correspond to 
patients’ diagnosis and general CRC treatment patterns. Time since diagnosis runs along the x-axis in 
months, starting with CRC diagnosis on the far left side. The mean time since diagnosis at the first data 
collection was 9.7 months for the CRC sample [denoted by the first dotted vertical line] (SD = 1.6, median 
= 9.5, min = 5.5, max = 21.3). The follow-up data collection occurred approximately 17.3 months after 
diagnosis for the CRC sample [denoted by the second dotted vertical line] (SD = 2.0, median = 17.0, min 
= 12.8, max = 26.4). The tan bars indicate approximately one standard deviation above and below the 
mean number of months since diagnosis when patients participated in the MY-Health survey. Typical 
treatment trajectories are shown by CRC stage (green, blue, and pink bars). The main takeaway from 
Figure 3.1 is that most CRC patients were likely transitioning off CRC treatment around the Month 10 
data collection.  
 
Figure 3.1. MY-Health study data collection for individuals diagnosed with CRC and typical CRC 
treatment timeframe. 
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3.4.1 Dependent Variables 
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance 
items were administered to patients at Month 10 and Month 17 data collections. PROMIS Sleep 
Disturbance measures concepts such as trouble staying asleep, not getting enough sleep, restlessness, 
feeling refreshed after sleep, and difficulty falling sleep in “the past 7 days.” Results of the full 
psychometric evaluations of the PROMIS Sleep Disturbance item bank
144
 and short forms
145
 were 
previously published. A custom 6-item short form was scored; the psychometric properties of the 6-item 
form were evaluated in individuals enrolled in the MY-Health study (Cronbach’s α = 0.88 – 0.95).
146
 
PROMIS Sleep Disturbance is a continuous variable scored on a t-score metric with a mean of 50 and 
standard deviation (SD) of 10 based on the referent population (mixture of clinical and the general U.S. 
population
147
), and higher scores indicate worse sleep disturbance. Change in sleep disturbance was 
calculated by subtracting PROMIS Sleep disturbance scores at 10 months from scores at 17 months after 
CRC diagnosis. Positive change is indicative of worsening sleep. 
3.4.2 Independent Variables 
Factors associated with sleep disturbance. 
The MY-Health dataset contained information on patient, disease, and treatment factors 
associated with sleep disturbance. There is a known link between cancer treatment and sleep 
disturbance, and some literature suggests that there is a relationship between time since treatment and 
sleep disturbance,
16-18,100,101
 though the trajectory of sleep disturbance throughout and after treatment for 
adults with CRC is unknown. Cancer treatment type (e.g., surgery.
91
 chemotherapy,
21,99
 radiation) and 
most recent date of treatment were self-reported. (Few CRC patients [Month 10: n = 13, 17.9%, Month 
17: n = 63, 8.6%] reported undergoing radiation, therefore radiation was not included in the analyses.) 
Categorical variables were derived to capture current/recent treatment compared to no treatment or less-
recent treatment at Month 10 and Month 17. Categories were based on relevant physical recovery 
periods post-treatment and data availability. Time since chemotherapy was coded using four categories 
(i.e., currently receiving chemotherapy, chemotherapy 1–2 months ago, chemotherapy more than 2 
months ago, never received chemotherapy [reference category]). Time since surgery was coded using 
three categories (i.e., surgery occurred within 0–4 months, surgery occurred more than 4 months ago, 
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never received surgery [reference category]). Comorbid conditions
73
 were self-reported at Month 10 and 
included in the models as a derived variable with three categories (i.e., no comorbid diseases [reference 
category], 1 comorbid disease, 2 or more comorbid diseases). In addition to PROMIS Sleep Disturbance, 
other PROMIS domains were included in the models as independent variables to assess aspects of 
health-related quality of life known to be associated with sleep disturbance.
73,79
 
80
 
81,90,92-95,148,149
 Anxiety 
(11 items), Depression (10 items), Fatigue (14 items), and Pain Interference (11 items). These PROMIS 
measures were normed to the general U.S. population
147
 and higher scores indicate worse anxiety, 
fatigue, and pain interference respectively. PROMIS measures were administered at Month 10 and Month 
17, therefore, change scores for PROMIS Anxiety, Depression, Fatigue, and Pain Interference were 
calculated (Month 17 – Month 10) and included in analyses modeling change in PROMIS Sleep 
Disturbance (negative change indicates improvement). Nausea severity was measured using a 5-point 
nausea
21
 item from the FACT-G Physical Well-Being (PWB) subscale
150
 with a recall period of the “past 7 
days” and response choices ranging from 0 = “not at all” to 4 = “very much.” Although the nausea item 
has not been psychometrically evaluated as a single measure of nausea, the entire FACT-G PWB scale, 
which has been evaluated extensively in cancer patients, covers concepts that overlap with PROMIS 
measures such as pain and fatigue. Therefore, only the nausea item was included in the models as a 
continuous variable and change in nausea from Month 10 to Month 17 was included in analyses modeling 
change in sleep disturbance (negative change indicates improvement). Other characteristics known to be 
associated with different levels of sleep disturbance were included in the models such as age at 
diagnosis,
2,21,97
 sex,
72
 time since diagnosis,
93
 employment status (collected at Month 10 only),
84
 and an 
indicator for living with children under 18 (collected at Month 10 only)
83,84
 were included in the models. 
Age and race were also included in the model to account for the over-sampling of younger and minority 
persons from SEER registries. Race, employment status, and the living-with-child(ren) indicator were self-
reported, and age at diagnosis, sex, and diagnosis date were obtained via SEER registry data.  
Exercise. 
The MY-Health study included three exercise-related survey items covering patient-perceived 
exercise intensity and patient-reported frequency of exercise in the previous 7 days:  
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1. “Now think about vigorous activities you did in your free time that take hard physical 
effort, such as aerobics, running, soccer, fast bicycling, or fast swimming. Do not 
include walking. In the past 7 days, how many times did you do vigorous activities?” 
2. “Now think about activities that take moderate physical effort that you did in your free 
time during the last 7 days. Moderate physical activities make you breathe somewhat 
harder than normal, such as bicycling, dancing, swimming, and gardening. Do not 
include walking. In the past 7 days, how many times did you do moderate activities?” 
3. “Now think about walking that you did in your free time during the last 7 days, such as 
walking for fun, relaxation, exercise or walking the dog. Please do not include walking 
for transportation. In the past 7 days, how many times did you walk during your free 
time?” 
Response choices for all three exercise questions were: 
 None 
 Once 
 2 to 4 times 
 5 to 7 times 
 8 to 10 times 
 11 times or more 
Exercise items were administered at Month 10 and Month 17 data collection, capturing patients’ 
exercise routines during each slice of time during their treatment trajectory. Information on duration of 
exercise was not collected, but a recent Cochrane Review investigating the effect of exercise 
interventions on HRQOL reported that exercise sessions ranged from 20 to more than 90 minutes for 
cancer patients,
121
 and another study reviewed a number of exercise interventions that included sessions 
where most were between 20 and 30 minutes in length.
151
 It was assumed that one exercise session was 
approximately 20–30 minutes, meaning that patients would need to exercise at least 5 to 6 times at 
moderate intensity in the past 7 days to achieve the minimum American College of Sports Medicine 
(ACSM) guideline.
24
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We obtained guidance and feedback from two exercise physiologists on classifying patients into 
exercise categories based on their responses to the exercise items. A series of in-person meetings and 
phone and email communications were conducted from May 2016 through June 2016.
152
 Patients’ 
exercise was categorized into one of four activity levels:  
1. Not active: This "not active" group includes patients who reported no vigorous, moderate, or 
walking activities in the past 7 days or only one vigorous, moderate, or walking activity in the 
past 7 days.  
Rationale: One day of exercise per week is not associated with significant physiological changes, 
therefore patients who exercised 0 or 1 day a week were included in this group. 
2. Slightly active: The slightly active group is composed of two groups of patients: 
a. patients who walked 2–4 times in the past 7 days but did not participate in any other 
activities in the past 7 days (e.g., no moderate or vigorous activities) 
b. patients who participated in 2 exercise activities at any intensity in the past 7 days total 
(i.e., patients who chose the “once” in the past 7 days response to two exercise items) 
Rationale: This level of exercise per week is beneficial to adults diagnosed with CRC but not as 
physiologically beneficial as 3 or more activities, therefore this group is separated from moderately active 
individuals. 
3. Moderately active: The moderately active category is characterized by three groups of 
patients: 
a. patients walked 5 or more days in the past 7 days and did not participate in any other 
moderate or vigorous activity 
b. patients who walked at least 2–4 times in the past 7 days in addition to at least one day 
of moderate or vigorous activity.  
c. patients who exercised at moderate or vigorous levels at least 2 times in the past 7 days 
but could not have exercised more than 4 times in the past 7 days based on the minimum 
days reported in each response choice (regardless of walking). For example, patients 
were categorized as having participated in the moderately active if they participated in 2–
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4 moderate and 2–4 walking days (and no vigorous days) because their minimum 
number of days exercising would be 4. 
Rationale: Patients who meet the moderately active threshold may have met the minimum ACSM 
guideline for 150 minutes of moderate-intensity exercise per week, but only if they were exercising closer 
to the maximum number of days provided in each response choice. In other words, patients would have 
had to exercise closer to 4 times in the past week when they responded “2-4 times a week.” 
4. Highly active: The highly active category was defined as at least 5 days of moderate or 
vigorous activity in the past 7 days (regardless of the number of walking days). Days of 
activity were defined by the minimum number of days that each patient could have exercised 
based on the response choice. For example, patients were categorized as highly active if 
they participated in 5–7 vigorous and 2–4 moderate days of activity because their minimum 
number of days exercising would be 7.  
Rationale: Patients who meet the highly active threshold likely met the minimum ACSM guideline 
for 150 minutes of moderate-intensity exercise per week. 
Exercise level was set to missing when responses to 2 or more exercise items were missing.  
Patients classified in the “not active” or “slightly active” groups likely did not meet the minimum 
ACSM guideline of 150 minutes of moderate-intensity exercise per week or 75 minutes of vigorous 
exercise per week,
15
 but patients in the “moderately active” or “highly active” groups likely met or 
exceeded the ACSM guideline. Exercise level was entered in the cross-sectional models as an indicator 
variable with “not active” as the reference category.  
Change in exercise (Month 17 – Month 10) summarizes the change in exercise categories from 
10 to 17 months after CRC diagnosis. Change in exercise was entered in the model as a categorical 
variable with five categories: (1) less active by 2 or 3 exercise categories, (2) less active by 1 exercise 
category, (3) no change in exercise activity, (4) more active by 1 exercise category, and (5) more active 
by 2 or 3 exercise categories. A second six-category change-in-exercise variable was derived for 
sensitivity analyses and provided more detail on patients who did not change exercise activity but were 
still active: (1) less active by 2 or 3 exercise categories, (2) less active by 1 exercise category, (3) no 
change in exercise activity—persistently not active or slightly active [reference category], (4) no change in 
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exercise activity—persistent moderately or highly active, (5) more active by 1 exercise category, and (6) 
more active by 2 or 3 exercise categories.  
Factors associated with participation in exercise. 
MY-Health variables also collected information on determinants of exercise participation 
(treatment selection). Exercise participation is partially determined by patients’ ability to perform 
activities,
153-155
 thus patients’ PROMIS Physical Function scores were included as a covariate (higher 
scores indicate better physical functioning).
156
 Social support is associated with participation in exercise 
and was measured using PROMIS Ability to Participate in Social Roles and Activities.
153-155,157
 Both 
PROMIS measures, PROMIS Physical Function and PROMIS Ability to Participate in Social Roles and 
Activities, were collected at Month 10 and Month 17, therefore change scores were also calculated for 
models addressing change in sleep disturbance (Month 17 – Month 10: positive change indicates 
improvement). Higher weight is associated with less exercise, therefore body mass index (BMI) was 
derived from patient-reported weight and height (collected at Month 10 only).
72
 Other factors already 
included in the model that are associated with participation in exercise and affect sleep include increased 
age, parenthood, sex, and race.
153-155
 
3.5 Analytic Methods  
Descriptive statistics were calculated and tabulated to describe the patient sample and 
distributions of variables included in analyses for each manuscript. The analytic method used to evaluate 
heterogeneity in the relationship between sleep disturbance (or change in sleep disturbance) and patient, 
disease, and treatment factors or exercise was regression mixture models (RMMs).
158,159
  
3.5.1 Rationale for RMMs.  
Previous research on the relationship between exercise and sleep in CRC shows mixed results. 
The most compelling study, a randomized trial including Stage IV lung and CRC patients, showed a 
decrease in sleep disturbance with exercise.
117
 A host of other studies (including observational and 
randomized studies) showed no effect or mixed results when assessing the relationship between exercise 
and sleep in CRC and other populations.
119-121,160
 In these studies, the effect of exercise on sleep 
disturbance could be lost in the average effects for the exercisers. RMMs provide an opportunity to 
identify subgroups of patients for which the relationship between exercise and sleep disturbance may 
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vary. An extreme but illustrative example is a case in which for one group of patients, exercise has a 
negative relationship with sleep disturbance (better sleep), but for another group, exercise has a positive 
relationship with sleep disturbance (worse sleep). The average of these groups is 0. This result is 
misleading, suggesting that there is no relationship between exercise and sleep disturbance for the 
exercise group when, in fact, for a subgroup of patients, exercise is associated with better-quality sleep. 
RMMs are particularly useful in identifying these types of subgroups of patients, or in other words, the 
heterogeneity in the relationship between exercise and sleep disturbance.  
3.5.2 RMM Estimation 
RMMs are special cases of finite mixture models, which model weighted combinations of different 
distributions. With RMMs, the component membership to each distribution is unobservable (a latent 
variable) and discrete. These distributions are called classes. Each patient in the dataset is associated 
with a probability of being in each class. Regression coefficients vary by class. The base equation for the 
cross-sectional mixture models was: 
𝑆𝑙𝑒𝑒𝑝 𝐷𝑖𝑠𝑡𝑢𝑟𝑏𝑎𝑛𝑐𝑒(𝑖) =  𝛽0(𝐶) + 𝛽1(𝐶)𝐴𝑛𝑥𝑖𝑒𝑡𝑦 (𝑖) +  𝛽2(𝐶)𝑃𝑎𝑖𝑛(𝑖) + 𝛽3(𝑐)𝐹𝑎𝑡𝑖𝑔𝑢𝑒(𝑖) + ⋯ + ∈(𝑐) 
where β signifies the regression coefficients for each variable in the model, the subscript C 
indicates the coefficient for that class, i is the value for an individual i, and є represents error in the model. 
Variables discussed in Section 3.4.2 were added in the ellipses depending on the research objective. For 
example, for Manuscript 2, in addition to other patient, disease, and treatment characteristics, exercise 
was added to the model with other variables accounting for participation in exercise. The RMM equation 
for models evaluating change in sleep disturbance included change in sleep disturbance from Month 10 
to Month 17 data collection as the outcome variable and change in HRQOL factors (e.g., anxiety, pain, 
fatigue) as well as change in other factors that were collected at Month 10 and Month 17. Patient and 
cancer characteristics that were only captured at Month 10 were included in the change models at Month 
10 (e.g., age, parent status). CRC treatment information was captured at Month 10 and Month 17, so the 
most recent treatment information was included in the change models (Month 17). Change models 
included PROMIS Sleep Disturbance at Month 10 as a covariate to account for starting sleep disturbance 
scores.
161
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RMMs were estimated using Dual Quasi-Newton optimization.
162
 Models ranging from 1 to 4 
classes were evaluated. Four classes were chosen as the maximum because anything beyond that would 
likely stretch the available sample size too far to obtain meaningful and interpretable estimates. For 
simplicity, the probability distribution for each component was set to a normal (Gaussian) distribution, and 
the link function was the Identity function. Class size was allowed to vary depending on the best model fit. 
The final models (e.g., choice of number of classes) were chosen based on fit (e.g., smallest Bayesian 
Information Criterion Index (BIC)) and interpretability. RMMs are preferable to multiple regression for 
assessing heterogeneity in patient, disease, and treatment characteristics related to sleep disturbance 
because multiple regression assumes a single association pattern apply to the whole study population. If 
only one class of sleep disturbance was found, then multiple regression (which assumes one common 
class of sleep disturbance and one common linear relationship between each x-variable and sleep 
disturbance) was used to model factors associated with sleep disturbance.  
If RMM results point to more than one class, it would be concluded that the relationship between 
sleep disturbance and other patient-level factors (i.e., demographics, disease characteristics, treatment 
characteristics, exercise) was different for subgroups of patients. These subgroups are akin to interaction 
terms in a regression model, except that with RMMs, we can identify subgroups of patients with 
unobserved/unmeasured (latent) variables.  
Relationships between candidate independent variables were evaluated for collinearity by 
calculating bivariate correlations and variance inflation factor (VIF) within multiple regression models. VIF 
values greater than 10 were considered a symptom of multicollinearity. Residuals were evaluated 
between candidate independent variables and PROMIS Sleep Disturbance to determine if higher-order 
terms needed to be included in the models.  
Logistic regression was used to identify factors associated with patient attrition or incomplete 
surveys. The logistic regression models included patient characteristics collected at Month 10 that were 
related to sleep disturbance and potentially associated with survey compliance: sex, race, employment 
status, survey language, time between most recent chemotherapy and survey completion (Manuscript 1 
only), level of exercise activity (Manuscripts 2 and 3 only), PROMIS Sleep Disturbance, and PROMIS 
Physical Functioning. 
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3.5.3 Analysis Conventions 
Regression coefficients were reviewed to describe the relationship between sleep disturbance 
and covariates in the models. Complete case analyses were conducted for all models. An alpha of 0.05 or 
less was chosen as the criterion for statistical significance of the covariates in the RMMs. All analyses 
were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). More specifically, we used a 
SAS procedure called PROC FMM to fit RMMs.
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3.5.4 RMM Starting Values 
RMMs’ Dual Quasi-Newton optimization
162
 requires initial model parameter values that give the 
model a place to start optimization, called starting values. SAS PROC FMM supplies starting values for 
each class, but RMM results can be sensitive to starting values,
164
 therefore a user-defined set of starting 
values were tested to evaluate the impact SAS PROC FMMs starting values on the number of classes 
chosen in each manuscript. A SAS macro was developed to generate starting values for all primary 
models. The generated starting values were tested and model fit results were tabulated. SAS starting 
values were derived and evaluated in 5 steps: 
First, median sleep disturbance was calculated using PROMIS Sleep Disturbance (depending on 
the model’s dependent variable, PROMIS Sleep Disturbance at Month 10, Month 17, or change from 
Month 10 to Month 17 was used). The analysis sample was divided into two subgroups: patients who 
scored below the median on PROMIS Sleep Disturbance and patients who scored greater than or equal 
to the median on PROMIS Sleep Disturbance.  
The second step was to run a set of multiple regression models, one model for patients who 
scored below the median on PROMIS Sleep Disturbance and a second model for patients who scored at 
or above the median on PROMIS Sleep Disturbance. Coefficients were stored for use in Step 3. For 
example, age was an independent variable entered into all models and two coefficients on age were 
calculated—one for the patients who scored below the median on PROMIS Sleep Disturbance and one 
for patients who scored at or above the median on PROMIS Sleep Disturbance.  
In Step 3, each regression coefficient estimate calculated in Step 2 was then randomized using a 
normal distribution and a standard deviation of 10 times the standard error of the coefficient. Step 3 was 
reiterated 100 times to calculate 100 sets of coefficient values. 
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In Step 4, two regression mixture models were calculated. First, a regression mixture model with 
one class (in other words, a multiple regression model) was calculated. Second, the randomized 
coefficient values from Step 3 were used as starting values in a regression mixture model with two 
classes. The regression mixture model with two classes was recalculated 100 times, with each set of 
coefficient values calculated in Step 3. Every time a regression ran, BIC was recorded.  
In Step 5, BIC for all 100 iterations of the two-class RMMs were compared against the BIC for the 
one-class model. Models with BIC values less than the one-class model were tabulated and reviewed for 
interpretability. 
The steps above describe the process for testing starting values for two classes, but this process 
could be expanded to test more than two classes. 
Results of RMM starting value analysis. 
Manuscript 1. 
Month 10 model. Six out of 100 two-class solutions yielded lower BIC values than the one-class 
(multiple regression) solution, but the mixing probabilities were very small with the smaller classes 
composed of less than 8% of the sample, implying that the smallest classes contained outliers (Table 
3.1). 
Change model. For the change model, 10 out of 100 two-class solutions yielded lower BIC values 
than the one-class (multiple regression) solution. The mixing probabilities were also very small, with the 
smallest class composed of less than 11% of the sample (Table 3.1). The model parameters for all 10 of 
these two-class solutions were uninterpretable.  
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Table 3.1. Manuscript 1 Starting Value Results 
Model BIC Iteration Mixing Probability 
for Smallest Class 
Variance Estimate 
for Smallest Class 
Standard Error for 
Variance of Smallest 
Class 
Month 
10 
     
 257.3 58 0.0647 0.0014 0.0003 
 286.0 71 0.0650 0.0030 0.0007 
 4301.7 53 0.0534 0.0014 0.0004 
 4317.4 8 0.0665 0.0069 0.0022 
 4330.9 52 0.0482 0.0015 0.0004 
 4331.2 65 0.0703 0.0122 0.0032 
 4344.4 One-class model 
(multiple regression) 
-   
      
Change      
 2378.0 92 0.0658 0.0000 0.0000 
 2394.4 2 0.0633 0.0003 0.0001 
 2406.2 76 0.0548 0.0000 0.0000 
 2410.7 37 0.0629 0.0003 0.0001 
 2447.1 51 0.0878 0.0091 0.0024 
 2448.9 84 0.0593 0.0005 0.0002 
 2455.7 41 0.0721 0.0031 0.0009 
 2468.1 55 0.0662 0.0077 0.0024 
 2474.4 73 0.1071 0.0021 0.0009 
 2482.3 96 0.0194 0.0000 0.0000 
 2490.6 One-class model 
(multiple regression) 
-   
 
Manuscript 2. 
Month 10 model. Only 2 out of 100 two-class solutions yielded lower BIC values than the one-
class (multiple regression) solution. The mixing probabilities for the smallest class were very small, 
suggesting that the smallest classes were picking up on outliers instead of modeling two interpretable 
classes of sleep disturbance (Table 3.2). 
Month 17 model. Five of the 100 two-class models yielded better fit statistics than the one-class 
model (Table 3.2). Most of the smallest classes were over 10% of the sample, about 30–40 patients. On 
review of the model results for these solutions, parameter estimates were almost all statistically 
significant, suggesting that the smallest classes were composed of outliers.  
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Table 3.2. Manuscript 2 Starting Value Results 
Model BIC Iteration Mixing Probability for 
Smallest Class 
Variance Estimate 
for Smallest Class 
Standard Error for 
Variance of Smallest 
Class 
Month 10      
 145.5 28 0.0565 0.0003 0.0001 
 180.9 75 0.0170 0.0000 0.0000 
 4
188.6 
One-class model 
(multiple regression) 
-   
Month 17      
 589.6 55 0.0421 0.0000 0.0000 
 592.4 56 0.1362 0.0062 0.0014 
 607.2 48 0.1024 0.0053 0.0015 
 612.6 52 0.1120 0.0127 0.0032 
 617.3 86 0.1220 0.0156 0.0035 
 643.6 One-class model 
(multiple regression) 
-   
 
Manuscript 3. 
Eleven out of 100 two-class solutions yielded lower BIC values than the one-class (multiple 
regression) solution. Most of the mixing probabilities for the smallest class were less than 10% of the 
sample, a suggested cut-off for the size of the smallest class.
165
 The coefficients on the smallest classes 
that represented more than 10% of the sample were all statistically significant, suggesting that the 
smallest classes were picking up on outliers instead of modeling two interpretable classes of sleep 
disturbance (Table 3.3). 
 
Table 3.3. Manuscript 3 Starting Value Results 
BIC Iteration Mixing Probability for 
Smallest Class 
Variance Estimate for 
Smallest Class 
Standard Error for 
Variance of Smallest Class 
2272.5 65 0.0940 0.0001 0.0000 
2283.9 69 0.0886 0.0000 0.0000 
2308.2 42 0.1022 0.0003 0.0001 
2309.0 7 0.1121 0.0020 0.0005 
2323.5 78 0.1036 0.0008 0.0002 
2325.4 34 0.1120 0.0010 0.0002 
2333.4 92 0.0962 0.0007 0.0002 
2333.5 19 0.0402 0.0000 0.0000 
2349.3 33 0.1063 0.0026 0.0006 
2363.5 37 0.1305 0.0153 0.0036 
2403.6 4 0.0287 0.0000 0.0000 
2424.2 One-class model 
(multiple regression) 
-   
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Conclusions—RMM starting value analysis. 
The results of the starting value assessment show that even though two-class models were 
sometimes better fitting models than the one-class models, the two-class models were uninterpretable. 
The results of the RMM starting value evaluation provide evidence that the one-class solutions in 
Manuscripts 1, 2, and 3 were not driven by PROC FMM’s built-in starting value algorithm. 
3.5.5 Power 
Two types of power analyses were conducted. First, we assessed power to detect two classes 
using RMMs. Second, we assessed power to detect a relationship between exercise and sleep 
disturbance (Manuscript 2), or a change in exercise and change in sleep disturbance (Manuscript 3). 
Power to detect two classes. 
A power analysis was conducted to ensure that the MY-Health sample was sufficiently large 
enough to detect two classes if two classes were present. The ability to detect two classes is a 
prerequisite of detecting more than two classes, thus power analyses for RMMs focused on detection of 
two classes. 
Simulation methods. 
Power to detect two classes was evaluated and confirmed using simulations based on MY-Health 
study data, which provided the covariance structure among the independent variables. A simulated 
covariance structure is based on hypothesized relationships that may not guarantee a good 
approximation of the actual relationships. By using the MY-Health study data as a starting point, actual 
relationships among variables were incorporated into the power analyses.  
Sub-samples were randomly drawn from the study dataset to simulate 1000 datasets 
(replications) for each of the parameter modifications in the simulation: overall sample size, numeric 
differences between coefficients in each latent class, variance of the error term used to simulate sleep 
disturbance scores and proportion of sample within each class. Table 3.4 presents the characteristics 
modified to create simulations for cross-sectional (severity of sleep disturbance) or change analyses 
(change in sleep disturbance), and includes justification for the characteristics tested. 
Regression coefficients (relationships between sleep disturbance and other independent 
variables in the model) were identified in published literature
93,91
 and used to provide estimates of the 
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relationship between sleep disturbance and independent variables in the model. Regression coefficients 
from the literature were converted to quantify the relationship between a 100-point sleep disturbance 
scale and other independent variables.  
A simulated sleep disturbance variable was calculated by applying regression coefficients 
identified in the literature to a regression equation using data for independent variables from the MY-
Health study. To simulate two classes of sleep disturbance that were closer or further apart, two 
regression equations were calculated by splitting the sample into two subsamples and calculating two 
regression equations modeling the simulated sleep disturbance variable. The first equation included 
regression coefficients that were smaller than the regression coefficients found in the literature. The 
second equation included regression coefficients that were larger than the regression coefficients from 
the literature. The “distance” between regression coefficients (and classes) was varied allowing the 
classes to be closer or further apart. 
The resulting simulated sleep disturbance data were modeled using SAS PROC FMM
163
 to 
evaluate the number of times PROC FMM would identify two classes when two classes were indeed 
present. Fit statistics and the number of classes associated with the smallest Bayesian Information 
Criterion Index (BIC) were tabulated for each replication. 
  
Table 3.4. Simulation Parameters  
 Cross-sectional analyses (Manuscript 1 and 2) Change analyses (Manuscript 1 and 3) 
Characteristic 
Values 
tested 
Justification 
Values 
tested 
Justification 
Sample size 360, 600, 700 Approximate sample sizes yielded from models  200, 300, 
380 
Same justification as cross-sectional analyses 
Numeric difference 
between coefficients 
in each latent class 
0.05, 0.1, 
0.15,  
0.3 
A well-accepted rule of thumb for identifying 
minimally important group differences from the 
patient perspective on a PRO measure is the 
half standard deviation
166
. At Month 10, the half 
standard deviation of PROMIS Sleep 
Disturbance was approximately 5 points. In 
order for classes to be meaningfully different, it 
was anticipated that the classes should be 
separated by the half standard deviation at the 
minimum. 
 A distance of .05 resulted in a 
difference of approximately 3 points on the 
simulated sleep disturbance scores, less 
than the half standard deviation cutoff.  
 A distance of .1 yields a difference of 
approximately 6 points, which is close to the 
half standard deviation cutoff.  
 A distance of .15 yields a difference of 
around 9 points between classes.  
 A distance of .3 yields a difference of 
approximately 17.5 points between classes. 
3, 5, 6, 9 Regression coefficients identified in the literature 
for change analyses were generally larger than the 
cross-sectional regression coefficients, therefore 
the distance between coefficients was increased.
 
 
 Distance = 0.6, 0.9, 1.5 and 3, Mean 
difference between classes < 3 
 Distance = 5, Difference between classes 
≈ 5 
 Distance = 6, Difference between classes 
≈ 6 
 Distance = 9, Difference between classes 
≈ 9.6 
Size of the error term 
in the regression 
equation used to 
calculate the 
simulated sleep 
disturbance scores 
RMSE = 1, 3, 
4, 5, 8 
Using sample data, a simple linear regression 
regressing PROMIS Sleep Disturbance on 
three independent variables provided an upper 
bound for the size of the error term in the final 
models (which will likely result in a better fit). 
The RMSE in the simple model was 8, 
therefore all the error term sizes were 8 and 
smaller. 
RMSE = 1, 3, 
4, 5, 7 
Using sample data, a simple linear regression 
regressing PROMIS Sleep Disturbance on three 
independent variables provided an upper bound 
for the size of the error term in the final models 
(which will likely result in a better fit). The RMSE in 
the simple model was 7, therefore all the error 
term sizes were 7 and smaller. 
Group size for healthy 
sample 
80%, 70%, 
50% 
A recent systematic review found that the 
prevalence of sleep disorders in the cancer 
population can’t be ascertained because 
studies do not measure sleep disturbance in a 
standard way
50
, therefore a wide range of class 
sizes was tested differentiating poorer sleepers 
from better sleepers. 
80%, 70%, 
50% 
Same as cross-sectional analyses. 
4
6
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Simulation results for cross-sectional models. 
Figure 3.2 illustrates simulation results for the Month 10 cross-sectional models when the sample 
size was 360, 600, or 700 and the latent classes comprised 50% of the sample each. The y-axis shows 
the percent of simulated cases in which two classes were identified (power) and the x-axis displays 
numeric difference between coefficients in each class divided by error. The x-axis ranges from 0.006 to 
0.050, with small numbers indicating smaller distance-to-error ratios (smaller distance between 
coefficients in each class and more error) and larger numbers representing larger distance-to-error ratios 
(larger distance between coefficients in each class and less error). For example, an x-axis value of 0.006 
corresponds to a distance between class coefficients of 0.05 and an error term of 8 for simulated sleep 
disturbance. On the other end of the scale, an x-axis value of 0.05 corresponds to a distance between 
coefficients in classes of 0.15 and an error term of 3 or a distance of 0.05 and an error term of 1. One 
circle represents the results of 1000 simulated replications drawn from the MY-Health study dataset all 
with the same simulation parameters applied. The color of the circles represents the sample size.  
Ideally, RMMs would be able to detect the two simulated latent classes in all circumstances, but 
the dynamic relationships between each characteristic (e.g., sample size, error term size, distance 
between classes) made it easier or harder for the model to identify two classes when two classes exist. 
Circles closer to the top of the figure represent simulations in which two classes were detected more often 
than one class. Circles close to the bottom of the figure represent simulations in which only one class was 
detected more often. At a distance between coefficients of 0.15 or above, which was equivalent to 
approximately 9 points on the simulated sleep disturbance scale and considered a meaningful difference, 
two classes were detected regardless of the other characteristics permeated in the simulation (x-axis 
values ≥ .038). If the distance between coefficients in each class was small and error was large (smaller 
x-axis values), then the RMMs were not able to identify two classes (bottom left corner of the figures). The 
proportion of the sample within each class had very little effect on power. Additional values on the x-axis 
were tested above 0.05 to 0.30 (distance = .3, error = 1), but after 0.050, regardless of the permutations 
of the simulation characteristics, power was always 100%. Results were almost identical for different 
class sizes with the largest class comprised of 70% of the sample (Figure 3.3), and 80% of the sample 
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(Figure 3.4). Based on the characteristics discussed above, the cross-sectional models should be 
sufficiently powered to detect two classes.  
 
Figure 3.2. Simulation results for cross-sectional models (proportion of patients in class with healthier 
sleepers = 50% of sample, proportion of patients in class with poorer sleepers = 50% of sample). 
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Figure 3.3. Simulation results for cross-sectional models (proportion of patients in class with healthier 
sleepers = 70% of sample, proportion of patients in class with poorer sleepers = 30% of sample). 
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Figure 3.4. Simulation results for cross-sectional models (proportion of patients in class with healthier 
sleepers = 80% of sample, proportion of patients in class with poorer sleepers = 20% of sample). 
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Simulation results for change models. 
The simulation results for change models are presented in Figure 3.5 through Figure 3.7. These 
figures are analogous to the cross-sectional simulation figures except that they present results of the 
change model simulations with a sample size of 200, 300, and 380. Change models should be sufficiently 
powered to detect two classes when error variance of the simulated sleep disturbance variable is 
relatively small (error < 4, x-axis ≥ 0.2), or when the distance between coefficients is at least 5 or larger 
(corresponding to a mean difference in sleep disturbance between classes of about 5 points, considered 
a meaningful difference based on the half-SD method, x-axis value > 0.7). Larger distance-to-error values 
were tested but left out of the x-axis because the power to detect two classes was 100 or very close to 
100 for all permutations of the simulation characteristics beyond 0.214 (distance between coefficients = 
1.5, error = 7). 
 
Figure 3.5. Simulation results for change models (proportion of patients in class with healthier sleepers = 
50% of sample, proportion of patients in class with poorer sleepers = 50% of sample) 
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Figure 3.6. Simulation results for change models (proportion of patients in class with healthier sleepers = 
70% of sample, proportion of patients in class with poorer sleepers = 30% of sample). 
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Figure 3.7. Simulation results for change models (proportion of patients in class with healthier sleepers = 
80% of sample, proportion of patients in class with poorer sleepers = 20% of sample). 
 
 
Power to detect exercise effect. 
Background and methods. 
Exercise was evaluated in Manuscripts 2 and 3, thus this section applies only to these 
manuscripts. Plausible effect sizes were abstracted from published randomized controlled trials 
investigating the effect of an exercise intervention on sleep disturbance in other populations. Partial 
correlations varied greatly across studies, therefore a wide range of plausible effect sizes were tested for 
the power analyses. One study included adults diagnosed with stage IV CRC and yielded a partial 
correlation of 0.64 for a home-based exercise intervention of four days or more sessions per week.
117
 
Two other studies included women diagnosed with stage I–III breast cancer and yielded partial 
correlations of 0.14
140
 and 0.05.
141
  
Because RMMs may yield multiple classes, each a portion of the total sample size for the model, 
power to detect exercise was evaluated by possible class size. Estimates for the prevalence of sleep 
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disorders in the cancer population vary;
50
 latent class size was varied in the power analyses to test 
various possible outcomes. Depending on the number of classes that emerged from the mixture models 
and the size of each class, a wide range of sample sizes within each class were possible.  
Exercise power results. 
Figure 3.8 and Figure 3.9 show the power results for the hypotheses in Manuscripts 2 and 3 
respectively. The x-axis displays plausible partial correlations and the y-axis shows power. The bar colors 
correspond to sample sizes.  
As the partial correlations increased (relationship between sleep disturbance and exercise 
increase), the power to detect statistically significant exercise effects also increased. Based on available 
published literature, we would expect the partial correlation to fall between .05 and .6, an extremely wide 
range. Nonetheless, for the cross-sectional models (Figure 3.8), the power for all partial correlations 
except .05 is sufficient for class sample sizes of 220 or larger. Similarly, the power to detect an exercise 
effect in the change models was sufficient when the partial correlation was 0.40 or higher, when the 
partial correlation was 0.14 and the class sample size was 400, or when the partial correlation was 0.20 
and the class sample size was 200 or larger (Figure 3.9). When partial correlations were above 0.20, the 
power to detect an exercise effect was 100%, thus the figures show x-axis values up to 0.20. 
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Figure 3.8. Power results for cross-sectional exercise models (Manuscript 2) 
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Figure 3.9. Power results for exercise change model (Manuscript 3) 
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CHAPTER 4. SLEEP QUALITY IN INDIVIDUALS DIAGNOSED WITH COLORECTAL CANCERS: 
FACTORS ASSOCIATED WITH SLEEP DISTURBANCE AS PATIENTS TRANSITION OFF 
TREATMENT (MANUSCRIPT 1) 
4.1 Background  
Colorectal cancer (CRC) is the third most common adult cancer,
4
 with more than 1.1 million 
individuals currently living with the disease in the United States.
5
 Of these patients, it is estimated that half 
experience decrements in sleep.
3
 Consequences of sleep disturbance include decreased cognitive 
functioning
9
 and fatigue.
10,11
 Cancer patients have attributed sleep disturbance with impaired daytime 
functioning, trouble keeping up at work and with social activities, and mood disturbance.
12
 Sleep 
disturbance is also a risk factor for infectious and cardiovascular diseases, and depression.
13
 It is also 
shown to be associated with a loss in work productivity, work quality, and an increased number of visits to 
health professionals.
14
  
Although sleep disturbance is prevalent in the cancer population (between 30% and 87%
2
), most 
individuals diagnosed with cancer do not discuss sleep difficulties with their clinicians.
167
 Sleep has rarely 
been included as an outcome in CRC research. Given the lack of communication between patients and 
clinicians regarding sleep, clinicians could benefit from knowing which patients are at risk for worse sleep 
outcomes, and researchers would benefit from being able to target high-risk sleep populations for future 
intervention studies. 
Research on sleep disturbance in the general population is much more comprehensive than in 
the cancer literature. In the general population, comorbidities such as cardiovascular diseases (e.g., 
stroke, heart attack, angina), respiratory conditions (e.g., asthma, bronchitis), diabetes, and 
gastroesphageal reflux
73
 affect sleep quality. Men experience more awakenings but women typically have 
more trouble falling asleep.
72
 Being a parent is associated with worse sleep quality.
83,84
 Retirement from 
work is associated with better sleep quality.
73
 Less is known about correlates of sleep disturbance in the 
cancer population. 
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In cancer patients, depression,
90,92,93,95
 anxiety,
94,95
 and pain
94,95
 were often associated with sleep 
disturbance, but these variables were not always statistically significant in published research. Other 
factors include physical health and functioning,
90,92,93
 patient characteristics (e.g., gender, age),
90-92
 
sedative use,
94
 fatigue,
94
 cigarette use,
92
 and having undergone surgery.
91
 Cancer treatment–related 
factors may impact patients’ emotional and physical health (either directly or because of side effects). For 
example, medications commonly administered to patients diagnosed with cancer such as opioids, 
antiemetic medications, and corticosteroids are associated with sleep disruption.
98
 Symptoms associated 
with cancer treatment such as dyspnea, gastrointestinal symptoms, and pain are associated with sleep 
impairment.
21
 There is a known link between cancer treatment and sleep disturbance, and some literature 
suggests that there is a relationship between time since treatment and sleep disturbance.
16-18,100,101
 Two 
studies in breast cancer patients undergoing chemotherapy found that sleep quality was poor prior to 
chemotherapy but there was little change in sleep quality during chemotherapy.
16,17
 Another study in 
breast cancer found persistent sleep problems before and after surgery for breast cancer.
101
 HRQOL 
(including sleep) was assessed as part of a randomized trial of chemotherapy in ovarian cancer 
patients,
18
 and researchers found an immediate deterioration in sleep and other aspects of HRQOL 
around the first cycle of chemotherapy and then a statistically-significant improvement in sleep and other 
aspects of HRQOL throughout chemotherapy.
18
 The relationship between trajectories of sleep 
disturbance and CRC treatment over time is unknown. 
Individuals diagnosed with CRC may experience a range of sleep quality stretching from no sleep 
disturbance to severe insomnia (or another diagnosed sleep disorder). The etiology and severity of sleep 
disturbance may vary from patient to patient. For example, sleep disturbance may be caused by anxiety 
related to cancer diagnosis for one person, but another person may attribute sleep disturbance to 
physical symptoms such as pain or nausea, and these factors may vary by severity of sleep disturbance. 
By understanding patient-level factors associated with poorer or better quality sleep, studies could 
provide new insight to clinicians on the patient, disease, and treatment characteristics associated with 
worse sleep disturbance or worsening sleep disturbance. Identifying patient-level factors associated with 
sleep disturbance may also provide insight in the design of future randomized studies designed to identify 
patients who would benefit most from an intervention for severe sleep disturbance.  
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The purpose of this study is to identify patient, disease, and treatment characteristics associated 
with of sleep disturbance (and change in sleep disturbance) in individuals diagnosed with stage I, II, or III 
CRC. Specifically, the first objective is to investigate whether there was variation in patient, disease, and 
treatment characteristics across levels of sleep disturbance severity. We test the hypothesis that 
associations between factors (e.g., patient, disease, and treatment characteristics) and sleep disturbance 
differ by severity of sleep disturbance. The second objective of this study is to identify correlates of sleep 
disturbance; we test the hypothesis that patients who were currently undergoing chemotherapy or those 
who had more recently undergone chemotherapy would report worse sleep disturbance than patients who 
never had chemotherapy. We go further by evaluating change in sleep disturbance after CRC diagnosis. 
The third objective is to investigate whether there was variation in patient, disease, and treatment 
characteristics across magnitude of change in sleep disturbance severity as patients transition off of CRC 
treatment with the hypothesis that associations between sleep disturbance and patient-level factors (e.g., 
patient, disease, and treatment characteristics) vary by magnitude of change in sleep disturbance. The 
final and fourth objective was exploratory: to identify correlates of change in sleep disturbance. 
4.2 Methods 
4.2.1 MY-Health Study Design 
This secondary data analysis was conducted using data from Georgetown University’s Measuring 
Your Health (MY-Health) study which included over 5000 patients who enrolled between 2010 and 
2012.
143
. Potential study participants were identified from four SEER cancer registries located in California 
(2), Louisiana, and New Jersey. Individuals age 21–84 years diagnosed with one of seven cancers (CRC, 
prostate, non-small cell lung, non-Hodgkin lymphoma, female breast, uterine, or cervical) were invited to 
participate in the MY-Health study via mail. Mail-in hard copy questionnaires were administered to 
patients at two time points: Time 1 data collection occurred approximately 10 months after diagnosis and 
Time 2 data collection occurred 17 months after diagnosis on average. The MY-Health study 
oversampled black, Hispanic, and Asian cancer patients and patients under 50. Questionnaires were 
administered in three languages English, Spanish, and Mandarin (simple and traditional). Additional 
details on the study design and procedures are published.
143
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4.2.2 Participants  
Patients who were identified as being diagnosed with stage I, II, or II CRC were included in the 
analyses for this study: Round 1 of data collection occurred at 10 months on average after diagnosis and 
included 734 patients (range: 5.5 to 21.3); 400 patients participated in Round 2, which was collected 
approximately 17 months after diagnosis on average (range: 12.8 to 26.4). Although the data collection 
windows were approximately 15 and 13 months wide respectively, for brevity, the first data collection will 
be called the Month 10 data collection and the second data collection will be referred to as the Month 17 
data collection. 
4.2.3 Measures 
Dependent variable. 
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance 
items were administered to patients at 10 and 17 months after CRC diagnosis. PROMIS Sleep 
Disturbance includes a seven-day recall and measures concepts such as trouble staying asleep, not 
getting enough sleep, restlessness, feeling refreshed after sleep, and difficulty falling sleep. Results of the 
full psychometric evaluations of the PROMIS Sleep Disturbance item bank
144
 and short forms
145
 were 
previously published. A custom six-item short form was scored; the psychometric properties of the six-
item form were evaluated in individuals enrolled in the MY-Health study (Cronbach’s α = 0.88 – 0.95).
146
 
PROMIS Sleep Disturbance is a continuous variable scored on a t-score metric with a mean of 50 and 
standard deviation (SD) of 10 based on the referent population (mixture of clinical and the general U.S. 
population
147
), and higher scores indicate worse sleep disturbance. Change in sleep disturbance was 
calculated by subtracting PROMIS Sleep disturbance scores at 10 months from scores at 17 months after 
CRC diagnosis. Positive change is indicative of worsening sleep. A recent study by Leung et al.
168
 
provided a cut point on PROMIS Sleep Disturbance indicative of clinically significant sleep disturbance (≥ 
57, area under the curve = 0.92).  
Independent variables. 
The MY-Health dataset contains information on patient, disease, and treatment factors 
associated with sleep disturbance. Cancer treatment type (surgery,
91
 chemotherapy,
21,99
 radiation) and 
most recent date of treatment were self-reported. Categorical variables were derived to capture 
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current/recent treatment compared to no treatment or less-recent treatment. Categories were based on 
relevant physical recovery periods post-treatment and data availability. Time since chemotherapy was 
coded using four categories (i.e., currently receiving chemotherapy, chemotherapy 1–2 months ago, 
chemotherapy more than 2 months ago, never received chemotherapy [reference category]). Time since 
surgery was coded using three categories (i.e., surgery occurred within 0–4 months, surgery occurred 
more than 4 months ago, never received surgery [reference category]). Comorbid conditions
73
 were self-
reported and included in the models as a derived variable with three categories (i.e., no comorbid 
diseases [reference category], 1 comorbid disease, 2 or more comorbid diseases). Three PROMIS 
domains were included in the models as independent variables to assess aspects of health-related quality 
of life known to be associated with sleep disturbance.
73,79
 
80
 
81,90,92-95
 Anxiety (11 items),
149
 Fatigue (14 
items),
148
 and Pain Interference (11 items).
149
 These PROMIS measures were normed to the general U.S. 
population
147
 and higher scores indicate worse anxiety, fatigue, and pain respectively. Nausea severity 
was measured using a five-point nausea
21
 item from the FACT-G Physical Well-Being (PWB) subscale
150
 
with a recall period of the “past 7 days” and response choices ranging from 0 = “not at all” to 4 = “very 
much.” Although the nausea item has not been psychometrically evaluated as a single measure of 
nausea, the entire FACT-G PWB scale, which has been evaluated extensively in cancer patients, covers 
concepts that overlap with PROMIS measures such as Pain Interference and Fatigue. Therefore, only the 
nausea item was included in the models as a continuous variable. Other characteristics known to be 
associated with different levels of sleep disturbance were included in the models such as age at 
diagnosis,
2,21,97
 sex,
72
 time since diagnosis,
93
 employment status,
84
 and an indicator for living with children 
under 18
83,84
 were included in the models. Age and race were also included in the model to account for 
the over-sampling of younger and minority persons from SEER registries. Race, employment status, and 
the living-with-child(ren) indicator were self-reported, and age at diagnosis, sex, and diagnosis date were 
obtained via SEER registry data.  
4.2.4 Analyses 
The overall purpose of this study is to identify patient, disease, and treatment characteristics 
associated with of sleep disturbance (and change in sleep disturbance) in individuals diagnosed with 
stage I, II, or III CRC. Analyses were divided into two sub-analyses by addressing cross-sectional 
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objectives in the first sub-analysis (objectives 1-2), and addressing change in sleep disturbance in the 
second sub-analysis (objectives 3-4). In the first sub-analysis incorporates data collected approximately 
10 months after diagnosis. This time point is important in patients’ cancer trajectories because it 
evaluates factors associated with sleep when patients are transitioning off of treatment. Although patients 
included in these analyses completed study questionnaires between 5 and 21 months after CRC 
diagnosis, the mean number of months since CRC diagnosis was 10 months. Therefore, for brevity, these 
analyses will be referred to as Month 10 analyses. The second analysis focuses on change in sleep 
disturbance from roughly 10 months after diagnosis to approximately 17 months after diagnosis (referred 
to as the Change analyses). This timeframe is important because it captures changes in patients’ sleep 
disturbance and changes in other factors (e.g., anxiety, pain, fatigue) as patients transition off of 
treatment into a more stable recovery phase and survivorship.  
Methods.  
Descriptive statistics were tabulated. Relationships between candidate independent variables 
were evaluated for collinearity by calculating bivariate correlations and variance inflation factor (VIF) 
within multiple regression models. VIF values greater than 10 were considered a symptom of 
multicollinearity. The correlation coefficient between PROMIS Anxiety and PROMIS Depression was 
strong (r = 0.87) suggesting collinearity between scores. PROMIS Anxiety was included in the model and 
PROMIS Depression was excluded for simplicity (anxiety is associated with disturbed sleep, but 
depression is associated with both disturbed sleep and hypersomnia
169
). Residuals were evaluated 
between candidate independent variables and PROMIS Sleep Disturbance to determine if higher-order 
terms needed to be included in the models. 
Regression mixture models (RMMs)
158,159
 are special cases of finite mixture models, which model 
weighted combinations of different distributions. With RMMs, the component (class) membership to each 
distribution is unobservable (a latent variable). In this study, we employed RMMs to test if heterogeneity 
was present in the associations between sleep disturbance severity (and change in sleep disturbance) 
and other patient, disease, and treatment characteristics. Specifically, if patient, disease, and treatment 
factors varied by severity of sleep disturbance approximately 10 months after CRC diagnosis (objective 1) 
or from 10 to 17 months after CRC diagnosis (objective 3).  
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RMMs were estimated using Dual Quasi-Newton optimization.
162
 Models ranging from one to four 
classes were evaluated. The final models (e.g., choice of number of classes) were chosen based on fit 
(smallest Bayesian Information Criterion Index (BIC) and Akaike information criterion (AIC)) and 
interpretability. RMMs are sensitive to starting values,
164
 thus user-provided starting values were also 
tested to confirm the number of classes identified by SAS-generated starting values. If only one class of 
sleep disturbance was identified, then multiple regression (which assumes one common class of sleep 
disturbance) was used to model factors associated with sleep disturbance.  
A logistic regression was used to identify factors associated with patient survey completion Month 
10 (outcome = 1) versus participating in the Month 10 survey but not completing enough questions to be 
included in the analyses. The logistic regression model included patient characteristics at Month 10 that 
were related to sleep disturbance and potentially associated with survey compliance: sex, race, 
employment status, survey language, time between most recent chemotherapy and survey completion, 
PROMIS Sleep Disturbance, PROMIS Physical Functioning. 
There was substantial patient attrition from the Month 10 survey data to the second survey data 
collection (approximately 17 months after CRC diagnosis); factors associated with patient persistence in 
survey participation from Month 10 data collection to the second data collection were evaluated using 
descriptive statistics and logistic regression to address participant drop-out in the Change model. Patients 
who participated in the first (approximately 10 months post-diagnosis) and second survey (approximately 
17 months post-diagnosis) administrations (outcome = 1) were compared with patients who participated 
in the Month 10 but not the second data collection (approximately 7 months later) (outcome = 0) using 
logistic regression. The model included patient characteristics that were related to sleep disturbance and 
potentially associated with patient attrition: sex, race, employment status, survey language, time since 
most recent chemotherapy and Month 10 survey completion, PROMIS Sleep Disturbance, PROMIS 
Physical Functioning.  
A sensitivity analysis was conducted to describe the impact of including anxiety in the models 
instead of depression. Anxiety was removed from the Month 10 and Change models, and depression was 
added. Model results were compared. 
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Power.  
Power to detect multiple classes was evaluated and confirmed using simulations based on MY-
Health study data, which provided information about the covariance structure among the independent 
variables. Sub-samples were randomly drawn from the study dataset to simulate 1000 datasets for each 
of the parameter modifications in the simulation: overall sample size, numeric differences between 
coefficients in each latent class, variance of the error term used to simulate sleep disturbance scores, and 
proportion of sample within each class. A well-accepted rule of thumb for identifying minimally important 
group differences on a PRO measure is the half standard deviation.
166,170
 The half standard deviation of 
PROMIS Sleep Disturbance was approximately 5 points for the Month 10 analysis. For classes to be 
meaningfully different, we anticipated that the classes should be separated at a minimum by the threshold 
for minimal important difference. For the Month 10 analyses, based on a sample size of 600, a mean 
difference between sleep disturbance scores in each class approximately 6 points apart, equal-size 
classes (i.e., proportion of patients in class 1 = 50% and proportion of patients in class 2 = 50%) and an 
error term variance of 3 or less, the power to detect multiple classes was 100%. When the variance of the 
error term used to compute the simulated sleep disturbance scores increased to 4, 5, or 8 and all other 
parameters were the same, power reduced to 61.1%, 9.2%, and 1.6%, respectively. Power to detect 
multiple classes was above 95% for all circumstances when the mean difference between simulated 
sleep disturbance between classes differed by approximately 9 and 17 points and the variance of the 
error term used to simulate sleep disturbance scores was less than 8. The proportion of the sample 
designated to each class was modified in the simulations but the effect on power was negligible. 
Regarding the Change model, power to detect multiple classes was also evaluated for a sample size of 
360. When the classes were of equal sizes, the mean difference between sleep disturbance scores in 
each class was over 5.4 points apart, and the variance of the error term used to simulate the sleep 
disturbance scores was 1 or greater, then power to detect multiple classes was approximately 100%. The 
proportion of the sample within each class had very little effect on power. 
Analysis conventions.  
Regression coefficients were reviewed to describe the relationship between sleep disturbance 
and covariates in the models. An alpha of 0.05 or less was chosen as the criterion for statistical 
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significance of the covariates in the RMMs. All categorical and ordinal variables (except for the nausea 
item which was entered as a continuous variable) were entered in the models as dummy variables. 
Analyses were performed using SAS software (SAS Institute Inc, Cary NC). 
4.3 Results 
The mean patient age at diagnosis was 62.3 years (SD = 12.3, range from 22 to 84 years), and 
just over half the sample was female (52.7%) (Table 4.1). Almost two thirds of the patients were 
diagnosed with at least one comorbid condition (61.2%). Most patients (82.5%) underwent surgery more 
than four months before the first round of data collection (approximately 10 months after diagnosis), and 
just over half of the sample had undergone chemotherapy by the first data collection (54.6%). Less than 
20% of the patient sample at the first data collection received radiation (18.5%). The mean FACT-G 
Physical Well-being Nausea score was 0.6, between “Not at all” and “A little bit.” 
The mean PROMIS Sleep Disturbance score was similar to the average scores observed in the 
referent population (i.e., patients who went to sleep clinics and healthy sleepers) at Month 10 data 
collection (mean = 50.6), with 25.0% of patients classified as likely experiencing clinically significant sleep 
disturbance per Leung’s cut point. 
On average, there was little change in mean PROMIS Sleep Disturbance scores from 
approximately 10 to 17 months after CRC diagnosis, with a mean change of -0.1 (Table 4.2). Based on 
the distribution-based threshold of 5 points, 21% of the sample (n = 75) experienced potentially 
meaningful improvement in sleep disturbance, and 23% (n = 82) experienced worsening from Month 10 to 
Month 17 data collection [data not shown]. 
4.3.1 Regression Mixture Models 
Model fit and heterogeneity. 
To address objectives 1 and 3, RMMs were estimated to examine whether patient, disease or 
treatment factors varied by severity of sleep disturbance (objective 1) or by magnitude of change in sleep 
disturbance (objective 2). Models with one through four classes were estimated for the cross-sectional 
Month 10 model, and the Change model. Table 4.3 presents BIC statistics for both models based on 
SAS-generated starting values.  
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For the Month 10 model, the smallest BIC and AIC were associated with the one-class model, 
therefore a multiple regression was determined to be the most appropriate model for the Month 10 
analyses. Regarding the Change model, BIC and AIC were lowest for the two-class model and the four-
class Change model did not converge. The two-class model was uninterpretable with the smallest of the 
two classes composed of only 32 patients (out of 361). Regression coefficients for the smallest class 
were all statistically significant, suggesting that the smaller class modeled outliers instead of a meaningful 
group of patients. Therefore, a multiple regression was determined to be the most appropriate model for 
the Change model. Together, the model fit statistics provide evidence that there are no meaningful 
subgroups (i.e., latent classes) of patient, disease, and treatment characteristics associated with different 
levels of sleep disturbance severity (objective 1) or magnitude of change in sleep disturbance (objective 
3).  
Relationship between sleep disturbance and patient, disease, and treatment 
characteristics. 
Month 10 model. 
Table 4.4 presents the results of the Month 10 model. Although not statistically significant, model 
coefficients support the hypothesized direction of the relationship between sleep disturbance and current 
chemotherapy: Patients who were currently undergoing chemotherapy reported more sleep disturbance 
than patients who had never undergone chemotherapy, on average. Patients who underwent 
chemotherapy in the past appeared to report better sleep quality compared to patients who never had 
chemotherapy, but this relationship was not statistically significant.  
Being diagnosed with two or more relevant comorbid conditions (compared to no comorbidities), 
retirement (compared to working full-time, part-time, or enrolled as a student), anxiety, fatigue, and pain 
were statistically significant factors in the model. Being diagnosed with two or more relevant comorbidities 
was associated with a PROMIS Sleep Disturbance score of 1.5 additional points (worse) on average 
compared to no comorbidities. Being retired was associated with better sleep quality compared to 
patients who were working (full-time, part-time, or enrolled as a student). Poorer anxiety, fatigue, or pain 
interference was associated with worse sleep disturbance, though the coefficients are small. 
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Change model.  
Change in anxiety and fatigue and sleep disturbance at Month 10 were statistically significant in 
the Change model (Table 4.5). A 25-unit worsening change (increase) in anxiety was associated with a 
3.4-point worsening in PROMIS Sleep Disturbance. The negative coefficient on PROMIS Sleep 
Disturbance at Month 10 indicates that poorer sleepers at Month 10 had greater improvement in sleep 
from Month 10 to Month 17 data collection. 
Sensitivity analysis: Anxiety and depression. 
Due to the collinearity between anxiety and depression, a sensitivity analysis was conducted to 
test depression in the model instead of anxiety for the Month 10 and Change models. The models 
including depression (instead of anxiety) yielded almost identical results to the primary models. The 
Month 10 RMM supported one class, and the multiple regression yielded statistically significant 
relationships between sleep disturbance and 2 or more comorbid conditions (B = 1.71), retirement (B = -
2.7), depression (B = 0.22), fatigue (B = 0.29), and pain interference (B = 0.09) [data not shown]. The 
Change model fit statistics supported two classes, but the two-class solution was uninterpretable, likely 
modeling outliers. The Change model (using multiple regression) including depression instead of anxiety 
yielded a very similar result compared to the Change model including anxiety with statistically significant 
relationships between change in sleep disturbance and change in depression (B = 0.12), change in 
fatigue (B = 0.22), and sleep disturbance at month 10 (B = -0.20) [data not shown]. 
4.3.2 Missing Data and Patient Attrition 
Due to missing data, 121 of the 734 CRC patients (stage I–III) included in the MY-Health study 
were removed from the RMM/multiple regression analyses leaving 613 participants in the Month 10 
analysis sample. The 121 patients who were not included in the Month 10 analyses were compared with 
the 613 patients who were included in the analyses using descriptive statistics and logistic regression 
(Supplemental Table 1). No patient characteristics were statistically significantly in the logistic regression 
model, suggesting that patient compliance completing survey questions at Month 10 was not related to 
any particular patient-level factor (e.g., age, sex, employment).  
Patient attrition and missing data were factors in the Change analysis sample size (n = 361), 
therefore patients who were included in the Change analysis were compared with the 373 patients who 
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participated in the Month 10 survey but were not included in the Change analysis (due to patient attrition 
in survey participation or missing data) (Supplemental Table 2). Retirement (OR = 1.6) was associated 
with continued participation in the survey from 10 to 17 months, and patients classified as “Other” or 
“multiple” races were more likely to not participate in the Month 17 data collection (OR = 0.63) [data not 
shown]. 
4.4 Discussion 
In this large sample of CRC survivors surveyed approximately 10 and 17 months following 
diagnosis, we found the majority of patients to have similar severity of sleep disturbance as the PROMIS 
Sleep Disturbance referent population, which was based on less-healthy patients than in the general 
population including patients who went to sleep clinics.
171
 Although some CRC patients experienced 
much more severe sleep disturbance than others, 10 Month RMM analyses identified only one class of 
sleep disturbance. These results are important because they provide evidence that the patient, disease, 
and treatment characteristics associated with sleep disturbance are consistent at every severity level of 
sleep disturbance. In other words, researchers and clinicians can consider the presence of 2 or more 
comorbid conditions, non-retirees, anxiety, pain interference, and fatigue as correlates of sleep 
disturbance in patients diagnosed with CRC regardless of how mild or severe sleep disturbance is for 
each patient. This knowledge is important in clinical practice; patients with severe anxiety, pain, or fatigue 
should also be assessed for sleep disturbance. Regarding the Change analyses, the variability in sleep 
change underscores the range of patients’ experiences with sleep disturbance from 10 to 17 months after 
diagnosis when they are transitioning off treatment. The RMM analyses did not identify patient, disease, 
or treatment characteristics that varied by magnitude of change in sleep disturbance, but the results show 
that poorer sleepers at Month 10 had greater improvement in sleep disturbance from Month 10 to Month 
17 data collection. These results are important for future clinical trial research because they suggest that 
some patients will improve more than others based on the quality of their sleep disturbance at baseline; 
future clinical trial endpoints regarding change in sleep disturbance should take baseline sleep 
disturbance into account in analyses. 
Based on previous research in other cancers showing that symptoms of cancer treatment are 
detrimental to sleep
21
 and other evidence that the initiation of chemotherapy is associated with 
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deterioration of sleep quality in another cancer population,
2
 we hypothesized that current or recent 
chemotherapy would be associated with worse sleep outcomes compared to no chemotherapy. The 
results of our analyses (non–statistically significant coefficients) did not support this hypothesis. It is 
possible that the factors driving sleep disturbance due to treatment are already included in the model, 
such as pain and fatigue. Also, failure to find an association between chemotherapy and sleep 
disturbance may well be because the worst symptoms had already passed by the time patients were 
surveyed approximately 10 months after diagnosis. Future research should address the temporal 
relationship between CRC treatment and sleep disturbance at different points in time during the treatment 
trajectory, especially right after diagnosis. By understanding the temporal relationship between sleep 
disturbance and patient, disease, and treatment characteristics, researchers could provide patients and 
clinicians with a clearer picture of what to expect with sleep disturbance immediately after diagnosis and 
thereafter, possibly pre-empting sleep disturbance issues due to treatment. For example, if future 
research shows that individuals diagnosed with CRC do indeed suffer from worse sleep disturbance due 
to chemotherapy initiation, clinicians could actively monitor patients’ sleep disturbance over time and 
intervene if necessary, or refer higher-risk patients for sleep therapy. 
Results of these analyses show a link between sleep disturbance and anxiety, depression, 
fatigue, and pain interference (Month 10 only), underscoring the concordance between sleep and other 
aspects of HRQOL. Addressing modifiable factors of HRQOL such as anxiety, depression, or fatigue (or 
both) may improve sleep disturbance. Likewise, addressing sleep disturbance may help improve 
symptoms of anxiety, depression, or fatigue. It should be noted that the coefficients were relatively small. 
These results are of particular importance because the correlates of sleep disturbance have yet to be 
investigated in a sample of individuals diagnosed with CRC as they transition off of treatment.  
Retirement was associated with better sleep quality 10 months after diagnosis. The relationship 
between employment and sleep disturbance has been previously investigated in other populations,
73,84
 
but these results are key because few studies investigate employment as an important factor in sleep 
disturbance within the CRC population. 
The results of this study should be considered in light of some limitations. Anxiety, depression, 
pain interference, fatigue, and sleep disturbance are known to be closely related and effects could be bi-
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directional. For example, pain may cause sleep disturbance, but if sleep disturbance is severe, it could 
cause pain due to increased inflammation or inability of the body to heal with less sleep. Endogeneity 
limits the conclusions that can be drawn from regression analyses: regression coefficients represent 
associations between sleep disturbance and the independent variables. Therefore, independent variables 
are not necessarily predictors of sleep disturbance. Another limitation to this study was loss to follow-up 
from Month 10 to Month 17 data collection. Minorities were less likely to participate in the follow-up survey 
and retirees were more likely to participate in both study data collections. Finally, we do not have 
information on patients’ sleep disturbance prior to CRC diagnosis; without this information, it is more 
difficult to extract the effect of CRC treatment on sleep disturbance. When patient attrition is not 
completely at random or missing at random, parameter estimates may be biased. Some patients may 
have already been experiencing poor sleep prior to CRC diagnosis; this omitted variable does not allow 
us draw conclusions about the relationship between the severity of sleep disturbance or changes in sleep 
disturbance strictly with CRC or treatment characteristics.  
PROMIS Sleep Disturbance, the outcome variable in all models in this study, was developed with 
some of the most rigorous qualitative and quantitative psychometric methods available,
12,77,144,149
 and the 
six-item scores were recently evaluated in the full MY-Health study cohort.
146
 One strength of PROMIS 
measures is that results of any study can be compared back to the referent population. Lab-based sleep 
measures are considered the gold standard for sleep measurement, but they may not adequately 
characterize sleep disturbances at home or sleep disturbances over time.
13
 The inclusion of PROMIS 
Sleep Disturbance in the MY-Health study allows researchers to gain a broader understanding of the 
patient-, disease-, and treatment-related factors associated with CRC than what would have been 
possible with lab-based measures. 
As a community-based observational study, the MY-Health data provide information on 
experiences from a very diverse sample of patients who were evaluated during the course of usual care 
without controlled interventions. Understanding the severity of sleep disturbance in patients with CRC 
without controlled interventions and the factors associated with sleep disturbance are building blocks to 
developing controlled trials for treatment of sleep disturbance. This information can be used to design 
future randomized control trials aimed at mitigating sleep disturbance. 
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4.5 Conclusion 
The results of this study confirm the relationships between sleep disturbance and other aspects of 
HRQOL (e.g., pain, anxiety, fatigue) that have been identified in other studies,
90-95
 and now in a sample of 
adults diagnosed with CRC. The association between retirement (compared to employment/enrolled as a 
student) and sleep disturbance is a new finding in the cancer literature that points to the importance of 
patients’ outside responsibilities as important factors in their symptom management. The results of this 
research are important because they confirm the relationship between well-established HRQOL factors 
associated with sleep disturbance in a CRC sample, all of which are modifiable. Strategies to reduce one 
factor may positively impact other aspects of HRQOL.  
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Table 4.1. Patient Characteristics at Month 10 Data Collection 
Characteristic 
Month 10 
(n = 613) 
Age at diagnosis
 
  
Mean (SD), Median, Min - Max 62.3 (12.3), 64.0, 22-84 
Sex
 
  
Female 323 (52.7%) 
Race   
Other or multiple 163 (26.6%) 
White 335 (54.6%) 
Black 115 (18.8%) 
Employment status
 
  
Work 237 (38.7%) 
Retired 264 (43.1%) 
Unemployed or disabled 112 (18.3%) 
Living status
 
  
Live with child(ren) under 18 years old 99 (16.2%) 
Relevant comorbidities
 
  
No comorbid conditions 238 (38.8%) 
1 comorbid condition 163 (26.6%) 
2 or more comorbid conditions 212 (34.6%) 
Cancer stage  
Stage I 178 (29.0%) 
Stage II 191 (31.2%) 
Stage III 244 (39.8%) 
Months between most recent chemotherapy and Month 10 data 
collection 
 
0 = never 278 (45.4%) 
1 = current 128 (20.9%) 
2 = 1-2 months 107 (17.5%) 
3 = > 2 months 100 (16.3%) 
Months between most recent surgery and Month 10 data collection  
0 = never 53 (8.6%) 
1 = 0-4 months 54 (8.8%) 
2 = more than 4 months 506 (82.5%) 
Radiation  
Ever received radiation 112 (18.5%) 
Months since diagnosis at Month 10 data collection  
Mean (SD), Median, Min – Max 9.7 (1.6), 9.5, 6-21 
PROMIS Sleep Disturbance T-Score  
Mean (SD), Median, Min – Max 50.6 (9.8), 51.4, 30-75 
Clinically-meaningful PROMIS Sleep Disturbance T-Score 
172
  
≥ 57 153 (25.0) 
PROMIS Anxiety T-Score  
Mean (SD), Median, Min – Max 49.5 (11.0), 49.6, 36-84 
PROMIS Depression T-Score  
Mean (SD), Median, Min – Max 48.4 (10.7), 48.0, 36-81 
PROMIS Fatigue T-Score  
Mean (SD), Median, Min - Max 52.2 (10.6), 51.8, 29-81 
PROMIS Pain Interference T-Score  
Mean (SD), Median, Min - Max 53.1 (10.9), 54.9, 40-79 
FACT-G Physical Well-being Nausea Item  
Mean (SD), Median, Min - Max 0.6 (1.0), 0.0, 0-4 
Survey language  
English 552 (90.0%) 
Spanish or Chinese 61 (10.0%) 
FACT-G = Functional Assessment of Cancer Therapy-General, max = maximum; min = minimum; PROMIS = 
Patient-Reported Outcomes Measurement Information System, SD = standard deviation. 
Note: Percent calculated out of non-missing responses. 
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Table 4.2. Descriptive Statistics for change in patient-reported outcome measures 
 
Characteristic 
Change (Month 17 – Month 
10) 
(n = 361) 
PROMIS Sleep Disturbance  
Mean (SD), Median, Min - Max -0.1 (7.2), 0.0, -25-19 
PROMIS Anxiety  
Mean (SD), Median, Min - Max 0.3 (9.0), 0.0, -28-28 
PROMIS Depression  
Mean (SD), Median, Min - Max 0.5 (8.6), 0.0, -34-29 
PROMIS Fatigue  
Mean (SD), Median, Min - Max -1.8 (8.3), -1.2, -27-24 
PROMIS Pain Interference  
Mean (SD), Median, Min - Max -1.8 (9.1), 0.0, -38-25 
FACT-G Physical Well-being Nausea 
Item 
 
Mean (SD), Median, Min - Max -0.2 (0.9), 0.0, -4-3 
FACT-G = Functional Assessment of Cancer Therapy-General, max = maximum; min = minimum; PROMIS = 
Patient-Reported Outcomes Measurement Information System, SD = standard deviation. 
 
 
 
 
 
 
 
 
Table 4.3. RMM Model Fit Statistics 
 Month 10 model Change model 
Number of classes BIC AIC BIC AIC 
1 4344.4 4251.6 2490.6 2405.0 
2 4485.6 4295.6 2392.8 2217.8 
3 4626.8 4339.6 2489.7 2225.2 
4 4768.0 4383.6 Did not converge Did not converge 
BIC = Bayesian Information Criterion Index, AIC = Akaike Information Criterion 
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Table 4.4. Multiple Regression Results, Relationship Between Sleep Disturbance and Patient, Disease, 
and Treatment Characteristics Approximately 10 Months After Diagnosis (n = 613) 
 
Effect Categories Estimate 
Standard 
Error Z P value 
Intercept  22.364 3.88 5.77 <.0001 
Months between 
chemotherapy and Month 10 
data collection 
Current 0.050 0.92 0.05 0.9562 
 1-2 months -1.271 0.90 -1.42 0.1558 
 > 2 months -0.219 0.92 -0.24 0.8114 
 Never ref - - - 
Months between surgery and 
Month 10 data collection 
0-4 months 0.090 1.52 0.06 0.9530 
 More than 4 months 0.101 1.12 0.09 0.9276 
 Never ref - - - 
Race  Black 1.094 0.83 1.32 0.1880 
 Other or multiple -0.136 0.74 -0.18 0.8535 
 White ref - - - 
Number of relevant 
comorbidities (collected at 
Month 10 data collection) 
1 comorbid condition 1.446 0.79 1.84 0.0659 
 2 or more comorbid 
conditions 
1.532 0.77 1.99 0.0461 
 No comorbid 
conditions 
ref - - - 
Sex (Collected via SEER) Female 0.324 0.62 0.52 0.6028 
 Male ref - - - 
Live with child under 18 years 
old (collected at Month 10 data 
collection) 
Checked 1.050 0.92 1.14 0.2525 
 Unchecked ref - - - 
Employment (collected at 
Month 10 data collection) 
Retired -2.488 0.87 -2.85 0.0044 
 Unemployed or 
disabled 
-0.628 0.93 -0.68 0.4974 
 Working full time, part 
time or student 
ref - - - 
Months between diagnosis 
and Month 10 data collection 
 -0.028 0.19 -0.15 0.8836 
Age at diagnosis (years) 
(Collected via SEER) 
 -0.038 0.04 -1.02 0.3098 
PROMIS Anxiety at Month 10 
data collection 
 0.218 0.04 5.46 <.0001 
PROMIS Fatigue at Month 10 
data collection 
 0.287 0.05 6.16 <.0001 
PROMIS Pain Interference at 
Month 10 data collection 
 0.093 0.04 2.39 0.0167 
FACT-G Physical Well-being 
Nausea Item at Month 10 data 
collection 
 0.067 0.41 0.16 0.8706 
Variance  56.226 3.21 _ _ 
FACT-G = Functional Assessment of Cancer Therapy-General, PROMIS = Patient-Reported Outcomes 
Measurement Information System. 
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Table 4.5. Multiple Regression Results, Relationship Between Change in Sleep Disturbance and Change 
in Patient, Disease, and Treatment Factors from Approximately 10 to 17 Months After Diagnosis (n = 361) 
Effect Categories Estimate 
Standard 
Error Z P value 
Intercept  10.385 4.91 2.11 0.0345 
Months between chemotherapy and 
Month 17 data collection 
Current 1.480 1.76 0.84 0.3994 
 1-2 months 0.710 1.80 0.40 0.6928 
 > 2 months -0.064 0.75 -0.09 0.9321 
 Never ref - - - 
Months between surgery Month 17 data 
collection 
0-4 months -1.714 1.77 -0.97 0.3339 
 More than 4 months 0.042 1.25 0.03 0.9729 
 Never ref - - - 
Race (Collected at Month 10) Black -0.192 0.92 -0.21 0.8341 
 Other or multiple -0.295 0.90 -0.33 0.7420 
 White ref - - - 
Number of relevant comorbidities 
(Collected at Month 10) 
1 comorbid condition 1.591 0.88 1.82 0.0694 
 2 or more comorbid 
conditions 
-0.074 0.85 -0.09 0.9306 
 No comorbid conditions ref - - - 
Sex (Collected via SEER) Female -0.166 0.68 -0.24 0.8075 
 Male ref - - - 
Live with child under 18 years old 
(Collected at Month 10) 
Checked -0.729 1.11 -0.66 0.5121 
 Unchecked ref - - - 
Employment (Collected at Month 10) Retired -0.578 0.96 -0.60 0.5482 
 Unemployed or disabled -0.440 1.12 -0.39 0.6944 
 Worked full time, part 
time or student 
ref - - - 
Months between diagnosis and Month 17 
data collection 
 0.091 0.17 0.53 0.5956 
Age at diagnosis (years) (Collected via 
SEER) 
 -0.018 0.05 -0.38 0.7026 
PROMIS Anxiety change (Month 17 – 
Month 10) 
 0.135 0.04 3.07 0.0021 
PROMIS Fatigue change (Month 17 – 
Month 10) 
 0.203 0.05 4.17 <.0001 
PROMIS Pain Interference change 
(Month 17 – Month 10) 
 -0.025 0.04 -0.62 0.5358 
FACT-G Physical Well-being Nausea 
Item change (Month 17 – Month 10) 
 0.100 0.40 0.25 0.8049 
PROMIS Sleep Disturbance at Month 10  -0.209 0.04 -5.59 <.0001 
Variance  40.544 3.02 _ _ 
FACT-G = Functional Assessment of Cancer Therapy-General, PROMIS = Patient-Reported Outcomes 
Measurement Information System. 
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Supplemental Table 4.1. Descriptive Comparison of Patients not in the Month 10 Analysis Due to Missing 
Responses Compared to Patients Included in the Month 10 Analysis 
Patient Characteristics Collected at 
Month 10  
Patients who participated in survey at Month 10 
but not included in the Month 10 analyses due to 
missing responses 
(n = 121) 
Month 10 analysis 
sample 
(n = 613) 
Age at diagnosis   
Mean (SD), Median, Min - Max 64.3 (11.1), 66.0, 36-84 62.3 (12.3), 64.0, 22-84 
Sex   
Female 58 (47.9%) 323 (52.7%) 
Race   
Other or multiple 29 (24.0%) 163 (26.6%) 
White 58 (47.9%) 335 (54.6%) 
Black 34 (28.1%) 115 (18.8%) 
Employment status   
Work 37 (37.4%) 237 (38.7%) 
Retired 51 (51.5%) 264 (43.1%) 
Unemployed or disabled 11 (11.1%) 112 (18.3%) 
Months between most recent 
chemotherapy and Month 10 data 
collection 
  
0 = never 44 (51.2%) 278 (45.4%) 
1 = current 15 (17.4%) 128 (20.9%) 
2 = 1-2 months 17 (19.8%) 107 (17.5%) 
3 = > 2 months 10 (11.6%) 100 (16.3%) 
PROMIS Sleep Disturbance   
Mean (SD), Median, Min - Max 50.3 (9.6), 52.2, 30-75 50.6 (9.8), 51.4, 30-75 
Survey language   
English 109 (90.1%) 552 (90.0%) 
Spanish or Chinese 12 (9.9%) 61 (10.0%) 
Max = maximum; min = minimum; PROMIS = Patient-Reported Outcomes Measurement Information System, SD = 
standard deviation. 
Note: Percent calculated out of non-missing responses. 
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Supplemental Table 4.2. Descriptive Comparison of Patients not Included in the Change Analysis 
Compared to Patients Included in the Change Analysis 
Patient Characteristics Collected at 
Month 10  
Patients who participated in survey at Month 10 
but not included in the Change analyses due to 
missing responses 
(n = 373) 
Change analysis sample 
(n = 361) 
Age at diagnosis   
Mean (SD), Median, Min - Max 61.5 (12.9), 63.0, 22-84 63.7 (11.2), 65.0, 30-84 
Sex   
Female 203 (54.4%) 178 (49.3%) 
Race   
Other or multiple 120 (32.2%) 72 (19.9%)* 
White 174 (46.6%) 219 (60.7%) 
Black 79 (21.2%) 70 (19.4%) 
Employment status   
Work 142 (40.5%) 132 (36.6%) 
Retired 136 (38.7%) 179 (49.6%)* 
Unemployed or disabled 73 (20.8%) 50 (13.9%) 
Months between most recent 
chemotherapy and Month 10 data 
collection 
  
0 = never 162 (46.2%) 160 (46.0%) 
1 = current 68 (19.4%) 75 (21.6%) 
2 = 1-2 months 56 (16.0%) 68 (19.5%) 
3 = > 2 months 65 (18.5%) 45 (12.9%) 
PROMIS Sleep Disturbance   
Mean (SD), Median, Min - Max 51.5 (9.6), 52.6, 30-75 49.5 (9.8), 50.2, 30-75 
Survey language   
English 327 (87.7%) 334 (92.5%) 
Spanish or Chinese 46 (12.3%) 27 (7.5%) 
Max = maximum; min = minimum; PROMIS = Patient-Reported Outcomes Measurement Information System, SD = 
standard deviation. 
Note: Percent calculated out of non-missing responses. 
*p < 0.05. 
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CHAPTER 5. RELATIONSHIP BETWEEN SLEEP AND EXERCISE IN A SAMPLE OF INDIVIDUALS 
DIAGNOSED WITH COLORECTAL CANCER (MANUSCRIPT 2) 
5.1 Background  
Colorectal cancer (CRC) is the third most common adult cancer,
4
 with more than 1.1 million 
individuals currently living with the disease in the United States.
5
 It is estimated that at least half of all 
individuals diagnosed with CRC experience decrements in sleep.
3
 Consequences of sleep disturbance 
include decreased cognitive functioning
9
 and fatigue.
10,11
 Sleep disturbance is associated with financial 
implications as well, such as loss in work productivity and work quality and increased number of visits to 
health professionals.
14
 Poor sleep is also linked to long-term implications such as being a risk factor for 
infectious diseases, cardiovascular diseases, and depression.
13
  
Despite the substantial repercussions of sleep disturbance, few treatment options are available to 
help individuals with CRC who experience sleep disturbance improve their sleep. The two most widely 
used treatment options include cognitive behavioral therapy (CBT) and pharmacotherapies. CBT is 
recommended by the American Academy of Sleep Medicine as a first-line therapy for patients with 
insomnia. CBT for sleep disturbance includes relaxation therapy, sleep hygiene, and cognitive therapy. 
Unfortunately, there are an inadequate number of providers trained in CBT for sleep disturbance, and 
patient adherence issues pose considerable barriers to the adequacy of sleep treatment.
9
 Pharmacologic 
treatments (e.g., benzodiazepine-receptor agonists, antidepressants, melatonin agonists) are associated 
with adverse daytime side effects such as sedation or dizziness. Further, cancer patients may experience 
disturbed sleep for a substantially longer duration than the 4 to 6 weeks for which pharmacologic sleep 
aids are recommended.
20,21
.  
Neither CBT nor pharmacologic treatments are directly associated with additional health benefits. 
However, exercise is an alternative treatment option that improves aerobic fitness
112
 and other aspects of 
quality of life such as anxiety, pain, and fatigue, all of which are associated sleep disturbance.
113-115
 
Exercise has been evaluated as a treatment for sleep disturbance in the healthy U.S. population
23,116
 and 
a number of RCTs and observational studies have investigated exercise as a possible treatment for sleep 
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disturbance in cancer patients.
113,117-121
 Exercise is generally accessible and a low-cost alternative 
treatment for sleep disturbance, but only three studies have investigated the relationship between 
exercise and sleep disturbance in individuals diagnosed with CRC: two observational studies
120,119
 and 
one randomized controlled trial (RCT).
117
 Of these studies, the RCT showed the most promising results 
for exercise, showing that an 8-week home-based exercise program improved sleep in a sample of stage 
IV colorectal and lung cancer patients.
117
 Because the RCT included a mixture of individuals diagnosed 
with colorectal or lung cancer, the results of this study are not conclusive specifically for individuals 
diagnosed with CRC.  
Two observational studies that explored the relationship between sleep and exercise did not find 
a statistically significant effect, but both studies were small, with 119 individuals diagnosed with 
colorectal, breast, or ovarian cancer 
119
 and 45 adults diagnosed with stage II or III CRC,
120
 respectively, 
and sleep was not the primary outcome of the study; studies were not powered to detect differences in 
sleep outcomes. Because of the study designs, a causal effect of exercise on sleep disturbance could not 
be concluded. 
There are a number of possible explanations for the inconsistent results between the RCT and 
observational studies including differences among participants in the study (e.g., cancer stage, cancer 
type), differences in exercise prescription of intensity and frequency, and differences in the slice of time 
during patients’ cancer treatment trajectories. Another possible explanation is that exercise may be more 
effective in ameliorating sleep disturbance for some individuals and not for others, which could attenuate 
sleep outcomes between exercise treatment groups and usual care groups. Future randomized trials 
testing the effect of exercise on sleep disturbance in CRC should tailor the population of interest to 
patients whose sleep would benefit the most from exercise. Prior to conducting an RCT, it is important to 
identify the characteristics of CRC patients who may benefit most from an exercise intervention. 
Regression mixture models uncover possible variability among patients and provide a way to reveal 
relationships between sleep disturbance and exercise that may differ depending on severity of sleep 
disturbance.  
This study builds on the published literature by examining the relationship between sleep and 
exercise in individuals diagnosed with CRC using observational patient-reported data from individuals 
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approximately 10 months after a diagnosis of non-metastatic colorectal cancer. The purpose of this study 
is two-fold. First, we investigated whether the relationship between exercise and sleep disturbance 
differed by severity of sleep disturbance in a sample of adults diagnosed with CRC. The second objective 
of this study was to evaluate the relationship between exercise and sleep disturbance specifically in a 
sample of adults diagnosed with stage I–III CRC in which it was hypothesized that patients whose 
exercise was categorized as moderately or highly active would experience less sleep disturbance than 
patients who did not exercise.  
5.2 Methods 
5.2.1 MY-Health Study Design 
This secondary data analysis was conducted using data from the Measuring Your Health (MY-
Health) study which included over 5000 patients enrolled between 2010 and 2012.
143
 Potential study 
participants were identified from four SEER cancer registries located in three states: California (2 SEER 
registries), Louisiana, and New Jersey. Individuals age 21–84 years diagnosed with one of seven cancer 
types (colorectal, prostate, non-small cell lung, non-Hodgkin lymphoma, female breast, uterine, or 
cervical) within 6 to 13 months of diagnosis were invited to participate in the MY-Health study via mail. 
Participants completed questionnaires using mail-in hard copy questionnaires at two time points: The first 
data collection occurred approximately 10 months after diagnosis (mean = 9.73, range = 6-30 months) 
and the second data collection occurred around 17 months after diagnosis on average (mean = 17.42, 
range = 11-36 months). The MY-Health study oversampled racial/ethnic minorities and younger patients, 
and questionnaires were available in three languages (English, Spanish, Mandarin). Additional details on 
the study design and procedures were previously published.
143
  
5.2.2 Participants 
Patients who were identified as being diagnosed with stage I, II, or III colorectal cancer based on 
SEER information were included in the analyses for this study. Because exercise was the main 
independent variable of interest, the sample was further limited to patients who were able to perform 
physical activity, defined as patients who were able to get out of bed (based on a patient-reported survey 
question). The first round of data collection approximately 10 months on average after diagnosis included 
734 patients, and 400 patients participated in the second round, which was collected approximately 17 
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months after diagnosis on average. For brevity, these data collection time points will be referred to as 
Month 10 and Month 17 respectively. 
5.2.3 Measures 
Dependent variable. 
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance 
items were administered to patients at Month 10 and Month 17. PROMIS Sleep Disturbance measures 
concepts included trouble staying asleep, not getting enough sleep, restlessness, feeling refreshed after 
sleep, and difficulty falling sleep. Results of the full psychometric evaluations of the PROMIS Sleep 
Disturbance item bank
144
 and short forms
145
 were previously published. A custom six-item short form was 
scored; the psychometric properties of the six-item form were evaluated in individuals enrolled in the MY-
Health study (Cronbach’s α = 0.88 – 0.95).
146
 PROMIS Sleep Disturbance is a continuous variable scored 
on a t-score metric with a mean of 50 and standard deviation (SD) of 10 based on the referent population 
(mixture of clinical and the general U.S. population
147
), and higher scores indicate worse sleep 
disturbance. Change in sleep disturbance was calculated by subtracting PROMIS Sleep Disturbance 
scores at 10 months from scores at 17 months after CRC diagnosis. Positive change is indicative of 
worsening sleep. The recall period was “the past 7 days.” A recent study by Leung et al.
168
 provided a cut 
point on PROMIS Sleep Disturbance indicative of clinically significant sleep disturbance (≥ 57, area under 
the curve = 0.92). 
Independent variables. 
Exercise.  
The MY-Health study included three exercise-related survey items covering patient-perceived 
exercise intensity and patient-reported frequency of exercise in the previous 7 days. Exercise items were 
administered at Month 10 and Month 17 data collection, capturing patients’ exercise routines during each 
slice of time during their treatment trajectory. Based on patients’ responses to the exercise items, 
patients’ exercise was categorized into one of four activity levels: (1) not active, (2) slightly active, (3) 
moderately active, and (4) highly active. The four exercise categories reflect the American College of 
Sports Medicine’s (ACSM) recommendation that individuals diagnosed with cancer achieve 150 minutes 
of moderate-intensity exercise per week or 75 minutes of vigorous exercise per week.
15
 Patients 
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classified in the “not active” or “slightly active” groups likely did not meet the minimum ACSM guideline of 
150 minutes of moderate-intensity exercise per week or 75 minutes of vigorous exercise per week,
15
 but 
patients in the “moderately active” or “highly active” groups likely met or exceeded the ACSM guideline. 
The primary independent variable of interest in each model, exercise, summarizes patients’ exercise 
routines at 10 and 17 months after CRC diagnosis. Exercise level was entered in the model as an 
indicator variable with “not active” as the reference category. 
Patient-level factors associated with sleep disturbance.  
The MY-Health dataset contains information on patient, disease, and treatment factors 
associated with sleep disturbance. There is an established link between cancer treatment and sleep 
disturbance, and some literature suggests that there is a relationship between time since treatment and 
sleep disturbance,
16-18,100,101
 though the trajectory of sleep disturbance throughout and after treatment for 
adults with CRC is unknown. Cancer treatment type (e.g., surgery,
91
 chemotherapy,
21,99
 radiation) and 
most recent date of treatment were self-reported. Categorical variables were derived to capture 
current/recent treatment compared to no treatment or less-recent treatment. Categories were based on 
relevant physical recovery periods post-treatment and data availability. Time since chemotherapy was 
coded using four categories (i.e., currently receiving chemotherapy, chemotherapy 1–2 months ago, 
chemotherapy more than 2 months ago, never received chemotherapy). Time since surgery was coded 
using three categories (i.e., surgery occurred within 0–4 months, surgery occurred more than 4 months 
ago, never received surgery). Comorbid conditions
73
 were self-reported and included in the models as a 
derived variable with three categories (i.e., no comorbid diseases, 1 comorbid disease, 2 or more 
comorbid diseases). Three PROMIS domains were included in the models as independent variables to 
assess aspects of health-related quality of life known to be associated with sleep disturbance:
73,79
 
80
 
81,90,92-95
 Anxiety (11 items), Fatigue (14 items),
148
 and Pain Interference (11 items).
149
 These PROMIS 
measures were normed to the general U.S. population
147
 and higher scores indicate worse anxiety, 
fatigue, and pain, respectively. Nausea severity was measured using a 5-point nausea
21
 item from the 
FACT-G Physical Well-Being (PWB) subscale
150
 with a recall period of the “past 7 days” and response 
choices ranging from 0 = “not at all” to 4 = “very much.” Although the nausea item has not been 
psychometrically evaluated as a single measure of nausea, the entire FACT-G PWB scale, which has 
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been evaluated extensively in cancer patients, covers concepts that overlap with PROMIS measures 
such as pain and fatigue. Therefore, only the nausea item was included in the models as a continuous 
variable. Other characteristics known to be associated with different levels of sleep disturbance were 
included in the models such as age at diagnosis,
2,21,97
 sex,
72
 time since diagnosis,
93
 employment status,
84
 
and an indicator for living with children under 18
83,84
 were included in the models. Age and race were also 
included in the model to account for the over-sampling of younger and minority persons from SEER 
registries. Race, employment status, and the living-with-child(ren) indicator were self-reported, and age at 
diagnosis, sex, and diagnosis date were obtained via SEER registry data. 
Factors associated with exercise.  
MY-Health variables also addressed determinants of exercise participation (treatment selection). 
Exercise participation is partially determined by patients’ ability to perform activities,
153-155
 thus patients’ 
PROMIS Physical Function scores were included as a covariate in the model (higher scores indicate 
better physical function).
156
 Social support is associated with participation in exercise and was measured 
using PROMIS Ability to Participate in Social Roles and Activities (higher scores represent fewer social 
limitations).
153-155,157
 Higher weight is associated with less exercise, therefore body mass index (BMI) was 
derived from patient-reported weight and height.
72
 Other factors already included in the model that are 
associated with participation in exercise and affect sleep include increased age, parenthood, sex, and 
race.
153-155
 
5.2.4 Analyses 
Patients’ exercise information was captured at two time points in the MY-Health study. Therefore, 
analyses were conducted twice to assess the relationship between sleep disturbance and exercise level 
at two time points after CRC diagnosis. Month 10 analyses evaluate factors associated with sleep when 
patients are first transitioning out of CRC treatment. The second analysis employs the same variables 
and methods but using data that were collected on patients 17 months after diagnosis. This timeframe 
captures patients’ experiences with sleep disturbance and their exercise participation as they transition 
out of treatment into a more stable recovery phase. Complete case analyses were conducted for all 
models. Due to missing data, 587 participants out of the 734 identified as diagnosed with stage I–III CRC 
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were included in the Month 10 analyses. For the follow-up assessment, approximately 7 months later, 
356 participants were included in the Month 17 analyses.  
Methods.  
Descriptive statistics were tabulated. Relationships between candidate independent variables 
were evaluated for collinearity by calculating bivariate correlations and variance inflation factor (VIF) 
within multiple regression models. VIF values greater than 10 were considered a symptom of 
multicollinearity. The correlation coefficient between PROMIS Anxiety and PROMIS Depression was 
strong (r = 0.87), suggesting collinearity between scores; PROMIS Anxiety was included in the model and 
PROMIS Depression for simplicity (anxiety is associated with disturbed sleep, but depression is 
associated with both disturbed sleep and hypersomnia
169
). Although some categorical variables appear to 
be ordinal in nature, all categorical variables were entered into the model as indicator variables (except 
for the FACT-G PWB item, which was entered as a continuous variable) because categorical response 
choices/levels were not necessarily evenly spaced. Residuals were evaluated between candidate 
independent variables and PROMIS Sleep Disturbance to determine if higher-order terms needed to be 
included in the models.  
Regression mixture models (RMMs)
158,159
 are special cases of finite mixture models, which model 
weighted combinations of different distributions. With RMMs, the component membership to each 
distribution is unobservable (a latent variable). In this study, we employed RMMs to test if heterogeneity 
was present in the associations between sleep disturbance and exercise, specifically, if factors 
associated with sleep disturbance (especially exercise) varied by severity of sleep disturbance or another 
unknown mechanism (objective 1) at Month 10 and Month 17. RMMs were estimated using Dual Quasi-
Newton optimization
162
 and models ranging from one to two classes were evaluated. The final models 
(e.g., choice of number of classes) were chosen based on fit (smallest Bayesian Information Criterion 
Index (BIC)) and interpretability. RMMs are sensitive to starting values,
164
 thus user-provided starting 
values were also tested to confirm the number of classes identified by SAS-generated starting values. If 
the single class model was identified, then multiple regression (which assumes one common class of 
sleep disturbance) was used to model factors associated with sleep disturbance. Regression coefficients 
were reviewed; a statistically significant coefficient on the exercise indicator variable signified a 
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relationship between sleep disturbance and exercise (objective 2). Objective 2 was assessed at 
approximately 10 and 17 months after CRC diagnosis. 
A logistic regression was used to identify factors associated with patient survey completion at 
Month 10 (outcome = 1) versus participating in the Month 10 survey but not completing enough questions 
to be included in the analyses. The logistic regression model included patient characteristics at Month 10 
that were related to sleep disturbance and potentially associated with survey compliance: sex, race, 
employment status, survey language, level of exercise activity, PROMIS Sleep Disturbance, and PROMIS 
Physical Functioning. 
There was substantial patient attrition from the Month 10 survey data collection to Month 17 
survey data collection; factors associated with patient persistence in survey participation from Month 10 
data collection to Month 17 data collection were evaluated using descriptive statistics and logistic 
regression. Patients who participated in Month 10 and Month 17 survey administrations (outcome = 1) 
were compared with patients who participated in Month 10 but not Month 17 (outcome = 0) using logistic 
regression. The model included patient characteristics at Month 10 that were related to sleep disturbance 
and potentially associated with patient attrition: sex, race, employment status, survey language, level of 
exercise activity, PROMIS Sleep Disturbance, and PROMIS Physical Functioning. A sensitivity analysis 
was also conducted by including the Month 17 analysis sample in the Month 10 model (including 
variables that were collected at Month 10 only).  
Another sensitivity analysis was conducted to describe the impact of including anxiety in the 
models instead of depression. Anxiety was removed from the Month 10 and Month 17 models and 
depression was added. Model results were compared. 
Power.  
Power to detect multiple classes was evaluated and confirmed using simulations based on MY-
Health study data, which provided information about the covariance structure among the independent 
variables. Sub-samples were randomly drawn from the study dataset to simulate 1000 datasets for each 
of the parameter modifications in the simulation: overall sample size, numeric differences between 
coefficients in each latent class, variance of the error term used to simulate sleep disturbance scores, and 
proportion of sample within each class. A well-accepted rule of thumb for identifying minimally important 
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group differences on a PRO measure is the half standard deviation.
166,170
 The half standard deviation of 
PROMIS Sleep Disturbance was approximately 5 points at Month 10. For classes to be meaningfully 
different, we anticipated that the classes should be separated at a minimum by the threshold for minimal 
important difference. For the Month 10 analyses, based on a sample size of 600, a mean difference 
between sleep disturbance scores in each class approximately 6 points apart, equal-size classes (i.e., 
proportion of patients in class 1 = 50% and proportion of patients in class 2 = 50%), and an error term of 3 
or less, the power to detect multiple classes was 100%. When the variance of the error term used to 
compute the simulated sleep disturbance scores increased to 4, 5, or 8 and all other parameters were the 
same, power reduced to 61.1%, 9.2%, and 1.6%, respectively. Power to detect multiple classes was 
above 95% for all circumstances when the mean difference between simulated sleep disturbance 
between classes differed by approximately 9 and 17 points and the variance of the error term used to 
simulate sleep disturbance scores was less than 8. The proportion of the sample designated to each 
class was modified in the simulations but the effect on power was negligible. Regarding the Month 17 
analyses, power to detect multiple classes was also evaluated for a sample size of 360. When the 
classes were of equal sizes, the mean difference between sleep disturbance scores in each class was 
almost 6 points apart and the variance of the error term used to simulate the sleep disturbance scores 
was 3 or less, then power to detect multiple classes was at least 94.1%. The proportion of the sample 
within each class had very little effect on power. 
Power to detect the effect of exercise was calculated for a sample size of 600 and 350. When 
sample size was 600 and the partial correlation between exercise and sleep disturbance was 0.14 or 
greater, power was 0.93 or above. When the sample size was 600 and the partial correlation was very 
small (0.05), power was reduced to 23.2. When the sample size was 350 and the partial correlation was 
set at 0.20 or higher, power was 0.85 at the lowest. When the sample size was 350 and the partial 
correlation dipped to 0.14, power was 0.75. 
Analysis conventions.  
Regression coefficients were reviewed to describe the relationship between sleep disturbance 
and covariates in the models. An alpha of 0.05 or less was chosen as the criterion for statistical 
significance of the covariates in the RMMs. All analyses were performed using SAS version 9.3 (SAS 
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Institute Inc., Cary, NC, USA). More specifically, we used a SAS procedure called PROC FMM to fit 
RMMs.
163
  
5.3 Results 
Patient, disease, and treatment characteristics were similar for the Month 10 and Month 17 
analysis samples (Table 5.1). The mean patient age at diagnosis was 62 years for participants in the 
Month 10 analysis. Approximately half the sample was female (Month 10: 52.5%, Month 17: 48.9%). Less 
than half of all study participants were working full-time, part-time, or were students (Month 10: 39.7%, 
Month 17: 37.1%). Sixty percent of patients had at least one comorbid condition (Month 10: 60.5%, Month 
17 sample: 60.1%).  
Descriptive statistics for variables entered in the RMM and multiple regression models were 
computed (Supplemental Table 5.1); data that were collected at the Month 17 data collection were 
entered in the Month 17 model. Almost two-thirds of the sample was moderately or highly active at Month 
10 (60.3%) and over two-thirds of the sample was moderately or highly active at Month 17 (68.8%). Only 
22.5% of patients were not active at Month 10 and 17.4% were not active at Month 17.  
At both Month 10 and Month 17, mean PROMIS Sleep Disturbance scores hovered around the 
average scores observed in the referent population (i.e., patients who went to sleep clinics and healthy 
sleepers) (Month 10: mean = 50.4; Month 17 mean = 49.7). Applying Leung’s cut point to our data 
(PROMIS Sleep Disturbance ≥ 57), we found that 24.0 and 20.8 percent of patients were likely 
experiencing clinically significant sleep disturbance at Month 10 and Month 17 respectively [data not 
shown]. 
The mean PROMIS Sleep Disturbance scores for each level of exercise follows the predicted 
pattern, with higher (more severe sleep disturbance) PROMIS Sleep Disturbance scores among patients 
reporting less exercise (No exercise mean: Month 10 = 53.0, Month 17 = 52.3) and lower (better sleep 
quality) PROMIS Sleep Disturbance scores among patients reporting more exercise (highly active mean: 
Month 10 = 48.5, Month 17 = 46.7) (Table 5.2). At Month 17, the difference between mean sleep 
disturbance scores in the not active group and the highly active group was 5.6 points, just above the 
threshold likely indicating a meaningful difference in sleep disturbance. 
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5.3.1 Regression Mixture Models 
Model fit. 
RMMs were estimated to examine whether distinct classes of sleep disturbance were present. 
Models with one through four classes were estimated for the two cross-sectional models (Month 10 and 
Month 17). Table 5.3 presents BIC statistics for both models based on SAS-generated starting values. 
For the Month 10 and Month 17 models, the smallest BIC and AIC were associated with the one-class 
model. Therefore, a multivariable regression was chosen for the Month 10 and Month 17 models.  
Relationship between sleep disturbance and exercise. 
Month 10 model. 
Table 5.4 presents the results of the Month 10 model. Although patients categorized as highly 
active or moderately active had positive coefficients in the model, which would suggest that more active 
individuals experienced worse sleep disturbance, this result was not statistically significant. Being retired 
(compared to working), worse anxiety, and worse fatigue had statistically significant relationships with 
worse sleep disturbance. Retirement was associated with PROMIS Sleep Disturbance score 2.4 points 
lower than working full-time, part-time, or being a student, a difference smaller than the five-point 
meaningful difference threshold. The positive coefficients on the anxiety and fatigue scales show that 
patients with less anxiety or fatigue experience less sleep disturbance. Although the coefficients on 
anxiety and fatigue were statistically significant, they were small (less than 1); a 25-point improvement in 
PROMIS Fatigue would be associated with a six-point improvement in PROMIS Sleep Disturbance.  
Month 17 model. 
Table 5.5 presents the results of the Month 17 cross-sectional model. Exercise levels did not 
exhibit statistically significant relationships with sleep disturbance. Anxiety and fatigue had statistically 
significant relationships with sleep disturbance such that worse anxiety and fatigue were associated with 
poorer sleep. 
Sensitivity analysis: Anxiety and depression. 
Due to the collinearity between anxiety and depression, a sensitivity analysis was conducted to 
test depression in the model instead of anxiety at Month 10 and Month 17. The models including 
depression (instead of anxiety) yielded almost identical results to the primary models at Month 10 [data 
not shown] with no statistically significant relationship between exercise and sleep disturbance and 
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statistically significant relationships between sleep disturbance and retirement (B = -2.6), depression (B = 
0.20), and fatigue (B = 0.24). The Month 17 model including depression instead of anxiety yielded a very 
similar result compared to the Month 17 model including anxiety with statistically significant relationships 
between sleep disturbance and depression (B = 0.14) and fatigue (B = 0.36) [data not shown]. 
5.3.2 Missing Data and Patient Attrition 
Due to missing data, 147 of the 734 CRC patients (stage I–III) included in the MY-Health study 
were removed from the RMM/multiple regression analyses, leaving 587 participants in the Month 10 
analysis sample. The 147 patients who were not included in the Month 10 analyses were compared with 
the 587 patients who were included in the analyses using descriptive statistics and logistic regression 
(Supplemental Table 5.2). Being slightly active (OR = 2.43) (compared to those who were not active) and 
having a better physical functioning (OR = 1.03) were factors statistically significantly related to patient 
compliance completing survey questions at Month 10 and Month 17. Patients who identified as black 
were more likely to not complete survey items and not be included in the Month 10 analysis (OR = 0.60). 
Patient attrition and missing data were factors in the size of the Month 17 analysis (n = 356), 
therefore patients who were included in the Month 17 analysis were compared with the 378 patients who 
participated in the Month 10 survey but were not included in the Month 17 analysis (due to patient attrition 
in survey participation or missing data) (Supplemental Table 5.3). Retirement (OR = 1.48) and more 
exercise activity (“slightly active” was the only statistically significant exercise category: OR = 1.66, but 
descriptive statistics imply that participants in the Month 17 analyses were more active overall) were 
factors associated with continued participation in the survey from Month 10 to Month 17, but identifying as 
“other or multiple” races (not white and not black) was associated with patient attrition/missing responses 
(OR = 0.51). 
A sensitivity analysis was also conducted to describe the impact of patient attrition/missing data in 
the results of the Month 10 and Month 17 models: The Month 10 model was rerun including only patients 
were included in the Month 17 analyses (n = 356). Results were similar with similar magnitudes of 
regression coefficients and as in the primary Month 10 model, anxiety (B = 0.25) and fatigue (B = 0.19) 
were statistically significant. Some new statistically significant relationships emerged between sleep 
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disturbance and identifying as black (B = 3.1), having one comorbid condition (B = 0.03), and age at 
diagnosis (B = -0.13) [data not shown].  
5.4 Discussion 
This study builds on the published literature by examining the relationship between sleep and 
exercise specifically in individuals diagnosed with stage I, II, or III CRC using observational data 
representing patients’ exercise habits without intervention. This study did not find a statistically significant 
relationship between sleep disturbance and exercise, and this relationship did not differ by severity of 
sleep disturbance. These findings provide evidence that the relationship between sleep disturbance and 
exercise is consistent at any level of sleep disturbance severity in this CRC sample, meaning that no 
specific subgroup of patients with normal, mild, moderate, or severe sleep disturbance (compared to 
healthy and non-healthy sleepers) emerged as being associated with any particular level of exercise (or 
lack of exercise).  
Approximately 40% of individuals diagnosed with CRC in this study likely did not achieve the 
ACSM recommendations for exercise (150 minutes of moderate-intensity exercise per week or 75 
minutes of vigorous exercise per week
15
) approximately 10 months after diagnosis. Although the exercise 
items presented some measurement limitations that precluded us from objectively categorizing patients 
as achieving or not achieving ACSM exercise recommended levels (e.g., duration of exercise not 
captured, items not psychometrically evaluated), patients classified in the “moderately active” or “highly 
active” groups likely met or exceeded ACSM guidelines. Nonetheless, the results of this study are similar 
to a large U.S. study using data from the 2009 Behavioral Risk Factor Surveillance System (BRFSS) 
survey showing that 40% of male and 30% of female CRC patients met the ACSM guidelines at least one 
year after diagnosis.
173
 The same study reported that only 30% of female patients with CRC met or 
exceeded the ACSM guidelines. Patients who do not meet ACSM exercise guidelines are at higher risk 
for cancer-related mortality,
174
 thus exercise is an important activity for individuals diagnosed with CRC 
regardless of the effect of exercise on sleep disturbance.  
Previous research advocates exercise as beneficial to sleep in other cancer populations.
117,121,142
 
Much of the previously published research showing an exercise benefit was conducted with women 
diagnosed with breast cancer
140
 
141
 or adults with mixed cancer diagnoses.
119
 
160
 
121
 Patients may attribute 
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sleep disturbance to general cancer-related factors such as the anxiety of cancer diagnosis, but reasons 
for sleep disturbance vary by cancer site. For example, estrogen deficiency caused by treatments for 
breast cancer are associated with hot flashes and sweating, both known disrupters of sleep.
109
 
Xerostomia (mouth dryness) is often experienced by individuals diagnosed with head and neck cancer 
and has been shown to be determinantal to sleep in this population.
175
 It is possible that exercise may be 
more effective in reducing particular aggravating factors of sleep disturbance in some cancer populations 
but not in others, thus explaining why exercise is associated with improved sleep disturbance in breast 
cancer or mixed cancer studies but not overwhelmingly so in CRC. Future research should focus 
evaluation of the relationship between sleep disturbance and exercise in specific cancer sites. 
A previously published randomized trial found a statistically significant relationship between sleep 
disturbance and exercise in individuals diagnosed with stage IV lung cancer or CRC,
117
 but two other 
observational studies did not find the same relationship between exercise and sleep. Stage IV patients 
were not included in our study because their treatment trajectories and HRQOL experiences are different 
from CRC patients diagnosed with non-metastatic disease; it is possible, even though Cheville’s 
randomized trial and our study included CRC patients, that exercise is more efficacious in metastatic 
disease than in earlier stages. The first observational study, conducted by Lin and colleagues, included 
patients diagnosed with stage II or III CRC undergoing chemotherapy on a supervised exercise 
intervention compared to a usual-care group.
120
 The supervised exercise intervention included 120 
minutes of moderate-intensity exercise, less than the ACSM guidelines. Though patients could exercise 
outside of the supervised exercise program in the intervention group and in the usual-care group, 
exercise frequency, duration, and intensity was not measured, therefore complicating the interpretation of 
the results and the ability to draw conclusions about the relationship between amount of exercise and 
sleep disturbance. Patients were not randomized to their treatment groups and statistical models did not 
control for HRQOL-based factors such as anxiety, depression, fatigue, etc. The second observational 
study, conducted by Cho and colleagues, included women with breast, colorectal, or ovarian cancer 
beginning their first cycle of chemotherapy.
119
 Cho did not find a statistically significant effect of exercise 
on sleep disturbance. The criteria for being classified as an exerciser was less stringent than the ACSM 
guidelines of 150 minutes of moderate-intensity exercise per week or 75 minutes of intense exercise per 
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week. Patients who exercised a minimum of three times a week for 20 minutes per session were 
classified as exercisers and compared against patients who did not meet these criteria. Similar to our 
study, both observational studies were faced with challenges in classifying patients as achieving exercise 
levels, which could affect mean differences between “treatment” groups. Cheville and colleagues did not 
collect information on patients’ exercise routines in the control group, thus it is possible that as stage IV 
patients, the control group was less active than the patients in the “control” groups in the observational 
studies, separating the mean differences in sleep disturbance further in the randomized study than in the 
observational studies. Future observational studies should collect data on exercise frequency, intensity, 
and duration of exercise to more easily differentiate patients who achieve ACSM guidelines, providing 
more clarity on the differences in sleep disturbance between exercise groups. Although our study showed 
no statistically significant relationship between sleep disturbance and exercise, the results should not be 
considered conclusive because of the observational nature of this study and possible exercise 
measurement issues. Therefore, future prospective research may still be warranted. 
In our study sample, we found a slight reduction in clinically significant sleep disturbance over the 
course of 7 months from approximately 24% to 21%. Although the trajectory of sleep disturbance severity 
over the full course of the cancer continuum is unknown in the CRC population, there is evidence of 
change in sleep disturbance over time in ovarian cancer.
18
 Previous research also shows that exercise 
fluctuates over time after CRC diagnosis and exercise decreases during CRC treatment.
118
 Given the 
likely fluctuation in sleep disturbance and exercise over time, future studies should prospectively collect 
data at different time windows to investigate possible temporal differences in the relationship between 
sleep disturbance and exercise. For example, patients undergo more drastic quality of life (and likely 
sleep outcome) changes immediately following diagnosis and through the active treatment phase than in 
the post-treatment recovery phase. 
Holding the relationship between exercise and sleep disturbance constant, the results of the 
Month 10 and Month 17 models were very similar, with anxiety and fatigue moving in the same direction 
as sleep disturbance. These results suggest that there might be a symptom cluster at play, with 
symptoms of anxiety (and depression), fatigue, and sleep disturbance improving or worsening together, 
though the coefficients on fatigue and anxiety were very small. The direction of the relationship among 
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these symptoms is unclear, but the size of the coefficients suggest that a large change in fatigue would 
be associated with a small change in sleep disturbance. Retirement was associated with better sleep 
disturbance in the Month 10 model, but the relationship was not statistically significant in the Month 17 
model. It is possible that missing data/patient attrition played into these results because retirement was 
strongly associated with participation in Month 17 data collection.  
Other factors associated with patient attrition were being classified as “other or multiple” races 
and being less active. It is unclear why minority patients (non-white and non-black) were less likely to be 
in the Month 17 analyses, but a recent study on recruitment and retention strategies for minorities 
diagnosed with breast cancer suggests that barriers to survey participation may vary by race/ethinicity.
176
 
The results of this study should be considered in light of some limitations. Patients were not 
randomized to participate in exercise, introducing selection bias. Although predictors of exercise 
participation were included in the models, the observational nature of this study limits the conclusions that 
can be drawn from analyses; instead of causal relationships, we can only infer associations. Therefore, 
independent variables, including exercise, are not necessarily predictors of sleep disturbance. There are 
a few omitted variables that that would be beneficial to include in the models discussed in this study, 
without which it is more difficult to control for selection into the exercise. The dataset did not include 
information on self-efficacy, one of the most important predictors of exercise. We also did not have 
access to an indicator for previous exercise habits prior to CRC diagnosis. Prior exercise habits are 
indicative of current or future exercise habits. Another omitted variable is information on patients’ physical 
activity, which is a much broader concept including any body movement that requires energy expenditure. 
Some patients may not exercise but engage in significant physical activity throughout the day. For 
example, some patients may walk to work, or have a labor-intensive job that involves heavy lifting. 
Exercise may be more relevant to patients with higher socioeconomic status because exercise is a 
planned, structured activity that requires time outside of other daily tasks and may also cost money. By 
only including exercise in the model, we may limit the conclusions and recommendations on exercise to 
patients above a certain socioeconomic threshold who have the means to exercise; some estimates may 
be biased because we are not including information on more general physical activity.  
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A strength of the MY-Health study was the inclusion of PROMIS measures, which were 
developed using rigorous qualitative and quantitative psychometric methods.
12,77,144,149
 Using these data, 
we were able to include a wide range of HRQOL variables in our models to control for factors related to 
sleep disturbance and exercise participation beyond what most observational studies have included in 
previous research. 
As a large community-based observational study, the MY-Health data provide information on 
experiences from a very diverse sample of patients who were evaluated during the course of usual care 
without controlled interventions. Understanding the relationship between sleep disturbance and exercise 
in patients with CRC 10 and 17 months after diagnosis is a building block to defining the trajectory of 
sleep disturbance and factors associated with sleep disturbance as patients transition off treatment.  
5.5 Conclusion 
The results of this study suggest a lack of significant relationship between exercise and sleep 
disturbance in individuals diagnosed with stage I, II and III CRC approximately 10 and 17 months after 
CRC diagnosis. A more granular understanding of this relationship could be evaluated through 
prospective research with longer follow up. 
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Table 5.1. Patient Characteristics at Month 10 
Patient Characteristics Collected at Month 10 
Month 10 Analysis 
Sample 
(n = 587) 
Month 17 Analysis 
Sample 
(n = 356) 
Age at diagnosis
 
   
Mean (SD), Median, Min - Max 62.1 (12.4), 64.0, 
22-84 
63.5 (11.2), 65.0, 
30-84 
Sex
 
   
Female 308 (52.5%) 174 (48.9%) 
BMI
 
   
Mean (SD), Median, Min - Max 28.8 (7.1), 27.4, 14-
71 
29.2 (7.3), 27.8, 17-
71 
Race    
Other (Asian, American Indian, Alaska native, Asian Hawaiian, 
Pacific Islander) or multiple 
154 (26.2%) 71 (19.9%) 
White 325 (55.4%) 215 (60.4%) 
Black 108 (18.4%) 70 (19.7%) 
Survey language    
English 531 (90.5%) 330 (92.7%) 
Spanish or Chinese 56 (9.5%) 26 (7.3%) 
Employment status
 
   
Working full time, part time or student 233 (39.7%) 132 (37.1%) 
Retired 250 (42.6%) 175 (49.2%) 
Unemployed or disabled 104 (17.7%) 49 (13.8%) 
Living status
 
   
Live with child(ren) under 18 years old 97 (16.5%) 50 (14.0%) 
Relevant comorbidities
 
   
No comorbid conditions 232 (39.5%) 142 (39.9%) 
1 comorbid condition 155 (26.4%) 94 (26.4%) 
2 or more comorbid conditions 200 (34.1%) 120 (33.7%) 
Cancer stage
 
   
Stage I 169 (28.8%) 102 (28.7%) 
Stage II 183 (31.2%) 117 (32.9%) 
Stage III 235 (40.0%) 137 (38.5%) 
Level of exercise activity    
Not active 132 (22.5%) 78 (22.0%) 
Slightly active 101 (17.2%) 63 (17.8%) 
Moderately active 271 (46.2%) 161 (45.5%) 
Highly active 83 (14.1%) 52 (14.7%) 
PROMIS Sleep Disturbance   
Mean (SD), Median, Min - Max 50.4 (9.7), 51.2, 30-
75 
49.5 (9.8), 50.3, 30-
75 
PROMIS Physical Functioning   
Mean (SD), Median, Min - Max 44.8 (9.1), 43.8, 15-
62 
45.1 (8.9), 44.6, 21-
62 
BMI = body mass index, max = maximum; min = minimum; PROMIS = Patient-Reported Outcomes Measurement 
Information System, SD = standard deviation. 
Note: Percent calculated out of non-missing responses. 
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Table 5.2. Bivariate Relationship Between PROMIS Sleep Disturbance and Exercise Categories 
 
PROMIS Sleep Disturbance Scores at Month 
10  
(n = 587) 
PROMIS Sleep Disturbance Scores at Month 17  
(n = 356) 
Exercise 
Category N 
Mea
n SD Median Min Max N Mean SD Median Min Max 
Not active 132 53.0 10.3 53.9 29.7 75.2 62 52.3 11.9 53.4 29.7 75.2 
Slightly 
active 
101 52.4 9.8 53.1 29.7 75.2 49 50.4 9.7 52.9 29.7 75.2 
Moderately 
active 
271 48.9 9.3 50.1 29.7 75.2 174 49.8 9.6 50.4 29.7 75.2 
Highly 
active 
83 48.5 8.8 48.8 29.7 71.6 71 46.7 9.5 48.0 29.7 68.7 
PROMIS = Patient-Reported Outcomes Measurement Information System, SD = standard deviation, Min = minimum, 
Max = maximum. 
 
 
 
 
 
 
Table 5.3. RMM Model Fit Statistics 
 Month 10 model Month 17 model 
Number of classes BIC AIC BIC AIC 
1 4188.6 4070.4 2643.6 2539.0 
2 4367.1 4126.4 2808.1 2595.0 
3 4545.6 4182.4 2972.6 2651.0 
4 4724.1 4238.4 3137.1 2707.0 
RMM = Regression mixture model, BIC = Bayesian Information Criterion Index, AIC = Akaike Information Criterion. 
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Table 5.4. Multiple Regression Results, Month 10 model (n = 587) 
Effect Categories Estimate 
Standard 
Error Z P value 
Intercept  35.799 7.48 4.78 <.0001 
Exercise Group at Month 10 Highly active 1.564 1.15 1.36 0.1738 
 Moderately active 0.451 0.86 0.53 0.5989 
 Slightly active -0.200 1.01 -0.20 0.8428 
 Not active ref - - - 
Months between chemotherapy and 
Month 10 data collection 
1 = current -0.286 0.96 -0.30 0.7650 
 2 = 1-2 months -1.540 0.92 -1.67 0.0956 
 3 = > 2 months -0.294 0.93 -0.31 0.7529 
 0 = never ref - - - 
Months between surgery and Month 
10 data collection 
1 = 0-4 months -0.560 1.56 -0.36 0.7200 
 2 = more than 4 
months 
-0.108 1.17 -0.09 0.9260 
 0 = never ref - - - 
Race (Collected at Month 10) Black 1.362 0.86 1.59 0.1113 
 Other (Asian, 
American Indian, 
Alaska native, Asian 
Hawaiian, Pacific 
Islander) or multiple 
0.090 0.76 0.12 0.9059 
 White ref - - - 
Number of relevant comorbidities at 
Month 10 
1 comorbid condition 1.517 0.80 1.91 0.0567 
 2 or more comorbid 
conditions 
0.826 0.81 1.03 0.3054 
 No comorbid 
conditions 
ref - - - 
Sex (Collected via SEER) Female 0.363 0.64 0.56 0.5722 
 Male ref - - - 
Live with child under 18 years old at 
Month 10 
Checked 1.070 0.93 1.15 0.2490 
 Unchecked ref - - - 
Employment at Month 10 Retired -2.426 0.89 -2.72 0.0066 
 Unemployed or 
disabled 
-0.686 0.96 -0.72 0.4732 
 Working full time, part 
time or student 
ref - - - 
Months between diagnosis and Month 
10 data collection 
 0.024 0.20 0.12 0.9034 
Age at diagnosis (years) (Collected 
via SEER) 
 -0.059 0.04 -1.53 0.1266 
BMI (Collected at Month 10)  0.046 0.05 1.00 0.3169 
PROMIS Anxiety at Month 10  0.207 0.04 4.90 <.0001 
PROMIS Fatigue at Month 10  0.243 0.06 4.38 <.0001 
PROMIS Pain Interference at Month 
10 
 0.044 0.04 1.04 0.2963 
PROMIS Physical Functioning at 
Month 10 
 -0.099 0.06 -1.62 0.1063 
PROMIS Social Functioning at Month 
10 
 -0.081 0.06 -1.37 0.1706 
FACT-G Physical Well-being Nausea 
Item at Month 10 
 0.014 0.41 0.03 0.9734 
Variance  54.840 3.20 _ _ 
BMI = body mass index, FACT-G = Functional Assessment of Cancer Therapy-General, PROMIS = Patient-Reported 
Outcomes Measurement Information System, SD = standard deviation 
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Table 5.5. Multiple Regression Results, Month 17 (n = 356) 
Effect Categories Estimate 
Standard 
Error Z P value 
Intercept  25.364 10.88 2.33 0.0197 
Exercise group at Month 17 Highly active -0.274 1.56 -0.18 0.8606 
 Moderately active 0.427 1.27 0.34 0.7368 
 Slightly active 0.149 1.61 0.09 0.9259 
 Not active ref - - - 
Months between chemotherapy and 
Month 17 data collection 
1 = current -0.899 2.22 -0.40 0.6857 
 2 = 1-2 months -0.944 2.27 -0.42 0.6769 
 3 = > 2 months -0.557 0.94 -0.59 0.5552 
 0 = never ref - - - 
Months between surgery and Month 
17 data collection 
1 = 0-4 months -3.964 2.26 -1.76 0.0790 
 2 = more than 4 months -0.725 1.60 -0.45 0.6508 
 0 = never ref - - - 
Race (Collected at Month 10) Black -0.010 1.18 -0.01 0.9933 
 Other (Asian, American 
Indian, Alaska native, 
Asian Hawaiian, Pacific 
Islander) or multiple 
0.012 1.17 0.01 0.9920 
 White ref - - - 
Number of relevant comorbidities at 
Month 10 
1 comorbid condition 1.754 1.11 1.58 0.1133 
 2 or more comorbid 
conditions 
-0.213 1.13 -0.19 0.8498 
 No comorbid conditions ref - - - 
Sex (Collected via SEER) Female -0.670 0.88 -0.76 0.4477 
 Male ref - - - 
Live with child under 18 years old at 
Month 10 
Checked -0.584 1.40 -0.42 0.6765 
 Unchecked ref - - - 
Employment at Month 10 Retired -1.597 1.22 -1.31 0.1904 
 Unemployed or 
disabled 
-1.859 1.45 -1.28 0.2002 
 Working full time, part 
time or student 
ref - - - 
Months between diagnosis and 
Month 17 data collection 
 -0.002 0.22 -0.01 0.9942 
Age at diagnosis (years) (Collected 
via SEER) 
 -0.075 0.06 -1.26 0.2069 
BMI (Collected at Month 10)  0.092 0.06 1.46 0.1445 
PROMIS Anxiety at Month 17  0.181 0.06 2.92 0.0035 
PROMIS Fatigue at Month 17  0.331 0.08 4.28 <.0001 
PROMIS Pain Interference at Month 
17 
 0.091 0.06 1.58 0.1138 
PROMIS Physical Functioning at 
Month 17 
 -0.053 0.08 -0.64 0.5254 
PROMIS Social Roles and Activities 
at Month 17 
 0.022 0.08 0.26 0.7924 
FACT-G Physical Well-being Nausea 
Item at Month 17 
 0.484 0.65 0.75 0.4550 
Variance  62.954 4.72 _ _ 
BMI = body mass index, FACT-G = Functional Assessment of Cancer Therapy-General, PROMIS = Patient-Reported 
Outcomes Measurement Information System, SD = standard deviation 
 
 
 
  
 99 
Supplemental Table 5.1. Descriptive Statistics for Variables Entered in RMM and Multiple Regression 
Models 
Characteristic 
Month 10 
(n = 587) 
Month 17 
(n = 356) 
Age at diagnosis
 
(collected at Month 10)   
Mean (SD), Median, Min - Max 62.1 (12.4), 64.0, 22-
84 
63.5 (11.2), 65.0, 
30-84 
Sex
 
(collected at Month 10)   
Female 308 (52.5%) 174 (48.9%) 
BMI
 
(collected at Month 10)   
Mean (SD), Median, Min - Max 28.8 (7.1), 27.4, 14-
71 
29.2 (7.3), 27.8, 
17-71 
Race (collected at Month 10)   
Other (Asian, American Indian, Alaska native, Asian Hawaiian, Pacific 
Islander) or multiple 
154 (26.2%) 71 (19.9%) 
White 325 (55.4%) 215 (60.4%) 
Black 108 (18.4%) 70 (19.7%) 
Employment status
 
(collected at Month 10)   
Working full time, part time or student 233 (39.7%) 132 (37.1%) 
Retired 250 (42.6%) 175 (49.2%) 
Unemployed or disabled 104 (17.7%) 49 (13.8%) 
Living status
 
(collected at Month 10)   
Live with child(ren) under 18 years old 97 (16.5%) 50 (14.0%) 
Relevant comorbidities
 
(collected at Month 10)   
No comorbid conditions 232 (39.5%) 142 (39.9%) 
1 comorbid condition 155 (26.4%) 94 (26.4%) 
2 or more comorbid conditions 200 (34.1%) 120 (33.7%) 
Level of exercise activity   
Not active 132 (22.5%) 62 (17.4%) 
Slightly active 101 (17.2%) 49 (13.8%) 
Moderately active 271 (46.2%) 174 (48.9%) 
Highly active 83 (14.1%) 71 (19.9%) 
Months Since Chemotherapy   
0 = never 263 (44.8%) 154 (43.3%) 
1 = current 123 (21.0%) 16 (4.5%) 
2 = 1-2 months 103 (17.5%) 15 (4.2%) 
3 = > 2 months 98 (16.7%) 171 (48.0%) 
Months Since Surgery   
0 = never 47 (8.0%) 30 (8.4%) 
1 = 0-4 months 54 (9.2%) 26 (7.3%) 
2 = more than 4 months 486 (82.8%) 300 (84.3%) 
Months since diagnosis at data collection   
Mean (SD), Median, Min - Max 9.7 (1.6), 9.5, 6-21 17.3 (2.0), 17.0, 
13-26 
PROMIS Sleep Disturbance   
Mean (SD), Median, Min - Max 50.4 (9.7), 51.2, 30-
75 
49.7 (10.2), 51.4, 
30-75 
PROMIS Anxiety   
Mean (SD), Median, Min - Max 49.3 (10.7), 49.4, 36-
84 
48.2 (11.3), 48.3, 
36-84 
PROMIS Depression (in sensitivity analysis only)   
Mean (SD), Median, Min - Max 48.2 (10.3), 48.0, 36-
81 
47.2 (10.6), 46.4, 
36-81 
PROMIS Fatigue   
Mean (SD), Median, Min - Max 51.9 (10.3), 51.7, 29-
78 
49.7 (10.6), 49.9, 
29-81 
PROMIS Pain Interference   
Mean (SD), Median, Min - Max 52.9 (10.8), 54.6, 40-
79 
50.3 (10.4), 49.0, 
40-79 
PROMIS Physical Functioning   
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Characteristic 
Month 10 
(n = 587) 
Month 17 
(n = 356) 
Mean (SD), Median, Min - Max 44.8 (9.1), 43.8, 15-
62 
46.2 (9.7), 46.0, 
15-62 
PROMIS Ability to Participate in Social Roles and Activities   
Mean (SD), Median, Min - Max 49.9 (10.0), 49.4, 25-
66 
52.2 (10.6), 52.1, 
25-66 
FACT-G Physical Well-being Nausea Item   
Mean (SD), Median, Min - Max 0.6 (1.0), 0.0, 0-4 0.3 (0.8), 0.0, 0-4 
BMI = body mass index, max = maximum; min = minimum; PROMIS = Patient-Reported Outcomes Measurement 
Information System, SD = standard deviation. 
Note: Percent calculated out of non-missing responses. 
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Supplemental Table 5.2. Effect of Missing Responses at Month 10: Month 10 Descriptive Statistics 
Patient Characteristics Collected at Month 
10 
Patients who participated in survey at Month 10 
but were not included in Month 10 analysis due to 
missing responses 
(n = 147) 
Month 10 Analysis 
Sample 
(n = 587) 
Sex
 
   
Female 73 (49.7%) 308 (52.5%) 
Race    
Other (Asian, American Indian, Alaska 
native, Asian Hawaiian, Pacific Islander) 
or multiple 
38 (25.9%) 154 (26.2%) 
White (reference category) 68 (46.3%) 325 (55.4%) 
Black 41 (27.9%) 108 (18.4%)* 
Survey language    
English 130 (88.4%) 531 (90.5%) 
Spanish or Chinese (reference category) 17 (11.6%) 56 (9.5%) 
Employment status
 
   
Working full time, part time or student 
(reference category) 
41 (32.8%) 233 (39.7%) 
Retired 65 (52.0%) 250 (42.6%) 
Unemployed or disabled 19 (15.2%) 104 (17.7%) 
Level of exercise activity    
Not active (reference category) 54 (38.6%) 132 (22.5%) 
Slightly active 17 (12.1%) 101 (17.2%)* 
Moderately active 53 (37.9%) 271 (46.2%) 
Highly active 16 (11.4%) 83 (14.1%) 
PROMIS Sleep Disturbance   
Mean (SD), Median, Min - Max 51.2 (9.9), 52.7, 30-75 50.4 (9.7), 51.2, 30-
75 
PROMIS Physical Functioning   
Mean (SD), Median, Min - Max 42.0 (10.3), 40.6, 15-62 44.8 (9.1), 43.8, 15-
62* 
Max = maximum; min = minimum; PROMIS = Patient-Reported Outcomes Measurement Information System, SD = 
standard deviation. 
Note: Percent calculated out of non-missing responses. 
* p < 0.05 in logistic regression. 
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Supplemental Table 5.3. Patient Attrition: Month 10 Descriptive Statistics 
Patient Characteristics Collected at Month 10 
Patients who participated survey at Month 10 but 
were not included in Month 17 analysis due to 
patient attrition or missing responses 
(n = 378) 
Month 17 
Analysis 
Sample 
(n = 356) 
Sex
 
   
Female 207 (54.8%) 174 (48.9%) 
Race    
Other (Asian, American Indian, Alaska native, 
Asian Hawaiian, Pacific Islander) or multiple 
121 (32.0%) 71 (19.9%)* 
White (reference category) 178 (47.1%) 215 (60.4%) 
Black 79 (20.9%) 70 (19.7%) 
Survey language    
English 331 (87.6%) 330 (92.7%) 
Spanish or Chinese (reference category) 47 (12.4%) 26 (7.3%) 
Employment status
 
   
Working full time, part time or student 
(reference category) 
142 (39.9%) 132 (37.1%) 
Retired 140 (39.3%) 175 (49.2%)* 
Unemployed or disabled 74 (20.8%) 49 (13.8%) 
Level of exercise activity    
Not active (reference category) 108 (29.0%) 78 (22.0%) 
Slightly active 55 (14.7%) 63 (17.8%)* 
Moderately active 163 (43.7%) 161 (45.5%) 
Highly active 47 (12.6%) 52 (14.7%) 
PROMIS Sleep Disturbance   
Mean (SD), Median, Min - Max 51.5 (9.6), 52.6, 30-75 49.5 (9.8), 
50.3, 30-75 
PROMIS Physical Functioning   
Mean (SD), Median, Min - Max 43.3 (9.8), 42.5, 15-62 45.1 (8.9), 
44.6, 21-62 
Max = maximum; min = minimum; PROMIS = Patient-Reported Outcomes Measurement Information System, SD = 
standard deviation. 
Note: Percent calculated out of non-missing responses.  
* p < 0.05 in logistic regression. 
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CHAPTER 6. RELATIONSHIP BETWEEN CHANGES IN SLEEP AND EXERCISE AS COLORECTAL 
CANCER SURVIVORS TRANSITION OFF TREATMENT (MANUSCRIPT 3) 
6.1 Background  
More than 1.1 million individuals in the United States are diagnosed with colorectal cancer 
(CRC)
5
 and at least half of these patients experience decrements in sleep.
3
 Consequences of sleep 
disturbance include decreased cognitive functioning
9
 and fatigue,
10,11
 loss in work productivity and work 
quality, and increased number of visits to health professionals.
14
 Poor sleep is also linked to long-term 
implications such as being a risk factor for infectious diseases, cardiovascular diseases, and 
depression.
13
 
Despite the negative ramifications associated with sleep disturbance, few treatment options are 
available to mitigate poor sleep. Cognitive behavioral therapy (CBT) and pharmacotherapies are the two 
most widely used treatment options for sleep disturbance. CBT is recommended by the American 
Academy of Sleep Medicine as a first-line therapy for patients with insomnia and includes relaxation 
therapy, sleep hygiene, and cognitive therapy. Unfortunately, there are an inadequate number of 
providers trained in CBT for sleep disturbance, and patient adherence issues pose considerable barriers 
to the adequacy of sleep treatment.
9
 Pharmacologic treatments (e.g., benzodiazepine-receptor agonists, 
antidepressants, melatonin agonists) are associated with adverse daytime side effects such as sedation 
or dizziness. Although they should only be administered for 4 to 6 weeks,
21
 cancer patients may 
experience disturbed sleep well beyond this period of time.
20
 CRC patients using pharmacologic therapies 
to mitigate sleep disturbance are faced with either continuing pharmacologic treatment beyond the 
recommended 4 to 6 weeks or discontinue treatment before their sleep disturbance has been resolved.  
Exercise is gaining support as a potential treatment for sleep disturbance in other populations. 
Exercise is a treatment option that, unlike CBT and pharmacologic treatments, is linked to additional 
benefits such as improved aerobic fitness.
112
 In addition, exercise reduces anxiety, pain, and fatigue, all of 
which are associated with sleep disturbance.
113-115
 Exercise has been evaluated as a treatment for sleep 
disturbance in the healthy U.S. population
23,116
 and a number of RCTs and observational studies have 
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investigated exercise as a possible treatment for sleep disturbance in cancer patients.
113,117-121
 Contrary to 
currently available treatments, exercise is generally accessible and less costly.  
We are aware of only three studies that have investigated the relationship between exercise and 
sleep disturbance in individuals diagnosed with CRC.
120
 
119
 
117
 Cheville and colleagues enrolled 66 
patients diagnosed with stage IV colorectal or lung cancer and followed patients over the course of 8 
weeks in a randomized control trial (RCT). They assessed a home-based exercise intervention in which 
patients exercised four or more days a week. The intervention resulted in a statistically significant 
improvement in sleep for the patients who participated in the exercise intervention versus those who were 
randomized to the usual care arm.
117
 Because the RCT included a mixture of individuals diagnosed with 
colorectal or lung cancer, the results of this study are not conclusive specifically for individuals diagnosed 
with CRC. The two other studies assessing exercise did not find a statistically significant effect, but both 
studies were small, with 119 adults participants
119
 and 45 adult participants,
120 
respectively, and sleep 
was not the primary outcome of the study; studies were not powered to detect differences in sleep 
outcomes. The first of these studies by Cho and colleagues included women with colorectal, breast, or 
ovarian cancer.
119
 The second study was a smaller observational study that included individuals 
diagnosed with stage II or III CRC and employed an opt-in exercise protocol such that participants were 
placed in a supervised exercise group or a usual care group based on their preference.
120
 The supervised 
exercise group participated in moderate-intensity aerobic and resistance exercise for 12 weeks.
120
 
Exercise intensity, duration, and frequency were not reported for the usual care group.
120
  
There are a number of possible explanations for the inconsistent results between these three 
studies including differences among participants enrolled in each study (e.g., cancer stage, cancer type), 
differences in exercise prescription of intensity and frequency, and differences in the slice of time during 
patients’ cancer treatment trajectories. Another possible explanation is that exercise may be more 
effective in ameliorating sleep disturbance for some individuals and not for others, which could attenuate 
sleep outcomes between exercise treatment groups and usual care groups. Future randomized trials 
testing the effect of exercise on sleep disturbance in CRC should tailor the population of interest to 
patients whose sleep would stand to benefit the most from exercise. For example, patients who report 
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worse sleep may benefit the most from exercise. Without this information, future trials may enroll a patient 
sample that is too diverse and the effect of exercise may be lost in the average outcomes.  
This study builds on the published literature by examining the relationship between sleep and 
exercise specifically in individuals diagnosed with CRC over a period of approximately 7 months as 
patients transition off of CRC treatment. Strenuous exercise has been shown to decrease during cancer 
treatment in individuals diagnosed with CRC, and the same study demonstrated that general physical 
activity levels likely increase to higher levels than before CRC diagnosis after treatment is complete.
177
 
However, the trajectory of sleep disturbance throughout and after treatment for patients with CRC is 
unknown. There is evidence in other cancer populations that cancer treatment is associated with a 
reduction and possible persistence of sleep disturbance,
16-18,21,99,101
 but it is unclear if exercise may play a 
role in mitigating sleep disturbance over time for CRC patients. Therefore, this study focuses on change 
in sleep disturbance and change in exercise after cancer diagnosis. We used observational data that 
represents patients’ exercise habits without intervention. Exercise activity was self-reported at two time 
points after CRC diagnosis, capturing change in exercise levels. Individuals enrolled in this study were 
recently diagnosed with stage I, II, or III CRC approximately 10 months after diagnosis, and their sleep 
and exercise were reassessed approximately 7 months later at roughly 17 months after diagnosis. This 
window of time represents an important aspect in patients’ treatment trajectories as patients phase out of 
treatment and into survivorship when they may be more physically active.
177
  
The purpose of this study is two-fold. First, we sought to uncover possible variability in the 
relationship between change in sleep and change in exercise among a sample of individuals diagnosed 
with CRC, informing patient enrollment in future controlled trials on exercise. We tested the hypothesis 
that the relationship between change in exercise activity and change in sleep disturbance differs by the 
magnitude of change in sleep disturbance from 10 to 17 months after diagnosis. The second objective of 
this study was to evaluate the relationship between change in exercise and change in sleep disturbance 
specifically in a sample of adults diagnosed with stage I–III CRC. The second hypothesis was that 
patients who increase exercise activity from 10 months to 17 months after diagnosis would experience a 
decline in sleep disturbance.  
 106 
6.2 Methods 
6.2.1 MY-Health Study Design 
This secondary data analysis was conducted using data from the Measuring Your Health (MY-
Health) study which included over 5000 patients enrolled between 2010 and 2012.
143
 Potential study 
participants were identified from four SEER cancer registries located in three states: California (2 SEER 
registries), Louisiana, and New Jersey. Individuals age 21–84 years diagnosed with one of seven cancers 
(i.e., colorectal, prostate, non-small cell lung, non-Hodgkin lymphoma, female breast, uterine, or cervical) 
within 6 to 13 months of diagnosis were invited to participate in the MY-Health study via mail. Participants 
completed questionnaires using mail-in hard copy questionnaires at two time points: The first data 
collection occurred approximately 10 months after diagnosis (mean = 9.73, range = 6-30 months), and 
the second data collection occurred 17 months after diagnosis, on average (mean = 17.42, range = 11-36 
months). The MY-Health study oversampled race/ethnic minorities and younger patients, and 
questionnaires were available in three languages (English, Spanish, Mandarin). Additional details on the 
study design and procedures were previously published.
143
  
6.2.2 Participants and Terminology 
Patients who were identified as being diagnosed with stage I, II, or II colorectal cancer based on 
SEER confirmation were included in the analyses for this study. Because exercise was the main 
independent variable of interest, the sample was further limited to patients who were able to perform 
physical activity, defined as patients who were able to get out of bed (based on a patient-reported survey 
question). The first round of data collection approximately 10 months on average after diagnosis included 
734 patients, and 400 patients participated in the second round, which was collected approximately 17 
months after diagnosis on average. Although the exact time of data collection after CRC diagnosis varied, 
for brevity, the data collection rounds are referred to as “Month 10” and “Month 17” data collection. 
6.2.3 Measures 
Dependent variable. 
PROMIS Sleep Disturbance items were administered to patients at Month 10 and Month 17. 
PROMIS Sleep Disturbance measures concepts such as trouble staying asleep, not getting enough 
sleep, restlessness, feeling refreshed after sleep, and difficulty falling sleep. Results of the full 
psychometric evaluations of the PROMIS Sleep Disturbance item bank
144
 and short forms
145
 were 
 107 
previously published. A custom six-item short form was scored; the psychometric properties of the six-
item form were evaluated in individuals enrolled in the MY-Health study (Cronbach’s α = 0.88 – 0.95).
146
 
PROMIS Sleep Disturbance is a continuous variable scored on a t-score metric with a mean of 50 and 
standard deviation (SD) of 10 based on the referent population (mixture of clinical and the general U.S. 
population
147
), and higher scores indicate worse sleep disturbance. Change in sleep disturbance was 
calculated by subtracting PROMIS Sleep disturbance scores at 10 months from scores at 17 months after 
CRC diagnosis. Positive change is indicative of worsening sleep. The recall period was “the past 7 days”. 
A recent study by Leung et al.
168
 provided a cut point on PROMIS Sleep Disturbance indicative of 
clinically significant sleep disturbance (≥ 57, area under the curve = 0.92). 
Independent variables. 
Exercise.  
The MY-Health study included three exercise-related survey items covering patient-perceived 
exercise intensity and patient-reported frequency of exercise in the previous 7 days. Exercise items were 
administered at Month 10 and Month 17 data collection. Based on patients’ responses to these questions, 
patients’ exercise was categorized into one of four activity levels: (1) not active, (2) slightly active, (3) 
moderately active, and (4) highly active. The four exercise categories reflect the American College of 
Sports Medicine’s (ACSM) recommendation that individuals diagnosed with cancer achieve 150 minutes 
of moderate-intensity exercise per week or 75 minutes of vigorous exercise per week.
15
 Patients 
classified in the “not active” or “slightly active” groups likely did not meet the minimum ACSM guideline of 
150 minutes of moderate-intensity exercise per week or 75 minutes of vigorous exercise per week,
15
 but 
patients in the “moderately active” or “highly active” groups likely met or exceeded the ACSM guideline. 
The primary independent variable of interest, change in exercise, summarizes the change in exercise 
categories from 10 to 17 months after CRC diagnosis. Change in exercise was entered in the model as a 
categorical variable with five categories: (1) less active by 2 or 3 exercise categories, (2) less active by 1 
exercise category, (3) no change in exercise activity, (4) more active by 1 exercise category, and (5) more 
active by 2 or 3 exercise categories. 
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Patient-level factors associated with sleep disturbance.  
The MY-Health dataset contains information on patient, disease, and treatment factors 
associated with sleep disturbance. Cancer treatment has been linked with decrements in sleep quality, 
and some studies suggest that recovery from treatment (i.e., time since treatment) is predictor of sleep 
quality.
16-18,100,101
 The trajectory of sleep disturbance throughout and after treatment for adults with CRC is 
unknown, thus this information will be included in the models to account for the possible effect of CRC 
treatment on sleep disturbance. Cancer treatment type (e.g., surgery, chemotherapy, radiation) and most 
recent date of treatment were self-reported at Month 17 data collection. Categorical variables were 
derived to capture current/recent treatment compared to no treatment or less-recent treatment. Treatment 
trajectory categories were based on relevant physical recovery periods post-treatment and data 
availability. Time since chemotherapy was coded using four categories (i.e., currently receiving 
chemotherapy, chemotherapy 1–2 months ago, chemotherapy more than 2 months ago, never received 
chemotherapy [reference category]). Time since surgery was coded using three categories (i.e., surgery 
occurred within 0–4 months, surgery occurred more than 4 months ago, never received surgery 
[reference category]). Comorbid conditions
73
 were self-reported and included in the models as a derived 
variable with three categories (i.e., no comorbid diseases [reference category], 1 comorbid disease, 2 or 
more comorbid diseases). Four PROMIS domains were included in the models as independent variables 
to assess aspects of health-related quality of life known to be associated with sleep disturbance:
73,79
 
80
 
81,90,92-95
 Anxiety (11 items), Depression (10 items), Fatigue
148
 (14 items), and Pain Interference (11 
items).
149
 These PROMIS measures were normed to the general U.S. population
147
 and higher scores 
indicate worse anxiety, depression, fatigue, and pain, respectively. PROMIS change scores (Month 17 – 
Month 10) were entered in the model as continuous variables with positive change indicating a worsening 
symptom. Nausea severity was measured using a five-point nausea
21
 item from the FACT-G Physical 
Well-Being (PWB) subscale
150
 with a recall period of the “past 7 days” and response choices ranging from 
0 = “not at all” to 4 = “very much.” Although the nausea item has not been psychometrically evaluated as 
a single measure of nausea, the entire FACT-G PWB scale, which has been evaluated extensively in 
cancer patients,
178-180
 covers concepts that overlap with PROMIS measures such as pain and fatigue. 
Therefore, only the nausea item was included in the models. Change in nausea severity was entered in 
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the model as a continuous variable. Other characteristics known to be associated with sleep disturbance 
were included in the models such as age at diagnosis,
2,21,97
 sex,
72
 time since diagnosis at Month 17 data 
collection,
93
 employment status at Month 10 (i.e., working, retired, unemployed/disabled [reference 
category]),
84
 and an indicator for living with children under 18 (collected during Month 10 data 
collection)
83,84
 were included in the models. Age and race were also included in the model to account for 
the over-sampling of younger and minority persons from SEER registries. Race, employment status, and 
the living-with-child(ren) indicator were self-reported, and age at diagnosis, sex, and diagnosis date were 
obtained via SEER registry data. 
Factors associated with exercise.  
MY-Health variables also addressed determinants of exercise participation (treatment selection). 
Exercise participation is partially determined by patients’ ability to perform activities,
153-155
 thus patients’ 
change PROMIS Physical Function scores (from Month 10 to Month 17) was included as a covariate in 
the model (positive change indicates improvement).
156
 Social support is associated with participation in 
exercise and was measured using PROMIS Ability to Participate in Social Roles and Activities;
153-155,157
 
change in social support was entered in the model as a continuous variable (positive change indicates 
improvement). Higher weight is associated with less exercise, therefore body mass index (BMI) was 
derived from patient-reported weight and height (collected at Month 10 only).
72
 Other factors already 
included in the model that are associated with participation in exercise and affect sleep include increased 
age, parenthood, sex, and race.
153-155
  
6.2.4 Analyses 
Methods.  
Descriptive statistics were calculated and tabulated. Relationships between candidate 
independent variables were evaluated for collinearity by calculating bivariate correlations and variance 
inflation factor (VIF) within multiple regression models. VIF values greater than 10 were considered a 
symptom of multicollinearity. Residuals were evaluated between candidate independent variables and 
change in sleep disturbance to determine if higher-order terms needed to be included in the models.  
Regression mixture models (RMMs)
158,159
 are special cases of finite mixture models, which model 
weighted combinations of different distributions. With RMMs, the component membership to each 
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distribution is unobservable (a latent variable). We employed RMMs to test if heterogeneity was present 
in the relationship between change in sleep disturbance and change in exercise. (For example, if factors 
associated with sleep disturbance (especially exercise) varied by magnitude of change in sleep 
disturbance.) RMMs were estimated using Dual Quasi-Newton optimization.
162
 Models ranging from one 
to four classes were evaluated. The final models (e.g., choice of number of classes) were chosen based 
on fit (e.g., smallest Bayesian Information Criterion Index (BIC), Akaike Information Criterion (AIC)) and 
interpretability. RMMs are sensitive to starting values,
164
 thus user-provided starting values were also 
tested to confirm the number of classes identified by SAS-generated starting values. If only one class of 
sleep disturbance was identified, then multiple regression (which assumes one common class of sleep 
disturbance) was used to model factors associated with change in sleep disturbance. 
Sensitivity analyses. Patients classified as having no change in exercise may have participated in 
a range of exercise activity from not participating in any exercise 10 and 17 months after diagnosis to 
being classified as highly active at 10 and 17 months after diagnosis. Therefore, a sensitivity analysis was 
conducted to evaluate the relationship between constant exercise, change in exercise and change in 
sleep disturbance. Six exercise categories were derived and included in an RMM model analogous to the 
primary model described above except with a six-category exercise variable instead of a five-level 
exercise variable: (1) less active by 2 or 3 exercise categories, (2) less active by 1 exercise category, (3) 
no change in exercise activity – persistently not active or slightly active [reference category], (4) no 
change in exercise activity – persistent moderately or highly active, (5) more active by 1 exercise 
category, and (6) more active by 2 or 3 exercise categories.  
Although collinearity analyses (Pearson correlations, VIF) did not identify collinearity issues 
among independent variables, HRQOL-related variables such as anxiety, depression, and fatigue are 
known to be highly correlated. A sensitivity analysis was conducted to test the exclusion of PROMIS 
Anxiety from the model because it yielded the largest VIF (VIF = 2.13) and the strongest correlations with 
other HRQOL change variables (PROMIS Anxiety change and PROMIS Depression change: r = 0.69; 
PROMIS Anxiety change and PROMIS Fatigue change: r = 0.43).  
Patient attrition. Factors associated with patient attrition in survey participation from Month 10 
data collection to Month 17 were evaluated using logistic regression. Patients who participated in Month 
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10 and Month 17 survey administrations (outcome = 1) were compared with patients who participated in 
Month 10 but not Month 17 (outcome = 0) using logistic regression. The model included patient 
characteristics at Month 10 that were related to sleep disturbance and potentially associated with patient 
attrition: sex, race, employment status, survey language, level of exercise activity, PROMIS Sleep 
Disturbance, and PROMIS Physical Functioning. 
Power.  
Power to detect multiple classes was evaluated and confirmed using simulations based on 
random samples drawn from the MY-Health study data, providing information about the covariance 
structure among the independent variables. Sub-samples were randomly drawn from the study dataset to 
simulate 1000 datasets for each of the parameter modifications in the simulation: overall sample size, 
numeric differences between coefficients in each latent class, variance of PROMIS Sleep Disturbance, 
and proportion of sample within each class. A well-accepted rule of thumb for identifying minimally 
important group differences on a patient-reported outcome is the half standard deviation.
166,170
 The half 
standard deviation of PROMIS Sleep Disturbance at Month 10 was approximately 5 points. For classes to 
be meaningfully different, we anticipated that the classes should be separated at a minimum by the 
threshold for minimal important difference. Based on a sample size of 300 and a mean difference 
between sleep disturbance scores in each class approximately 6 points (5.5) apart, a simulated sleep 
disturbance error variance between 1 and 7, and equal class sizes (proportion of sample in class 1 = 
50%, proportion of sample in class 2 = 50%), the power to detect multiple classes was 100%. When the 
distance between coefficients in each class dropped below 1.5 and the error variance of the simulated 
sleep disturbance variable was 4 or more, power reduced to below 70%. The proportion of the sample 
designated to each class was modified in the simulations but the effect on power was negligible.  
Power to detect the effect of exercise was calculated for a sample size of 300. When the partial 
correlation between exercise and sleep disturbance was 0.20 or greater, power was 0.94 or above. When 
the sample size was 300 and the partial correlation was very small (0.05 or 0.14), power was reduced to 
.14 and .69 respectively.  
 112 
Analysis conventions.  
Complete case analyses were conducted for all models: due to missing data, 348 participants 
were included in the analyses. Regression coefficients were reviewed to describe the relationship 
between sleep disturbance and covariates in the models. An alpha of 0.05 or less was chosen as the 
criterion for statistical significance of the covariates in the RMMs. All analyses were performed using SAS 
version 9.3 (SAS Institute Inc., Cary, NC, USA). More specifically, we used a SAS procedure called 
PROC FMM to fit RMMs.
163
  
6.3 Results 
Patient, disease, and treatment characteristics at Month 10 are presented in Table 6.1. The mean 
patient age at diagnosis was 63 years (SD = 11.3, range from 30 to 84 years) and approximately half the 
sample was female (48.6%). Almost 30% (28.4%) of the sample was diagnosed with Stage I disease, 
33% was diagnosed with Stage II CRC (32.5%), and almost 40% (39.1%) of the sample was diagnosed 
with Stage III CRC. The median number of months between data collections was 7.4 (range = 5.5 to 15.2) 
[data not shown]. Mean PROMIS Sleep Disturbance scores were similar to the average scores observed 
in the referent population (i.e., patients who went to sleep clinics and healthy sleepers) at Month 10 with a 
mean of 49.5. Applying Leung’s cut point, 21.6% and 20.1% of the Month 10 and Month 17 samples 
respectively were likely experiencing clinically-significant sleep disturbance [data not shown]. Almost two-
thirds of the sample was classified as having participated in “moderately active” or “highly active” exercise 
at Month 10 (60.9%), and only 21.6% of patients were not active at all at Month 10. 
Descriptive statistics for all variables entered in the models (that were not already present in 
Table 6.1) are presented in Table 6.2. A little over half the sample (52.3%) was classified as having no 
change in exercise activity, while 29.8% of patients increased activity levels, and 17.8% participated in 
less active exercise at Month 17 compared to Month 10. Mean change in PROMIS Sleep Disturbance 
from Month 10 to Month 17 was 0 (SD = 7.1) and ranged from -25 (improvement) to 19 (worsening). 
The bivariate relationship between change in sleep disturbance and change in exercise is 
presented in Table 6.3. The mean change in PROMIS Sleep Disturbance scores for patients who 
increased activity from month 10 to 17 were negative (PROMIS Sleep Disturbance score for more active 
by 1 exercise category: -0.57, More active by 2 or 3 exercise categories: -0.96), indicating improvement. 
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There was little change in mean PROMIS Sleep Disturbance scores for the patients that did not change 
exercise categories (mean = 0.15) or who were less active (0.04). 
6.3.1 Regression Mixture Models 
Model fit. 
RMMs were estimated to determine whether distinct classes of sleep disturbance were present. 
Models with one to four classes were estimated. The smallest BIC and AIC were associated with the two-
class model (one-class: AIC = 2308.8, BIC =2424.2; two-class: AIC = 2069.8, BIC = 2304.8, three-class: 
AIC = 2156.5, BIC = 2510.9, four-class: AIC = 2432.6, BIC = 2906.5,). The two-class model chosen using 
SAS starting values (Supplemental Table 6.1) included one large class (mixing probability = 0.90) and a 
small class (mixing probability = 0.10). The regression coefficients for the smallest class were all 
statistically significant and the variance for smallest class was less than 0.001 suggesting that class 2 
included outliers only. Therefore, a multiple regression (one-class model) was chosen for the analysis.  
Sleep disturbance and exercise. 
Multiple regression results are presented in Table 6.4. Change in exercise level was not 
statistically significantly associated with change in sleep disturbance from months 10 to 17. Change in 
fatigue and sleep disturbance at Month 10 had statistically significant relationships with change in sleep 
disturbance from Month 10 to Month 17. Patients reporting less fatigue were significantly more likely to 
report improved sleep quality, but the coefficient was small (change in fatigue = 0.15); a 35-point 
improvement in PROMIS Fatigue would be associated with a 5.3-point improvement in PROMIS Sleep 
Disturbance. Poor sleep disturbance 10 months after diagnosis was associated with improvement in 
sleep disturbance from 10 to 17 months after CRC diagnosis (B = -0.23). 
Sensitivity analysis. Similar to the primary model, the smallest AIC and BIC fit statistics were 
associated with a two-class model, but the second class was comprised of only 20 patients and 
regression coefficients in class 2 were mostly statistically significant and uninterpretable suggesting that 
class 2 contained outliers. Therefore, a multiple regression (one-class model) was chosen for the 
sensitivity analysis. Neither an increase in exercise from 10 to 17 months or persistent moderately or 
highly active exercisers were statistically associated with change in sleep disturbance. Change in fatigue 
and sleep disturbance at Month 10 had statistically significant relationships with change in sleep 
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disturbance from 10 to 17 months after diagnosis. Results of the sensitivity analysis are presented in 
Supplemental Table 6.2. 
For the sensitivity analysis evaluating the removal of PROMIS Anxiety, results were very similar 
to the primary model, with coefficients of similar magnitude. PROMIS Sleep Disturbance at Time 1 and 
change in PROMIS Fatigue were statistically significant in both models (p < 0.01 in both models) [data not 
shown]. Change in PROMIS Depression was not statistically significant in the primary model, but was 
statistically significant in the sensitivity analyses (B = 0.11, p = 0.02) [data not shown]. 
Patient attrition. 
A total of 734 individuals diagnosed with stage I, II, or III CRC participated in the 10 Month data 
collection, but only 348 participants were included in the models due to missing responses and patient 
survey attrition by the 17 month data collection (leaving 386 patients not included in the models). We 
compared patient characteristics for patients who were included in the RMM/multiple regression models 
(n = 348), with patients who were not included in the models due to missing values or survey attrition (n = 
386). Overall, factors associated with patient survey adherence were very similar to factors associated 
with survey attrition (Supplemental Table 6.3). Only two patient characteristics were statistically significant 
in the model: being retired (OR = 1.69) and race other than white or black (OR = 0.53). The odds of 
patients completing the Month 17 survey were 70% higher for patients who were retired compared to 
patients who were unemployed or disabled, and patients who characterized themselves as of 
other/multiple races (not black or white) were 47% less likely to complete the 17 Month survey. 
6.4 Discussion 
This study builds on the published literature by examining the relationship between change in 
sleep and change in exercise specifically in individuals diagnosed with stage I, II, or III CRC using patient-
reported observational data on patients’ exercise habits without intervention. The results of this study 
show no statistically significant relationship between change in patient-reported sleep disturbance and 
change in exercise among CRC patients 10 to 17 months from diagnosis. Further, we found the 
relationship between sleep and exercise did not differ by magnitude of change of sleep disturbance, 
meaning that no specific subgroup of patients with more improvement or more worsening in sleep 
disturbance emerged as being associated with any particular change in level of exercise. The sensitivity 
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analysis further confirmed these findings and also showed that there was not a strong relationship 
between change in sleep disturbance and persistent exercise likely at or above the ACSM guidelines 
between 10 and 17 months after diagnosis.  
The exercise items presented some measurement limitations that precluded us from objectively 
categorizing patients as achieving or not achieving ACSM exercise recommendations (e.g., duration of 
exercise not captured, items not psychometrically evaluated). Nonetheless, descriptive statistics show 
that a larger proportion of CRC patients in this sample increased exercise between 10 and 17 months 
after diagnosis compared to the proportion that decreased exercise levels. Approximately 40% of 
individuals diagnosed with CRC in this study likely did not achieve the ACSM recommendations for 
exercise (150 minutes of moderate-intensity exercise per week or 75 minutes of vigorous exercise per 
week
15
) approximately 10 months after diagnosis. Between Month 10 and Month 17, almost 30% of the 
sample increased exercise categories by at least one level and only 18% reduced exercise activity. These 
results reflect an early study on exercise habits in CRC survivors showing that after treatment, CRC 
patients increase exercise on average.
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A previously published randomized trial including individuals diagnosed with stage IV lung cancer 
or CRC found that sleep disturbance decreased for patients in the exercise arm on average and patients 
in the usual care arm did not experience much change in sleep disturbance.
117
 After 8 weeks on the 
exercise intervention, there was a statistically significant difference between sleep quality in the study 
arms. Stage IV patients were not included in our study because their treatment trajectories and HRQOL 
experiences are different from CRC patients diagnosed with non-metastatic disease; it is possible, even 
though Cheville’s randomized trial and our study included CRC patients, that exercise is more efficacious 
in metastatic disease than in earlier stages or that there is something inherently different about the effect 
of exercise on sleep in individuals with lung cancer (approximately 50% of Cheville’s sample). Also, 
measurement limitations of the exercise items in our study likely contribute to the differences in results. 
By evaluating patient attrition in survey participation, we gained insight on research participation 
patterns for future prospective research studies in CRC samples. We found that retirement is associated 
with patient survey adherence. This finding is consistent with the literature;
181
 patients with more leisure 
time on hand may be more willing to participate in surveys than patients who are employed or 
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unemployed/disabled. Being classified as a minority (non-white and non-black) was associated with 
survey attrition. Although the reasons for this finding are unknown for the MY-Health study, a recent study 
on recruitment and retention strategies for minorities diagnosed with breast cancer suggests that barriers 
to participation may vary by race/ethinicity.
176
  
There are a few omitted variables that would be beneficial to include in the models discussed in 
this study, without which it is more difficult to control for selection into the exercise. The dataset did not 
include information on self-efficacy, one of the most important predictors of exercise, though challenging 
to measure. We also did not have access to an indicator for exercise habits prior to CRC diagnosis. Prior 
exercise habits are indicative of current or future exercise habits. Another omitted variable is information 
on patients’ physical activity, which is a much broader concept including any body movement that 
requires energy expenditure. Some patients may not exercise but engage in significant physical activity 
throughout the day. For example, some patients may walk to work or have a labor-intensive job that 
involves heavy lifting. Exercise may be more relevant to patients with higher socioeconomic status 
because exercise is a planned, structured activity that requires time outside of other daily tasks and may 
also cost money. By only including exercise in the model, we limit the conclusions and recommendations 
on exercise to patients above a certain socioeconomic threshold who have the means to exercise; some 
estimates may be biased because we are not including information on more general physical activity.  
The exercise items presented some measurement limitations that introduce measurement error in 
the models. Duration of exercise was not captured and although the exercise items were not 
psychometrically evaluated. Further, there is evidence that patients overestimate or exaggerate self-
reported exercise (social desirability),
182
 also introducing bias into the models. 
Although polysomnography is considered the gold standard for sleep assessment, as a lab-based 
measure, polysomnography is burdensome to track changes in sleep quality over time and it may not 
adequately characterize sleep disturbance during real-life situations out of the lab.
13
 PROMIS Sleep 
Disturbance scale addresses this weakness because it is a short (six-item) questionnaire that assessed 
sleep quality during real-life situations outside of the lab.  
As a community-based observational study, the MY-Health data provide information on 
experiences from a very diverse sample of patients who were evaluated during the course of usual care 
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without controlled interventions. Understanding the relationship between sleep disturbance and exercise 
in patients with CRC is a building block to developing controlled trials for treatment of sleep disturbance. 
This information can be used to design future randomized control trials aimed at mitigating sleep 
disturbance. 
6.5 Conclusion 
This research addresses exercise at a critical time of change in the cancer continuum for CRC 
patients, the transition to survivorship when patients’ daily lives are less controlled by the negative 
impacts of treatment and they may have the capacity to increase exercise frequency or intensity. The 
results of this study suggest that as CRC patients transition off treatment, change in exercise levels are 
not closely tied to change in sleep disturbance from approximately 10 to 17 months after diagnosis, but 
that fatigue is associated with sleep disturbance. It is possible that this result is time-dependent; future 
studies should investigate the relationship between exercise and sleep disturbance during other time 
windows in the cancer continuum, especially before and during treatment when patients typically 
experience worse HRQOL. Knowledge of exercise duration or previous exercise habits may provide 
better understanding of the association between exercise and sleep disturbance in individuals diagnosed 
with CRC. 
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Table 6.1. Patient Characteristics at Month 10 
Characteristic 
Month 10 
(n = 348) 
Age at diagnosis  
Mean (SD), Median, Min - Max 63.4 (11.3), 65.0, 30-84 
Sex  
Female 169 (48.6%) 
BMI  
Mean (SD), Median, Min - Max 29.2 (7.4), 27.9, 17-71 
Race and ethnicity  
Non-Hispanic White 177 (50.9%) 
Non-Hispanic Black 63 (18.1%) 
Other 108 (31.0%) 
Employment status  
Working full time, part time or a student 131 (37.6%) 
Retired 169 (48.6%) 
Unemployed or disabled 48 (13.8%) 
Living status  
Live with child(ren) under 18 years old 50 (14.4%) 
Relevant comorbidities  
No comorbid conditions 140 (40.2%) 
1 comorbid condition 92 (26.4%) 
2 or more comorbid conditions 116 (33.3%) 
Cancer stage  
Stage I 99 (28.4%) 
Stage II 113 (32.5%) 
Stage III 136 (39.1%) 
Level of exercise activity  
Not active 75 (21.6%) 
Slightly active 61 (17.5%) 
Moderately active 160 (46.0%) 
Highly active 52 (14.9%) 
Months Since Chemotherapy  
0 = never 154 (45.8%) 
1 = current 72 (21.4%) 
2 = 1-2 months 65 (19.3%) 
3 = > 2 months 45 (13.4%) 
Months Since Surgery  
0 = never 21 (6.5%) 
1 = 0-4 months 28 (8.7%) 
2 = more than 4 months 272 (84.7%) 
Radiation  
Ever received radiation 58 (17.0%) 
Months since diagnosis at data collection  
Mean (SD), Median, Min - Max 9.5 (1.3), 9.4, 6-15 
PROMIS Sleep Disturbance  
Mean (SD), Median, Min - Max 49.5 (9.7), 50.2, 30-75 
PROMIS Anxiety  
Mean (SD), Median, Min - Max 47.6 (10.2), 47.4, 36-84 
PROMIS Depression  
Mean (SD), Median, Min - Max 46.6 (9.7), 45.2, 36-72 
PROMIS Fatigue  
Mean (SD), Median, Min - Max 51.2 (10.2), 51.4, 29-78 
PROMIS Pain Interference  
Mean (SD), Median, Min - Max 51.9 (10.8), 52.5, 40-79 
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Characteristic 
Month 10 
(n = 348) 
PROMIS Physical Functioning  
Mean (SD), Median, Min - Max 45.1 (8.8), 44.7, 21-62 
PROMIS Ability to Participate in Social Roles and Activities  
Mean (SD), Median, Min - Max 50.6 (9.8), 50.1, 25-66 
FACT-G Physical Well-being Nausea Item  
Mean (SD), Median, Min - Max 0.5 (0.9), 0.0, 0-4 
BMI = body mass index, FACT-G = Functional Assessment of Cancer Therapy-General, max = maximum; min = 
minimum; PROMIS = Patient-Reported Outcomes Measurement Information System, SD = standard deviation; 
Note: Percent calculated out of non-missing responses. 
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Table 6.2. Descriptive Statistics for Variables Collected at Month 17 or Describing Change 
Characteristic n = 348 
Change in exercise activity (Month 17 – Month 10)
a
  
Less active by 2 or 3 exercise categories 18 (5.2%) 
Less active by 1 exercise category 44 (12.6%) 
No change 182 (52.3%) 
 Persistently not active or slightly active
a
 49 (14.1%) 
 Persistently moderately or highly active
a
 133 (38.2%) 
More active by 1 exercise category 68 (19.5%) 
More active by 2 or 3 exercise categories 36 (10.3%) 
Months between chemotherapy and Month 17 data collection  
0 = never 149 (42.8%) 
1 = current 15 (4.3%) 
2 = 1-2 months 15 (4.3%) 
3 = > 2 months 169 (48.6%) 
Months between surgery and Month 17 data collection  
0 = never 29 (8.3%) 
1 = 0-4 months 25 (7.2%) 
2 = more than 4 months 294 (84.5%) 
Months since diagnosis at Month 17 data collection  
Mean (SD), Median, Min - Max 17.3 (2.0), 17.0, 13-26 
Change in PROMIS Sleep Disturbance (Month 17 - Month 10) 
a
  
Mean (SD), Median, Min - Max 0.0 (7.1), 0.0, -25-19 
Change in PROMIS Anxiety (Month 17 - Month 10)  
Mean (SD), Median, Min - Max 0.4 (8.8), 0.0, -26-28 
Change in PROMIS Depression (Month 17 - Month 10)  
Mean (SD), Median, Min - Max 0.6 (8.4), 0.0, -23-29 
Change in PROMIS Fatigue (Month 17 - Month 10)  
Mean (SD), Median, Min - Max -1.6 (8.2), -1.2, -24-24 
Change in PROMIS Pain Interference (Month 17 - Month 10)  
Mean (SD), Median, Min - Max -1.8 (9.1), 0.0, -38-25 
Change in PROMIS Physical Functioning (Month 17 - Month 10)  
Mean (SD), Median, Min - Max 1.2 (6.1), 0.2, -22-24 
Change in PROMIS Ability to Participate in Social Roles and Activities (Month 17 - 
Month 10) 
 
Mean (SD), Median, Min - Max 1.6 (8.4), 0.7, -23-26 
Change in FACT-G Physical Well-being Nausea Item (Month 17 - Month 10)  
Mean (SD), Median, Min - Max -0.2 (0.9), 0.0, -4-3 
BMI = body mass index, FACT-G = Functional Assessment of Cancer Therapy-General, max = maximum; min = 
minimum; PROMIS = Patient-Reported Outcomes Measurement Information System, SD = standard deviation; 
Note: Percent calculated out of non-missing responses. 
a
 Subset of the “No change” category. 
b
 Change in PROMIS Sleep Disturbance from Month 10 to Month 17 was the dependent variable of interest. PROMIS 
Sleep Disturbance at Month 10 was also entered in the model (see Table 1 for descriptive statistics). 
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Table 6.3. Mean Change in PROMIS Sleep Disturbance by Change in Exercise Categories (n = 348) 
 
 Change in PROMIS Sleep Disturbance 
Change in Exercise Categories N Mean SD Median Minimum Maximum 
Less active by 2 or 3 exercise categories 18 2.61 8.09 2.0 -14.8 19.2 
Less active by 1 exercise category 44 0.04 7.97 1.4 -20.0 12.6 
No change 182 0.15 7.18 0.0 -25.0 19.0 
 Persistently not active or slightly active
a
 49 -0.7 6.9 0.0 -21.7 15.8 
 Persistently moderately or highly active
a
 133 0.5 7.3 0.0 -25.0 19.0 
More active by 1 exercise category 68 -0.57 6.77 0.0 -22.3 14.2 
More active by 2 or 3 exercise categories 36 -0.96 5.49 0.0 -10.8 9.8 
PROMIS = Patient-Reported Outcomes Measurement Information System, SD = standard deviation. 
a
 Subset of the “No change” category. 
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Table 6.4. Multiple Regression Results: Relationship between Change in PROMIS Sleep Disturbance and 
Change in Exercise (n = 348) 
Effect Categories Estimate Standard Error Z P value 
Intercept  7.488 5.06 1.48 0.1390 
Exercise group change (Month 17 - 
Month 10) 
Less active by 1 exercise 
category 
0.365 1.08 0.34 0.7355 
 Less active by 2 or 3 exercise 
categories 
2.579 1.57 1.64 0.1006 
 More active by 1 exercise 
category 
-0.024 0.91 -0.03 0.9791 
 More active by 2 or 3 exercise 
categories 
0.318 1.20 0.26 0.7913 
 No change ref - - - 
Months between chemotherapy and 
Month 17 data collection 
1 = current 1.502 1.72 0.87 0.3823 
 2 = 1-2 months 0.515 1.76 0.29 0.7694 
 3 = > 2 months 0.151 0.76 0.20 0.8422 
 0 = never ref - - - 
Months between surgery and Month 
17 data collection 
1 = 0-4 months -2.570 1.77 -1.45 0.1458 
 2 = more than 4 months -0.451 1.25 -0.36 0.7185 
 0 = never ref - - - 
Race (Collected at Month 10) Black -0.421 0.90 -0.47 0.6418 
 Other or multiple -0.292 0.89 -0.33 0.7438 
 White ref - - - 
Number of relevant comorbidities at 
Month 10 
1 comorbid condition 0.915 0.89 1.03 0.3046 
 2 or more comorbid conditions -0.258 0.85 -0.30 0.7610 
 No comorbid conditions ref - - - 
Sex (Collected via SEER) Female -0.073 0.69 -0.11 0.9147 
 Male ref - - - 
Live with child under 18 years old at 
Month 10 
Checked -0.383 1.09 -0.35 0.7247 
 Unchecked ref - - - 
Employment at Month 10 Retired -1.297 0.95 -1.37 0.1710 
 Unemployed or disabled -0.636 1.11 -0.58 0.5651 
 Work ref - - - 
Months between diagnosis and Month 
17 data collection 
 0.124 0.17 0.73 0.4681 
Age at diagnosis (years) (Collected 
via SEER) 
 0.012 0.05 0.26 0.7931 
BMI (Collected at Month 10)  0.070 0.05 1.46 0.1451 
PROMIS Sleep Disturbance at Month 
10 
 -0.225 0.04 -6.01 <.0001 
PROMIS Anxiety change (Month 17 - 
Month 10) 
 0.091 0.06 1.63 0.1034 
PROMIS Depression change (Month 
17 - Month 10) 
 0.055 0.06 0.98 0.3267 
PROMIS Fatigue change (Month 17 - 
Month 10) 
 0.152 0.05 2.87 0.0042 
PROMIS Pain Interference change 
(Month 17 - Month 10) 
 -0.007 0.04 -0.16 0.8740 
PROMIS Physical Functioning (Month 
17 - Month 10) 
 0.006 0.07 0.09 0.9287 
PROMIS Social Roles and Activities 
(Month 17 - Month 10) 
 -0.083 0.06 -1.51 0.1322 
FACT-G Physical Well-being Nausea 
Item change (Month 17 - Month 10) 
 0.065 0.39 0.17 0.8688 
Variance  37.481 2.84 _ _ 
BMI = body mass index, FACT-G = Functional Assessment of Cancer Therapy-General, PROMIS = Patient-Reported 
Outcomes Measurement Information System. 
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Supplemental Table 6.1. Regression Mixture Model: Two-Class Solution (n = 348) 
Effect Categories Estimate 
Standard 
Error Z P value 
CLASS 1      
Intercept  11.934 4.42 2.70 0.0069 
Exercise group change (Month 17 - 
Month 10) 
Less active by 1 exercise 
category 
1.310 0.93 1.40 0.1601 
 Less active by 2 or 3 
exercise categories 
2.741 1.37 2.00 0.0459 
 More active by 1 exercise 
category 
0.526 0.78 0.68 0.4985 
 More active by 2 or 3 
exercise categories 
0.611 1.03 0.59 0.5538 
 No change ref - - - 
Months between chemotherapy and 
Month 17 data collection 
1 = current 1.990 1.58 1.26 0.2089 
 2 = 1-2 months 0.126 1.49 0.08 0.9324 
 3 = > 2 months 1.226 0.65 1.89 0.0588 
 0 = never ref - - - 
Months between surgery and Month 
17 data collection 
1 = 0-4 months -4.562 1.50 -3.05 0.0023 
 2 = more than 4 months -0.885 1.09 -0.82 0.4147 
 0 = never ref - - - 
Race (Collected at Month 10) Black 0.235 0.79 0.30 0.7675 
 Other or multiple -0.098 0.76 -0.13 0.8974 
 White ref - - - 
Number of relevant comorbidities at 
Month 10 
1 comorbid condition 0.707 0.77 0.92 0.3564 
 2 or more comorbid 
conditions 
0.024 0.75 0.03 0.9742 
 No comorbid conditions ref - - - 
Sex (Collected via SEER) Female -0.351 0.59 -0.59 0.5525 
 Male ref - - - 
Live with child under 18 years old at 
Month 10 
Checked -0.322 0.93 -0.34 0.7303 
 Unchecked ref - - - 
Employment at Month 10 Retired -1.599 0.83 -1.92 0.0553 
 Unemployed or disabled -0.487 0.96 -0.50 0.6140 
 Work ref - - - 
Months between diagnosis and 
Month 17 data collection 
 -0.025 0.15 -0.17 0.8664 
Age at diagnosis (years) (Collected 
via SEER) 
 -0.011 0.04 -0.28 0.7805 
BMI (Collected at Month 10)  0.052 0.04 1.29 0.1960 
PROMIS Sleep Disturbance at 
Month 10 
 -0.212 0.03 -6.43 <.0001 
PROMIS Anxiety change (Month 17 
- Month 10) 
 0.032 0.05 0.68 0.4957 
PROMIS Depression change (Month 
17 - Month 10) 
 0.119 0.05 2.55 0.0109 
PROMIS Fatigue change (Month 17 
- Month 10) 
 0.147 0.05 3.22 0.0013 
PROMIS Pain Interference change 
(Month 17 - Month 10) 
 0.057 0.04 1.56 0.1187 
PROMIS Physical Functioning 
(Month 17 - Month 10) 
 0.041 0.06 0.66 0.5065 
PROMIS Social Roles and Activities 
(Month 17 - Month 10) 
 -0.068 0.05 -1.40 0.1616 
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Effect Categories Estimate 
Standard 
Error Z P value 
FACT-G Physical Well-being 
Nausea Item change (Month 17 - 
Month 10) 
 0.125 0.33 0.38 0.7042 
CLASS 2      
Intercept  -9.666 0.08 -124.50 <.0001 
Exercise group change (Month 17 - 
Month 10) 
Less active by 1 exercise 
category 
-2.479 0.02 -160.19 <.0001 
 Less active by 2 or 3 
exercise categories 
-2.798 0.03 -84.37 <.0001 
 More active by 1 exercise 
category 
-3.229 0.01 -255.15 <.0001 
 More active by 2 or 3 
exercise categories 
-4.383 0.02 -188.91 <.0001 
 No change ref - - - 
Months between chemotherapy and 
Month 17 data collection 
1 = current -6.736 0.02 -323.86 <.0001 
 2 = 1-2 months 11.958 0.03 389.64 <.0001 
 3 = > 2 months -11.591 0.01 -954.33 <.0001 
 0 = never ref - - - 
Months between surgery and Month 
17 data collection 
1 = 0-4 months 23.975 0.04 674.37 <.0001 
 2 = more than 4 months 0.450 0.02 19.58 <.0001 
 0 = never ref - - - 
Race (Collected at Month 10) Black 2.852 0.01 222.71 <.0001 
 Other or multiple -12.519 0.02 -614.23 <.0001 
 White ref - - - 
Number of relevant comorbidities at 
Month 10 
1 comorbid condition 1.306 0.02 62.23 <.0001 
 2 or more comorbid 
conditions 
0.442 0.01 30.55 <.0001 
 No comorbid conditions ref - - - 
Sex (Collected via SEER) Female 0.819 0.02 53.70 <.0001 
 Male ref - - - 
Live with child under 18 years old at 
Month 10 
Checked 1.563 0.02 78.12 <.0001 
 Unchecked ref - - - 
Employment at Month 10 Retired 1.340 0.01 144.91 <.0001 
 Unemployed or disabled -0.324 0.02 -20.74 <.0001 
 Work ref - - - 
Months between diagnosis and 
Month 17 data collection 
 1.544 0.00 789.55 <.0001 
Age at diagnosis (years) (Collected 
via SEER) 
 0.173 0.00 290.80 <.0001 
BMI (Collected at Month 10)  -0.387 0.00 -373.38 <.0001 
PROMIS Sleep Disturbance at 
Month 10 
 -0.319 0.00 -587.71 <.0001 
PROMIS Anxiety change (Month 17 
- Month 10) 
 0.923 0.00 786.40 <.0001 
PROMIS Depression change (Month 
17 - Month 10) 
 -1.284 0.00 -779.49 <.0001 
PROMIS Fatigue change (Month 17 
- Month 10) 
 -0.470 0.00 -624.54 <.0001 
PROMIS Pain Interference change 
(Month 17 - Month 10) 
 -0.115 0.00 -251.80 <.0001 
PROMIS Physical Functioning 
(Month 17 - Month 10) 
 -0.341 0.00 -550.93 <.0001 
PROMIS Social Roles and Activities 
(Month 17 - Month 10) 
 -0.167 0.00 -282.60 <.0001 
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Effect Categories Estimate 
Standard 
Error Z P value 
FACT-G Physical Well-being 
Nausea Item change (Month 17 - 
Month 10) 
 1.223 0.01 131.89 <.0001 
Variance Class 1  24.858 1.98 _ _ 
Variance Class 2  0.000293 0.000072 _ _ 
BMI = body mass index, FACT-G = Functional Assessment of Cancer Therapy-General, PROMIS = Patient-Reported 
Outcomes Measurement Information System. 
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Supplemental Table 6.2. Multiple Regression Results: Sensitivity Analysis for Six Exercise Categories 
Assessing the Relationship Between Sleep Disturbance and Exercise Change/Persistence (n = 349) 
Effect Categories Estimate 
Standard 
Error Z P value 
Intercept  7.651 5.16 1.48 0.1383 
Exercise group change (Month 17 - 
Month 10) 
Less active by 1 exercise 
category 
0.048 1.34 0.04 0.9713 
 Less active by 2 or 3 
exercise categories 
2.269 1.76 1.29 0.1976 
 More active by 1 exercise 
category 
-0.284 1.20 -0.24 0.8130 
 More active by 2 or 3 
exercise categories 
0.425 1.43 0.30 0.7655 
 No change, 
moderately/highly active 
-0.390 1.08 -0.36 0.7186 
 No change, not/slightly 
active 
ref - - - 
Months between chemotherapy and 
Month 17 data collection 
1 = current 1.383 1.73 0.80 0.4229 
 2 = 1-2 months 0.398 1.76 0.23 0.8214 
 3 = > 2 months -0.015 0.76 -0.02 0.9846 
 0 = never ref - - - 
Months between surgery and Month 17 
data collection 
1 = 0-4 months -2.512 1.78 -1.41 0.1576 
 2 = more than 4 months -0.402 1.26 -0.32 0.7497 
 0 = never ref - - - 
Race (Collected at Month 10) Black -0.300 0.91 -0.33 0.7431 
 Other or multiple -0.322 0.90 -0.36 0.7195 
 White ref - - - 
Number of relevant comorbidities at 
Month 10 
1 comorbid condition 0.930 0.90 1.04 0.2997 
 2 or more comorbid 
conditions 
-0.208 0.86 -0.24 0.8091 
 No comorbid conditions ref - - - 
Sex (Collected via SEER) Female -0.150 0.69 -0.22 0.8272 
 Male ref - - - 
Live with child under 18 years old at 
Month 10 
Checked -0.504 1.09 -0.46 0.6446 
 Unchecked ref - - - 
Employment at Month 10 Retired -1.150 0.95 -1.21 0.2260 
 Unemployed or disabled -0.682 1.11 -0.61 0.5389 
 Work full time, part time or 
student 
ref - - - 
Months between diagnosis and Month 
17 data collection 
 0.154 0.17 0.89 0.3725 
Age at diagnosis (years) (Collected via 
SEER) 
 0.006 0.05 0.12 0.9041 
BMI (Collected at Month 10)  0.059 0.05 1.22 0.2227 
PROMIS Sleep Disturbance at Month 
10 
 -0.218 0.04 -5.82 <.0001 
PROMIS Anxiety change (Month 17 - 
Month 10) 
 0.083 0.06 1.49 0.1370 
PROMIS Depression change (Month 17 
- Month 10) 
 0.060 0.06 1.06 0.2875 
PROMIS Fatigue change (Month 17 - 
Month 10) 
 0.159 0.05 2.99 0.0028 
PROMIS Pain Interference change 
(Month 17 - Month 10) 
 -0.008 0.04 -0.20 0.8385 
PROMIS Physical Functioning (Month 
17 - Month 10) 
 0.001 0.07 0.02 0.9828 
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Effect Categories Estimate 
Standard 
Error Z P value 
PROMIS Social Roles and Activities 
(Month 17 - Month 10) 
 -0.076 0.06 -1.36 0.1729 
FACT-G Physical Well-being Nausea 
Item change (Month 17 - Month 10) 
 0.075 0.40 0.19 0.8504 
Variance  37.798 2.86 _ _ 
BMI = body mass index, FACT-G = Functional Assessment of Cancer Therapy-General, PROMIS = Patient-Reported 
Outcomes Measurement Information System. 
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Supplemental Table 6.3. Participant Survey Attrition: Comparison of Month 10 Descriptive Statistics and 
Logistic Regression Results 
Patient Characteristic 
Patients who participated 
at Month 10 but not in 
analysis 
(n = 386) 
Patients who participated in Month 
10 data collection and were 
included in analysis 
(n = 348) 
Odds 
Ratio 
95% Wald 
Confidence 
Limits 
Sex      
Female (compared to 
males) 
212 (54.9%) 169 (48.6%) 0.830 0.611 - 1.128 
Race      
Black  83 (21.5%) 66 (19.0%) 0.711 0.474 - 1.065 
Other/multiple 123 (31.9%) 69 (19.8%) 0.527* 0.362 - 0.769 
White 180 (46.6%) 213 (61.2%) Ref  
Employment status     
Work 143 (39.3%) 131 (37.6%) 1.201 0.751 - 1.921 
Retired 146 (40.1%) 169 (48.6%) 1.685* 1.072 - 2.648 
Unemployed or 
disabled 
75 (20.6%) 48 (13.8%) Ref  
Survey Language     
English (compared to 
Spanish or Chinese) 
338 (87.6%) 323 (92.8%) 1.495 0.866 - 2.582 
Level of exercise 
activity 
    
Not active 111 (29.3%) 75 (21.6%) Ref  
Slightly active  57 (15.0%) 61 (17.5%) 1.623 0.994 - 2.649 
Moderately active  164 (43.3%) 160 (46.0%) 1.124 0.749 - 1.688 
Highly active  47 (12.4%) 52 (14.9%) 1.199 0.685 - 2.099 
PROMIS Sleep 
Disturbance 
    
Mean (SD), Median, 
Min - Max 
51.4 (9.7), 52.6, 30-75 49.5 (9.7), 50.2, 30-75 0.996 0.978 - 1.014 
PROMIS Physical 
Functioning 
    
Mean (SD), Median, 
Min - Max 
43.4 (9.8), 42.4, 15-62 45.1 (8.8), 44.7, 21-62 1.012 0.991 - 1.033 
BMI = body mass index, FACT-G = Functional Assessment of Cancer Therapy-General, PROMIS = Patient-Reported 
Outcomes Measurement Information System, Ref = reference category. 
*p < 0.05. 
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CHAPTER 7. CONCLUSIONS 
7.1 Summary of Findings 
This dissertation represents the first attempt to evaluate sleep disturbance specifically in 
individuals diagnosed with stage I, II, and III CRC. Using data from the population-based MY-Health 
study, we examined sleep disturbance approximately 10 and 17 months after diagnosis. Overall, we 
sought to identify factors (patient, disease, and CRC treatment characteristics) associated with severity of 
sleep disturbance and to examine the relationship between sleep disturbance and exercise. We also 
sought to uncover possible heterogeneity in the relationships between sleep disturbance severity (and 
magnitude of change in sleep disturbance) and patient, disease, and treatment characteristics and 
exercise. Specific findings from each dissertation manuscript are summarized below. 
The objective of Manuscript 1 (Chapter 4) was to identify patient, disease, and treatment 
characteristics associated with of sleep disturbance (and change in sleep disturbance) in individuals 
diagnosed with stage I, II, or III CRC. Specifically, we investigated whether there was heterogeneity in 
patient, disease, and treatment characteristics across severity of sleep disturbance, and then we 
identified correlates of sleep disturbance with a focus on chemotherapy. We evaluated these relationships 
with sleep disturbance at approximately 10 months after diagnosis, and then we looked at change in 
sleep disturbance from around 10 to 17 months after CRC diagnosis. We found that patient, disease, and 
treatment characteristics associated with sleep disturbance did not differ depending on the severity of 
sleep disturbance. In addition, the presence of 2 or more comorbid conditions, working patients (full-time, 
part-time, or students), anxiety, pain, and fatigue were correlates of poorer sleep disturbance in patients 
diagnosed with CRC regardless of how mild or severe sleep disturbance was 10 months after diagnosis. 
Patient, disease, and treatment characteristics did not vary by magnitude of change in sleep disturbance. 
Poorer sleepers at Month 10 reported greater improvement in sleep disturbance from Month 10 to Month 
17, and worsening anxiety and fatigue were also indicators of worsening sleep disturbance over time. We 
hypothesized that current or recent chemotherapy would be associated with worse sleep outcomes 
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compared to no chemotherapy. The results of our analyses (non-statistically significant coefficients) did 
not support this hypothesis. 
In Manuscript 2 (Chapter 5), we investigated whether the relationship between exercise and sleep 
disturbance differed by severity of sleep disturbance at approximately 10 and 17 months after CRC 
diagnosis. The second objective of Manuscript 2 was to evaluate the relationship between sleep 
disturbance and exercise at about 10 and 17 months post-diagnosis. It was hypothesized that patients 
whose exercise was categorized as moderately or highly active would experience less sleep disturbance 
than patients who did not exercise. We found that the relationship between sleep disturbance and 
exercise was consistent at any level of sleep disturbance severity (at about 10 and 17 months after 
diagnosis), meaning that no specific subgroup of patients with normal, mild, moderate or severe sleep 
disturbance (compared to healthy and non-healthy sleepers) emerged as being associated with any 
particular level of exercise (or lack of exercise). Further, we did not find evidence that more exercise was 
associated with better sleep quality at around 10 and 17 months after CRC diagnosis. 
In Manuscript 3 (Chapter 6), we sought to uncover possible variability in the relationship between 
change in sleep and change in exercise and to evaluate the relationship between change in exercise and 
change in sleep disturbance. We found a weak (and non-statistically significant) relationship between 
change in sleep disturbance and change in exercise, and this relationship did not differ by magnitude of 
change of sleep disturbance from approximately 10 to 17 months after CRC diagnosis, meaning that no 
specific subgroup of patients with more improvement or more worsening in sleep disturbance emerged as 
being associated with any particular increase or decrease in exercise category (or lack of exercise). 
7.2 Strengths and Limitations 
The MY-Health study provided a large and demographically diverse sample of individuals 
diagnosed with CRC and included a fairly comprehensive set of HRQOL measures relevant to cancer 
(e.g., sleep disturbance, pain, anxiety, depression, fatigue). Although the MY-Health study was not 
representative of the SEER population, including higher proportions of younger and non-white 
participants, the study sample was uniquely diverse, providing context to results from studies with less-
generalizable samples (e.g., women only,
119
 non-U.S. sample
120
). The MY-Health study design also 
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allowed us to evaluate sleep disturbance at two important time points after CRC diagnosis, as patients 
were transitioning off treatment and when most patients were transitioning to survivorship.  
The MY-Health study collected information on HRQOL using PROMIS measures, which were 
developed using rigorous qualitative and quantitative psychometric methods.
12,77,144,149
 In particular, 
PROMIS Sleep Disturbance was the outcome variable in all primary dissertation analyses. In contrast to 
polysomnography, the gold-standard lab-based objective measure of sleep, PROMIS Sleep Disturbance, 
is a brief (less burdensome) measure of sleep quality from the patient perspective that tracks real-life 
sleep outside of the lab.
13
  
The results of this study should be considered in light of some limitations:  
Approximately 50% of patients were lost to follow-up from the Month 10 to Month 17 data 
collections. Minorities were more likely to not participate in the follow-up survey and retirees were more 
likely to participate in both study data collections. In Manuscript 2, more-active patients participated in the 
Month 17 data collection, though the only statistically significant difference was among the slightly active 
exercise group. When patient attrition is not completely at random or missing at random, parameter 
estimates may be biased. 
Endogeneity is a complicating factor for observational studies investigating HRQOL. Anxiety, 
depression, pain, fatigue, and sleep disturbance are known to be closely related and effects could be bi-
directional. For example, pain may cause sleep disturbance, but if sleep disturbance is severe, it could 
cause pain due to increased inflammation or inability of the body to heal with less sleep. Endogeneity 
limits the conclusions that can be drawn from regression analyses: regression coefficients represent 
associations between sleep disturbance and the independent variables; independent variables were not 
necessarily predictors of sleep disturbance.  
Observational studies limit our ability to draw causal conclusions about the impact of exercise on 
sleep disturbance. However, a randomized study evaluating exercise as we did in Manuscripts 2 and 3 
that compared exercise at or above ACSM recommendations to no exercise would be ethically infeasible 
because patients should not be denied the opportunity to exercise given its many benefits. Exercise is 
associated with clear cardiovascular and quality of life benefits,
136,138,137,139
 and without exercise, patients 
are at higher risk for developing additional comorbid conditions (e.g., heart disease, type 2 diabetes).
183
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A common limitation of secondary data analysis is omitted variables, which may bias model 
estimates. We did not have information on self-efficacy, one of the most important predictors of exercise. 
Although difficult to measure, a measure of self-efficacy would be beneficial to include because it would 
increase our ability to control for selection into the exercise. We also did not have access to an indicator 
for exercise habits prior to CRC diagnosis. Prior exercise habits are indicative of current or future exercise 
habits and would be helpful in controlling for selection into exercise.  
Although the exercise items provided information on frequency of exercise, they did not address 
duration of exercise. Duration is important because a 10-minute regimen could result in very different 
physiological effects than a 60-minute regimen. Another limitation of the exercise questions is that 
exercise intensity is subjectively assigned by the patients. In exercise physiology, exercise intensity is 
objectively quantified using validated measures. The exercise questions did not undergo psychometric 
evaluation; it is possible that one patient’s definition of “vigorous” activity is different from another patient’s 
definition. Or that (some) people have a tendency to overreport how much they exercise.
184
  
Another omitted variable is information on patients’ physical activity, which is a much broader 
concept including any body movement that requires energy expenditure. Some patients may not exercise 
but engage in significant physical activity throughout the day. For example, some patients may walk to 
work or have a labor-intensive job that involves heavy lifting. Exercise may be more relevant to patients 
with higher socioeconomic status because exercise is a planned, structured activity that requires time 
outside of other daily tasks and may also cost money. By only including exercise in the model, we limit 
the conclusions and recommendations on exercise to patients above a certain socioeconomic threshold 
who have the means to exercise; some estimates may be biased because we are not including 
information on more general physical activity.  
7.3 Policy Implications and Future Directions 
An unexpected finding from this dissertation was that CRC patients in our sample experienced 
sleep decrements at about the same severity level as the PROMIS referent group, which included 
community-based and clinical samples.
171
 Previous literature suggested that sleep disturbance would be 
more severe in CRC patients than in the general population. In previously published literature, the 
prevalence of sleep disturbance or insomnia in the cancer population was estimated to be approximately 
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three times higher than the general population,
49
 and results from an RCT estimated that half of 
individuals diagnosed with CRC experience decrements in sleep.
3
 To put our results in context, a recent 
study by Leung et al.
168
 provided a cut point on PROMIS Sleep Disturbance indicative of clinically 
significant sleep disturbance (area under the curve = 0.92; PROMIS Sleep Disturbance ≥ 57). Applying 
Leung’s cut point to our data, approximately 24% and 21% of CRC patients in the sample were likely 
experiencing clinically significant sleep disturbance at Month 10 and Month 17, respectively. Average 
sleep disturbance was not alarmingly severe compared to a more general sample (general and clinical 
population), but put in context using the cut point for clinically significant sleep disturbance, 1 in 4 patients 
from our sample would likely have benefited from a sleep intervention at Month 10, suggesting that sleep 
disturbance is not just a problem in CRC but also a general public health problem. The trajectory of sleep 
disturbance severity is not known during much of the CRC cancer continuum. Future research should 
focus on other slices of time in the CRC continuum when sleep disturbance may be more severe, such as 
the first six months after diagnosis when patients are undergoing treatment.  
Results of our analyses from Manuscript 1 show a link between sleep disturbance and other 
aspects of HRQOL such as anxiety, depression, fatigue, and pain. In the exercise-focused manuscripts (2 
and 3), we continued to find a relationship between sleep disturbance and fatigue, underscoring the 
concordance between sleep and other aspects of HRQOL identified in other cancers.
106-108
 Interestingly, 
the correlation coefficients on the HRQOL-related variables in our studies were small, suggesting that 
although there was a statistically significant relationship between sleep disturbance and other aspects of 
HRQOL, screening or treating clinically significant anxiety, depression, fatigue, or pain does not 
necessarily lead to identifying or improving sleep disturbance (and vice versa). Although sleep 
disturbance is prevalent in the cancer population, most individuals diagnosed with cancer do not have 
conversations with their clinicians about their sleep difficulties.
167
 Together, these results suggest that 
screening for sleep disturbance is warranted, and the fluctuation in sleep disturbance severity from Month 
10 to Month 17 provides evidence that sleep screening should occur throughout the cancer continuum, a 
recommendation mirrored in Clinical Practice Guidelines in Oncology:
185
 “Survivors should be screened 
for possible sleep disorders at regular intervals, especially when they experience a change in clinical 
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status or treatment”
185
 and in recent study of insomnia in cancer survivors, which called for systematic 
interventions to increase standardized screening for sleep disorders.
186
 
We found that 40% of the study sample was likely not achieving ACSM exercise 
recommendations for exercise 10 months after diagnosis. Although the exercise questions presented 
some limitations, these results are consistent with previous studies showing that cancer survivors likely do 
not meet strength and aerobic guidelines.
187
 Even though our studies did not identify a relationship 
between exercise and sleep disturbance, the clear cardiovascular and quality of life benefits
136,138,137,139
 of 
exercise in the cancer population support the need for interventions to motivate patients to exercise. 
A set of recommendations for designing clinical trials on exercise in the cancer population was 
published last year that stated, “It is also important to recruit patients to studies based on their need for 
improvement in the selected outcome, rather than the ‘all comers’ approach.”
188
 Our studies addressed 
this concern by evaluating possible heterogeneity among sleep disturbance and exercise, as well as 
heterogeneity among patient, disease, and treatment characteristics and sleep disturbance. We did not 
find evidence of subgroups of CRC patients whose sleep might benefit from exercise more than others. 
RMMs represent a powerful statistical tool for identifying heterogeneity, and future research should 
continue to employ this statistical tool to identify patients that may stand to benefit from a treatment more 
than others. 
Although our studies did not find a relationship between exercise and sleep disturbance, our 
results suggest that for some patients, severity of sleep disturbance diminishes from 10 to 17 months 
after CRC diagnosis. Previous research by Courneya and colleagues shows fluctuations in exercise 
activity after diagnosis.
118
 Future studies should evaluate the relationship between sleep disturbance and 
exercise at different time points in the CRC continuum. Exercise has many other benefits for physical and 
mental health, thus we do not recommend any policy associated with decreasing or not exercising. 
This is the first study we are aware of that provides a threshold for meaningful differences 
between groups of patients on the PROMIS Sleep Disturbance scale. PRO thresholds are important for 
interpreting classes derived from RMMs as well as treatment effects in future randomized studies. In lieu 
of anchor-based thresholds, we calculated a preliminary distribution-based threshold (half standard 
deviation at Month 10) to provide context on group differences. The threshold derived from this 
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dissertation should be reevaluated using other methods (including additional distribution-based methods 
and, more important, methods including the patient perspective), in other CRC samples (especially in 
patients with stage IV disease because they were not included in this dissertation), and during other time 
points during the cancer continuum.  
In conclusion, this dissertation provides important information on two policy-related issues. First, 
CRC patients should be screened for sleep disturbance throughout the cancer continuum because sleep 
disturbance is a general public health problem and no strong patient, CRC, or CRC-related treatment 
factors could be used to identify possible sleep disturbance in the clinic. Second, exercise has clear 
health benefits and although this study does not provide evidence that exercise is associated with better 
sleep quality, CRC patients should continue to be encouraged to exercise.  
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